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Abstract 
 
The adhesion G protein-coupled receptor 56 (GPR56) plays a major role in 
early brain development. Mutations in Gpr56 cause the developmental brain 
disease bilateral frontoparietal polymicrogyria (BFPP), which is recapitulated 
in Gpr56-/- mice. GPR56 interacts with collagen III in the brain pial basement 
membrane and with tissue transglutaminase (TG2) in melanoma, where it 
potentially acts as a tumour suppressor by antagonising TG2-related 
functions. In glioblastoma, however, GPR56 is highly overexpressed and 
might play an important role for the invasive behaviour of these cells, which 
could be regulated by TG2 in the tumour stroma.  
The main aim of this thesis was to analyse GPR56 signalling in response to 
TG2, thus exploring a potential link to cancer development and progression. 
Identifying downstream signalling pathways activated by GPR56 in response 
to TG2 could provide valuable information regarding potential targets for 
future therapeutic intervention in the context of anti-cancer therapies. 
In order to investigate GPR56 signalling, a cell-based assay was established 
that measures GPR56 activation as metalloproteinase-dependent 
ectodomain shedding of alkaline phosphatase-tagged amphiregulin (AP-AR) 
in HEK293 cells. The assay was used to demonstrate for the first time 
activation of GPR56 by TG2. RhoA/Rho-associated protein kinase (ROCK) 
are activated by GPR56, which likely requires Gα12/13 coupling to GPR56. 
RhoA/ROCK activity is required for the activation of a disintegrin and 
metalloproteinase 17 (ADAM17), the main metalloproteinase responsible for 
GPR56-dependent AP-AR shedding. Shedding of EGF-like ligands such as 
amphiregulin leads to the activation of epidermal growth factor receptors, 
inducing cellular responses such as cell proliferation and migration. 
Further investigations using different GPR56 mutants revealed that the N-
terminal domain of GPR56 is required for activation by TG2. The crosslinking 
activity of TG2 is dispensable for GPR56 activation and the C-terminal β-
barrel domains of TG2 are sufficient to stimulate GPR56 signalling. 
Moreover, two novel potential GPR56 ligands, TG6 and TG7, were shown to 
stimulate GPR56-dependent AP-AR shedding. 
Using confocal microscopy, GPR56-dependent internalisation of TG2 via 
clathrin-coated pits was demonstrated, a mechanism that is well known for 
agonist-activated GPCRs. Finally, the potential role of GPR56 in glioblastoma 
was investigated by generating stable GPR56 knockdown glioma cells. 
Analysis of GPR56 knockdown cells indicated that GPR56 may play a role for 
glioblastoma migration and invasion.  
These results present a novel signalling pathway activated by GPR56 in 
response to TG2 that is involved in cell proliferation, growth and migration, 
potentially providing an explanation for the supposed tumour promoting 
functions of GPR56 in glioblastoma. 
  
v 
 
1 Introduction ........................................................................................... 1 
1.1 Why study GPR56? ......................................................................... 1 
1.2 G protein-coupled receptors ............................................................ 3 
1.2.1 Phylogenetic classification of GPCRs ........................................ 3 
1.2.2 Structure of GPCRs .................................................................... 4 
1.2.3 Activation of GPCRs ................................................................... 6 
1.2.4 G protein-dependent signalling .................................................. 9 
1.2.5 Desensitisation of G protein-dependent signalling ................... 12 
1.2.6 Internalisation of GPCRs .......................................................... 13 
1.2.6.1 Clathrin-dependent endocytosis ........................................ 14 
1.2.6.2 Clathrin-independent endocytosis ...................................... 15 
1.2.6.3 Endosomal sorting ............................................................. 17 
1.2.7 G protein-independent signalling .............................................. 19 
1.2.8 EGFR transactivation ............................................................... 21 
1.2.8.1 A disintegrin and metalloproteinases (ADAMs) .................. 25 
1.2.8.1.1 Structure of ADAMs ...................................................... 26 
1.2.8.1.2 Biological functions of ADAMs ...................................... 27 
1.2.8.1.3 ADAM17 ....................................................................... 28 
1.2.8.1.4 ADAM inhibitors ............................................................ 29 
1.3 Adhesion GPCRs .......................................................................... 30 
1.3.1 Structure of adhesion GPCRs .................................................. 30 
1.3.2 GPS cleavage and the GAIN domain ....................................... 32 
1.3.3 Physiological functions of adhesion GPCRs ............................ 33 
1.3.3.1 De-orphanised adhesion GPCRs ....................................... 33 
1.3.3.2 Adhesion GPCRs in immunology ....................................... 34 
1.3.3.3 Adhesion GPCRs in embryonic developmental ................. 34 
1.3.3.4 Adhesion GPCRs in the CNS ............................................ 35 
1.3.4 Signalling by adhesion GPCRs ................................................ 36 
1.3.5 Adhesion GPCRs in tumorigenesis .......................................... 37 
1.4 GPR56 ........................................................................................... 39 
vi 
 
1.4.1 Expression of GPR56 ............................................................... 39 
1.4.2 Structure of GPR56 .................................................................. 39 
1.4.3 GPR56 interaction partners and potential ligands .................... 41 
1.4.4 GPR56 in brain development ................................................... 41 
1.4.4.1 GPR56 knockout mice ....................................................... 44 
1.4.5 GPR56 and cancer ................................................................... 45 
1.4.5.1 GPR56 as a tumour suppressor ........................................ 45 
1.4.5.2 GPR56 as a tumour promoter ............................................ 46 
1.4.6 GPR56 in immune cells ............................................................ 48 
1.4.7 The role of N-GPR56 in GPR56 activation ............................... 48 
1.4.8 Natural splice variants .............................................................. 49 
1.5 Transglutaminases ........................................................................ 51 
1.6 Tissue transglutaminase (TG2) ..................................................... 53 
1.6.1 Expression of TG2 in the human body ..................................... 53 
1.6.2 Enzymatic activities of TG2 ...................................................... 53 
1.6.3 Biological functions of TG2-mediated transamidation .............. 57 
1.6.4 Regulation of the transamidation activity .................................. 57 
1.6.5 TG2 as a GTPase and G protein .............................................. 59 
1.6.6 Non-enzymatic functions of extracellular TG2 and their 
physiological roles ................................................................................ 60 
1.6.7 TG2 and cancer........................................................................ 61 
1.6.8 TG2 knockout mice .................................................................. 62 
1.7 Glioblastoma multiforme ................................................................ 64 
1.8 Aims of the thesis .......................................................................... 67 
2 Material and methods ......................................................................... 68 
2.1 DNA manipulation .......................................................................... 68 
2.1.1 Agarose gel electrophoresis ..................................................... 68 
2.1.2 Restriction digest ...................................................................... 68 
2.1.3 Ligation ..................................................................................... 69 
2.1.4 Transformation ......................................................................... 69 
2.1.5 Identifying positive clones ........................................................ 69 
vii 
 
2.1.6 Plasmid DNA midiprep ............................................................. 70 
2.2 DNA mutagenesis .......................................................................... 70 
2.2.1 PCR reactions .......................................................................... 70 
2.2.2 Generating an intermediate GPR56 expression vector ............ 72 
2.2.3 Restriction digest of PCR reactions .......................................... 72 
2.2.4 Purification of cleaved PCR products ....................................... 73 
2.2.5 Cloning of C-terminal GPR56 phosphorylation mutants ........... 73 
2.3 Cell culture ..................................................................................... 74 
2.3.1 Cell lines ................................................................................... 74 
2.3.1.1 HEK293 model system ...................................................... 75 
2.3.1.2 HCA2 fibroblasts ................................................................ 75 
2.3.1.3 Glioblastoma cell line ......................................................... 76 
2.3.1.3.1 Generating GPR56 knockdown cells ............................ 76 
2.3.1.3.2 Linearization of shRNA plasmid DNA ........................... 76 
2.3.1.3.3 Phenol-chloroform extraction of shRNA plasmid DNA.. 77 
2.3.1.3.4 Stable transfection of cells ............................................ 77 
2.3.1.3.5 Hygromycin kill curve of U373 cells .............................. 78 
2.3.1.3.6 Selection of stably transfected cells.............................. 78 
2.3.1.3.7 Isolating single cell colonies ......................................... 78 
2.4 Alkaline phosphatase-Amphiregulin (AP-AR) shedding assay ...... 79 
2.4.1 Transient transfection of HEK293 cells .................................... 79 
2.4.2 Inhibition of ADAM10 and ADAM17 ......................................... 79 
2.4.3 Treatment with potential ligands for GPR56 ............................. 80 
2.4.4 Measurement of AP-activity in the medium .............................. 80 
2.4.5 Statistical analysis .................................................................... 81 
2.5 Protein analysis by Western Blotting ............................................. 82 
2.5.1 Production of cell lysates .......................................................... 82 
2.5.2 Protein concentration assay (DC assay) .................................. 82 
2.5.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) ............ 83 
2.5.4 Western blotting ....................................................................... 83 
viii 
 
2.6 Immunofluorescence ..................................................................... 85 
2.6.1 Immunodetection of GPR56 in eukaryotic cells ........................ 86 
2.6.1.1 Endogenous GPR56 expression in U373 cells as detected 
with N-GPR56 antibody ..................................................................... 86 
2.6.1.2 GPR56 expression in transiently transfected HEK293 cells86 
2.6.2 Immuno-colocalisation of GPR56 and TG2 in stable HEK293 
cells  ................................................................................................. 87 
2.6.3 SNAP-tag staining of GPR56 in HEK293 cells ......................... 87 
2.6.3.1 Immunolocalisation of TG2 ................................................ 88 
2.6.3.2 Immuno-colocalisation of TG2 and lysosomes or caveolae 88 
2.6.3.3 Co-staining of transferrin receptors .................................... 89 
2.6.3.4 Inhibition of endocytosis with sucrose ................................ 89 
3 Investigations of GPR56 downstream signalling using an AP-AR 
shedding assay .......................................................................................... 90 
3.1 Introduction .................................................................................... 90 
3.1.1 Aims of the chapter .................................................................. 93 
3.2 Results ........................................................................................... 94 
3.2.1 Principle of the AP-AR shedding assay .................................... 94 
3.2.2 Validation of the GPR56 signalling response ........................... 97 
3.2.2.1 C230-A TG2 activates GPR56 ............................................. 97 
3.2.2.2 Comparison of wild type TG2, C230-A TG2 and an anti-N-
GPR56 antibody .............................................................................. 102 
3.2.2.3 The putative ligand collagen III ........................................ 103 
3.2.3 Identification of the metalloproteinase involved in GPR56-
dependent AP-AR shedding ............................................................... 105 
3.2.4 Identifying mediator proteins downstream of GPR56 ............. 108 
3.2.4.1 Interfering with the Protein kinase C (PKC) / Phospholipase 
C (PLC) pathway ............................................................................. 108 
3.2.4.2 Inhibition of the RhoA signalling mechanism ................... 113 
3.2.4.3 Inhibition of the epidermal growth factor receptor (EGFR) 115 
ix 
 
3.3 Discussion ................................................................................... 117 
4 Characterisation of GPR56-TG interactions ................................... 125 
4.1 Introduction .................................................................................. 125 
4.1.1 Aims of the chapter ................................................................ 126 
4.2 Results ......................................................................................... 127 
4.2.1 GPR56 activation by TG2 is independent of transglutaminase 
activity  ............................................................................................... 127 
4.2.2 Other TG isoenzymes ............................................................ 129 
4.2.2.1 Neuronal transglutaminase (TG6, TGY) induces GPR56-
dependent AP-AR shedding ............................................................ 129 
4.2.2.2 Transglutaminase 7 (TG7, TGz) activates GPR56 ........... 131 
4.2.2.3 A transglutaminase lacking the β-barrel domains fails to 
activate GPR56 ............................................................................... 132 
4.2.2.4 The β-barrel domains of TG2 are sufficient to activate 
GPR56  ......................................................................................... 134 
4.3 Discussion ................................................................................... 135 
5 Identifying GPR56 structural domains involved in downstream 
signalling .................................................................................................. 141 
5.1 Introduction .................................................................................. 141 
5.1.1 Aims of the chapter ................................................................ 143 
5.2 Results ......................................................................................... 144 
5.2.1 Cloning of the C-terminal tail phosphorylation site mutants .... 144 
∆S-A-GPR56, T688A-GPR56, ∆S/T-A GPR56 ..................................... 144 
5.2.2 Analysis of wild type and mutant GPR56 expression levels in 
transiently transfected HEK293 cells .................................................. 148 
5.2.3 GPR56 mutants in the AP-AR shedding assay ...................... 153 
5.2.3.1 Basal- and C230-A TG2-induced AP-AR shedding is impaired 
in the BFPP-mutant R565W-GPR56 and the natural splice variant ∆430-
35-GPR56......................................................................................... 153 
x 
 
5.2.3.2 TG2-stimulated GPR56-dependent AP-AR shedding 
requires the N-terminal domain of the receptor ............................... 157 
5.2.3.2.1 The ligand interaction site deletion mutant ∆STP-GPR56 
  ................................................................................... 157 
5.2.3.2.2 The N-terminal domain deletion mutant ∆N-GPR56 ... 160 
5.2.3.3 Multiple mutations of six serine residues alone or in 
conjunction with threonine-688 in the C-terminal tail of GPR56 do not 
affect receptor-induced signalling .................................................... 162 
5.2.3.4 The GPR56 C-terminal tail regulates basal, but not TG2-
induced AP-AR shedding ................................................................ 168 
5.3 Discussion ................................................................................... 170 
6 Exploring the mechanism of GPR56-dependent internalisation of 
TG2 using confocal microscopy ............................................................. 175 
6.1 Introduction .................................................................................. 175 
6.1.1 Aims of the chapter ................................................................ 177 
6.2 Results ......................................................................................... 178 
6.2.1 Interaction of GPR56 and TG2 in stably transfected HEK293 
cells  ............................................................................................... 178 
6.2.2 Internalisation of GPR56 and TG2 in HEK293 cells transiently 
expressing SNAP-tagged GPR56 ....................................................... 184 
6.2.2.1 Optimisation of SNAP-GPR56 staining and comparison to 
the SNAP-β2-adrenergic receptor .................................................... 184 
6.2.2.2 Co-internalisation of SNAP-GPR56 and TG2 .................. 189 
6.2.2.3 Internalisation of GPR56 and TG2 is clathrin-dependent . 193 
6.2.2.3.1 The clathrin-inhibitor sucrose prevents internalisation 193 
6.2.2.3.2 SNAP-GPR56 internalises with transferrin receptors . 198 
6.2.2.3.3 Endocytosis of SNAP-GPR56 is caveolae-independent ... 
  ................................................................................... 201 
6.2.2.4 Internalised GPR56 and TG2 do not co-localise in 
lysosomes ....................................................................................... 204 
xi 
 
6.3 Discussion ................................................................................... 211 
7 Generation and preliminary characterisation of stable GPR56 
knockdown glioblastoma cells ............................................................... 218 
7.1 Introduction .................................................................................. 218 
7.1.1 Aims of the chapter ................................................................ 219 
7.2 Results ......................................................................................... 220 
7.2.1 Hygromycin dose-response .................................................... 220 
7.2.1.1 GPR56 expression levels and pattern ............................. 222 
7.3 Discussion ................................................................................... 225 
8 General discussion and future experiments .................................. 228 
8.1 Summary of the results ................................................................ 228 
8.2 Conclusions ................................................................................. 230 
8.2.1 TG2 stimulates GPR56-dependent activation of ADAM17 ..... 230 
8.2.2 TG2-dependent GPR56 signalling is independent of TG2 
crosslinking activity ............................................................................. 231 
8.2.3 GPR56 downstream signalling ............................................... 233 
8.2.3.1 GPR56 activates RhoA signalling .................................... 233 
8.2.3.2 GPR56-mediated ADAM17-activation is independent of 
Gq-signalling .................................................................................... 236 
8.2.3.3 A role for β-arrestins in GPR56-dependent signalling? .... 237 
8.2.4 Novel GPR56 ligands ............................................................. 238 
8.2.5 Internalisation of GPR56 ........................................................ 240 
8.2.6 Controversial roles of GPR56 in cancer ................................. 241 
8.3 Future outlook .............................................................................. 246 
References................................................................................................ 249 
Appendix I: Solutions and buffer ................................................................ 283 
Appendix II: Chemicals .............................................................................. 284 
Appendix III: Consumables and laboratory equipment ............................... 285 
Appendix IV: DNA sequences endcoding shRNAs used to stably transfect 
U373 glioblastoma cells ............................................................................. 287 
xii 
 
Appendix V: Sequence of wild type GPR56, 693 aa .................................. 288 
Appendix VI: Stably transfected HEK293 control cells stained for GPR56 and 
TG2. ........................................................................................................... 289 
 
  
xiii 
 
List of abbreviations 
 
7TM  Seven transmembrane 
aa  Amino acid 
AC  Adenylyl cyclase 
ADAM  A disintegrin and metalloproteinase 
ADPKD Autosomal-dominant polycystic kidney disease 
aGPCR Adhesion G protein-coupled receptor 
AP  Alkaline phosphatase 
AP-2  Adaptor protein-2 
AR  Amphiregulin 
ATR  Angiotensin II receptor  
ATP  Adenosine triphosphate 
BAI  Brain angiogenesis inhibitor 
β2AR  β2-adrenergic receptor 
BSA  Bovine serum albumine 
BFPP  Bilateral frontoparietal polymicrogyria 
BM  Basement membrane 
cAMP  Cyclic adenosine monophosphate 
CaMKII Calcium-calmodulin-dependent kinase II 
Cav-1  Caveolin-1 
Cdc42  Cell division control protein 42 homolog 
CD  Cluster of differentiation 
CHO  Chinese hamster ovary 
CIRL  Calcium-independent receptor of latrotoxin 
CNS  Central nervous system 
CXCR  Chemokine receptor 
DAF  Decay accelerating factor 
DAG  Diacylglycerol 
DAPI  2-(4-amidinophenyl)-1H-indole-6-carboxamidine 
DMEM Dulbecco’s modified eagle’s medium 
DMSO Dimethyl sulfoxide 
DOCK  Dedicator of cytokines protein 
xiv 
 
ECD  Ectodomain 
ECL  Extracellular loop 
ECM  Extracellular matrix 
EDTA  Ethylenediaminetetraacetic acid 
EGTA  Ethylene glycol tetraacetic acid 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
ELMO  Engulfment and cell motility 
EMEM Eagle’s minimum essential medium 
EMR  EGF-like module containing mucin-like receptor protein 
ER  Endoplasmic reticulum 
ETR  Endothelian receptor 
ERK  Extracellular signal-related kinase 
ESCC  Esophageal squamous cell carcinoma 
FXIII  Factor 13 
FLRT  Fibronectin leucine-rich repeat transmembrane protein 
FBS  Fetal bovine serum 
FN  Fibronectin 
GAIN  GPCR-autoproteolysis inducing  
GAG  Glycosaminoglycan 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GBM  Glioblastoma multiforme 
GDP  Guanine nucleotide diphosphate 
GEF  Guanine nucleotide exchange factor  
GPCR  G protein-coupled receptor 
GPR56 G protein-coupled receptor 56 
G protein Guanine nucleotide binding protein 
GPS  G protein-coupled receptor proteolytic site 
GRAFS Glutamate, rhodopsin, adhesion, frizzled/taste2, secretin 
GRK  G protein-coupled receptor kinase 
GTP  Guanine nucleotide triphosphate 
GTPγS Guanosine-(γ-thio)triphosphate 
HBF  heparin-binding epidermal growth factor 
xv 
 
HEK293 human embryonic kidney 293 
HRP  Horseradish peroxidase 
ICL  intracellular loop 
IgG  Immunoglobulin G 
IP3  Inositol triphosphate 
KD  Knockdown 
LAMP  Lysosome-associated membrane protein 
LPA  Lysophosphatidic acid 
LRP  Lipoprotein-receptor related protein 
MAPK  Mitogen-activated protein kinase 
MEK  Mitogen-activated protein kinase kinase 
MMP  Matrix metalloproteinase 
NF-κB  Nuclear factor κB 
NK  Natural killer 
NPC  Neural progenitor cell 
PAGE  Polyacrylamide gel electrophoresis 
PAR  Protease-activated receptor 
PBS  Phosphate buffered saline 
PCP  Planar cell polarity 
PDGF  Platelet derived growth factor 
PDZ  PSD95, Dlg, ZO-1/2 
PFA  Paraformaldehyde 
PI3K  Phosphatidylinositol 3-kinase 
PKD  Polycystic kidney disease 
PMA  Phorbol 12-myristate 13-acetate 
p-NPP para-nitrophenol phosphate 
PNGase F peptide-N-glycosidase F 
PKA  Protein kinase A 
PKC  Protein kinase C 
PLC  Phospholipase C 
PTEN  Phosphatase and tensin homolog 
PVDF  Polyvinyliden-difluorid 
Rab  Ras-related in brain 
xvi 
 
Rho  Ras homolog gene family  
ROCK  Rho-associated protein kinase 
RTK  Receptor tyrosine kinase 
SDS  Sodium dodecyl sulfate 
Sh  Short hairpin 
Src  Proto-oncogene tyrosine-protein kinase 
SRE  Serum-response element 
STP  Serine, threonine, proline 
TBST  Tris-buffered saline and Tween-20 
Tf  Transferrin 
TG  Transglutaminase 
TG2  Transglutaminase 2 
TGF  Transforming growth factor 
TM  Transmembrane 
TMPS  Triple-membrane-passing-signalling 
TR  Transferrin receptor 
V2R  Vasopressin receptor 2 
VEGF  Vascular endothelial growth factor 
VLGR  Very large G protein-coupled receptor 
  
 
 
 
 
CHAPTER 1: 
Introduction
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1 Introduction 
 
1.1 Why study GPR56? 
 
The adhesion G protein-coupled receptor 56 (GPR56) plays an important role 
during early brain development, where it regulates neural progenitor 
migration by interacting with its ligand collagen III in the pial basement 
membrane (Piao et al. 2004; Luo, Jeong, et al. 2011). Another potential 
function of GPR56 is related to the development and progression of cancer 
and GPR56 expression levels are deregulated in certain types of cancer (Xu 
et al. 2006; Ke et al. 2007; Sud et al. 2006; Huang et al. 2008; Shashidhar et 
al. 2005). GPR56 is down-regulated in highly metastatic melanoma and 
overexpression of GPR56 in melanoma cells leads to stop of tumour growth 
and metastasis in vivo (Xu et al. 2006; Yang et al. 2011). It was supposed 
that GPR56 interacts with its second known ligand tissue transglutaminase 
(TG2) in the tumour stroma, thus antagonising the tumour promoting effects 
of TG2 (Yang et al. 2014). In contrast to the situation in metastatic 
melanoma, GPR56 is highly overexpressed in glioblastoma and associated 
with cell adhesion, potentially contributing to the invasive properties of 
aggressive glioblastoma cells (Shashidhar et al. 2005). Glioblastoma 
multiforme (GBM) is a deadly disease and despite extensive treatments, 
most patients die shortly after diagnosis (Holland 2000). There is a strong 
need to identify and characterise novel cellular players involved in the 
development and progression of GBM, which could be targeted by drugs to 
treat the disease more efficiently. GPCRs and their signalling networks are 
involved in most physiological processes and they have important functions 
for many diseases including cancer, making them a major target for drug 
development (Dorsam and Gutkind 2007; Lappano and Maggiolini 2011). 
Being a member of this large protein family, GPR56 represents a potential 
candidate for novel therapeutic interventions in the context of glioblastoma 
and other tumours. 
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In addition to its controversial roles in different types and stages of cancer 
outlined above, a study by Edwards (2010) suggested that GPR56 might be 
involved in keratinocyte migration in response to TG2, as shown in the 
context of re-epithelialisation. The study showed that matrix TG2 induces a 
disintegrin and metalloproteinase 17 (ADAM17)-dependent shedding of 
epidermal growth factors, leading to the activation of epidermal growth factor 
receptor (EGFR) in keratinocytes, inducing migration and proliferation 
(Edwards 2010). The underlying signalling mechanism is also referred to as 
EGFR transactivation and it plays a major role in cellular migration, survival 
and proliferation, also in the context of cancer (Lappano and Maggiolini 2011; 
Gschwind et al. 2001; Fischer et al. 2003). It was hypothesised that the 
missing link between TG2 and ADAM17 activation might be GPR56 
(Edwards 2010). This working hypothesis and the published data about 
GPR56’s potential roles in cancer (Xu et al. 2006; Yang et al. 2011; Yang et 
al. 2014; Shashidhar et al. 2005) led to the current project, which set out to 
investigate GPR56-mediated signalling in response to TG2, potentially 
resulting in EGFR transactivation. Understanding this GPR56 downstream 
signalling pathway, which likely contributes to oncogenic transformation in 
tumours, as well as further characterising the nature and function of the 
GPR56-TG2 interaction could help to understand the potential role of GPR56 
in cancer. In order to connect these basic investigations with the situation in 
GBM, this projects set out to investigate the specific role of GPR56 in GBM 
by characterising the effects of depleting GPR56 in glioblastoma cells. This 
study could help to advance the existing knowledge of GPR56’s role in 
cancer and might help to identify points for therapeutic intervention in order to 
block invasion and proliferation of glioblastoma more efficiently in the future. 
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1.2 G protein-coupled receptors 
 
G protein-coupled receptors (GPCRs) are the largest family of membrane 
proteins involved in signal transduction, represented by more than 800 
members (~4 % of the coding sequence) in the human genome (Hill 2006). 
GPCRs are ubiquitously expressed in the human body and mediate most of 
cellular responses to neurotransmitters, hormones, amines, peptides, 
proteins, ions, nucleotides, growth factors, lipids or sensory stimuli like 
photons, odorants and taste ligands by transducing extracellular signals to 
intracellular effectors. GPCRs play very important roles in fundamental 
biological processes such as cellular growth, migration, differentiation, or 
apoptosis (Dorsam and Gutkind 2007). They are involved in physiological 
processes such as the visual sense, the sense of smell, immune responses, 
regulation of blood pressure, contraction of cardiac- and smooth-muscle, 
synaptic transmission and far more. They also play key functions in many 
diseases and are currently targeted by ~50 % of all therapeutic agents 
(Dorsam and Gutkind 2007; Hill 2006; Lagerström and Schiöth 2008; 
Rosenbaum et al. 2009). For ~120 receptors neither their physiological role, 
nor their endogenous ligands are known. These receptors are called “orphan 
GPCRs” (Lappano and Maggiolini 2011). 
 
1.2.1 Phylogenetic classification of GPCRs 
 
Due to physiological and structural similarities, the GPCR superfamily was 
originally subdivided into six classes (A-F classification system): class A - 
rhodopsin-like, class B - secretin receptor family, class C - metabotropic 
glutamate/pheromone, class D - fungal mating pheromone receptors, class E 
- cAMP receptors and class F - frizzled/smoothened (Kolakowski 1994). More 
recently, an alternative, phylogenetic classification system was established 
by Fredriksson et al. (2003), announcing five different GPCR families, called 
“GRAFS”: the glutamate, rhodopsin, adhesion, frizzled/taste2 and secretin 
GPCRs.  In 2008, the glutamate family consisted of 22, the rhodopsin family 
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of 672, the adhesion family of 33, the frizzled/taste2 family of 11/25 and the 
secretin family of 15 members (Lagerström and Schiöth 2008). The main 
difference between the classification by Kolakowski (1994) and Fredriksson 
et al. (2003) is the subdivision of class B receptors into the adhesion and 
secretin families. The new system also provides a subdivision of the largest 
group of GPCRs, the rhodopsin family, into four main groups with 13 sub-
branches (Fredriksson et al. 2003; Lagerström and Schiöth 2008).  
 
1.2.2 Structure of GPCRs 
 
The first identified GPCR was bovine rhodopsin, found in the rod 
photoreceptor cells of the retina. Its primary structure was resolved in 1983 
(Hargrave et al. 1983; Nathans and Hogness 1983) and its crystal structure 
in 2000, the first one of a GPCR (Palczewski et al. 2000). These analyses 
revealed that rhodopsin consists of the 40 kDa opsin that is linked to the 
chromophore 11-cis-retinal, a derivate of vitamin A (Hargrave et al. 1983). 
The binding of a photon induces a conformational change of rhodopsin 
through isomerisation of 11-cis-retinal to all-trans-retinal, which transiently 
activates opsin, before the all-trans-retinal is hydrolysed and dissociates. It 
was shown that the absorption of one photon activates hundreds of 
rhodopsin receptors, converting energy into intracellular signalling via the G 
protein transducin, thus enabling vision (Yoshizawa and Wald 1963; Fung et 
al. 1981; Palczewski et al. 2000). The amino acid sequence analysis 
predicted the existence of hydrophobic α-helical seven transmembrane 
(7TM) domains, waving in and out the membrane, as well as hydrophilic 
extracellular (ECLs) and intracellular loops (ICLs) connecting these 
transmembrane domains, as well as an extracellular N-terminus and a C-
terminal cytoplasmic tail (Hargrave et al. 1983). This model was later 
confirmed by x-ray structural analysis of the three-dimensional structure 
(Palczewski et al. 2000).  
Cloning of another GPCR, the β2-adrenergic receptor (β2AR), revealed 
significant homology with bovine rhodopsin (Dixon et al. 1986). However, the 
idea of a common protein family emerged later with the cloning and structural 
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analysis of other GPCRs. The existence of a 7TM domain as well as the 
ability to couple guanine nucleotide-binding proteins (G proteins) represent 
the two main requirements for a receptor to be called GPCR, although the 
latter requirement has not been demonstrated for all GPCRs, thus they are 
sometimes also referred to as 7TM-receptors (Fredriksson et al. 2003).   
In order to compare residues between the different receptors of the largest 
class of GPCRs, the rhodopsin-like GPCRs, different official GPCR 
nomenclatures were introduced. The Schwartz numbering scheme marks the 
most conserved residue within a TM-domain with a generic number 
according to its position within the helix (Schwartz 1994). For example, 
AspII:10 is the most conserved residue in TM2 and it is located at position 10 
within this helix. In the Ballesteros-Weinstein nomenclature, each residue is 
marked by two numbers (Ballesteros and Weinstein 1995). The first number 
refers to the helix the residue is located in and the second number provides 
information about the position of this residue relative to the most conserved 
residue, which has been given number 50, within the same TM-domain. For 
example, the most conserved residue within TM1 is Pro1.50, the next residue 
C-terminally to it is Asn1.51 and the residue N-terminally to it is Cys1.49. 
Comparison of rhodopsin-like GPCR structures using these numbering 
schemes has helped to identify certain highly conserved residues that are 
important for receptor activation, as discussed in section 1.2.3. 
Functionally, the N-terminal domain, ECLs and the 7TM domain comprise the 
ligand recognition parts, while the ICLs and cytoplasmic domain are involved 
in G protein-dependent/-independent signal transduction (Dorsam and 
Gutkind 2007). The greatest structural variance among the different GPCRs 
is observed in the N-terminus, which can be very short or very long, 
depending on the GPCR family (Fig. 1.1). 
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Figure 1.1 Secondary structure of a typical GPCR. 
All GPCRs consist of a seven transmembrane domain (TM1-7). The N-terminus and 
the extracellular loops (ECLs) comprise the extracellular domains, whereas the 
intracellular loops (ICLs) and the cytoplasmic C-terminus are located intracellularly. 
 
 
1.2.3 Activation of GPCRs 
 
Although there is huge ligand diversity, there seems to be a common 
mechanism of receptor activation. Analysis of rhodopsin demonstrated 
conformational changes occurring within the 7TM domain upon light 
activation. A rotation of TM6 relative to TM3, as well as conformational 
changes in the cytoplasmic ends of TM1, TM2 and TM7 were shown 
(Farrens et al. 1996; Altenbach et al. 2001). Analysis of the β2AR showed 
similar changes in TM3 and TM6 upon adrenalin binding (Ghanouni et al. 
2001). An ionic interaction between the cytoplasmic end of TM6 and the 
highly conserved D(/E)RY motif, localised in ICL2, was identified  (Yao et al. 
2006). This so-called “ionic lock” is one of several non-covalent interactions 
that keep GPCRs in their inactive state (Kobilka and Deupi 2007) and  its 
disruption upon agonist stimulation leads to the active receptor conformation. 
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GPCRs that are activated by completely different ligands can couple to the 
same G protein. Thus, the induced changes in their cytoplasmic regions upon 
agonist activation must be quite similar, as observed for rhodopsin and  β2AR 
(Kobilka 2007) and others (Warne et al. 2011; Xu et al. 2011; Deupi and 
Standfuss 2011; Lebon et al. 2012).  
Many GPCRs have some basal (constitutive) activity, which means they 
activate G protein signalling in the absence of agonist. The simplest kinetic 
model to explain activation of GPCRs is a two-state model, in which the 
GPCR exists primarily in an inactive (R) or active state (R*) (Leff 1995) (Fig. 
1.2 A). The constitutive activity of a GPCR is defined as the equilibrium 
between these two states in the absence of a ligand. A full agonist shifts the 
equilibrium to the active state R*, while an inverse agonist binds and 
stabilises the inactive state R, inhibiting basal activity. Partial agonists have 
some affinity for both states, thus shift the equilibrium less efficiently towards 
R* and activate only submaximal. Antagonists do not affect constitutive 
activity, thus the equilibrium between R and R*, but block access for other 
ligands (Fig. 1.2 B) (Kobilka 2007).  
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Figure 1.2 Activation of GPCRs. 
(A) Energy landscape diagram for a possible mechanism of GPCR activation. In this 
simple model, the GPCR can switch only between two conformations, an inactive 
(R) and an agonist-activated (R*) state. The energy difference between the two 
states determines the probability that the GPCR will undergo a conformational 
change. The height of the energy barrier defines the kinetics of the transition 
between the states. A binding ligand can provide energy that reduces the height of 
the energy barrier. 
(B) Different types of ligands have varying effects on a GPCR that shows some 
basal activity. 
Taken from (Deupi and Kobilka 2007). 
 
 
It must be noted that this is a very simple model and that most GPCRs are 
very dynamic proteins that may exist in multiple conformational states 
(Kobilka and Deupi 2007). In addition, each ligand could stabilize a unique 
receptor conformation, as indicated for the β2AR (Ghanouni et al. 2001). 
Rhodopsin is a special GPCR regarding receptor activation, since it shows 
no basal (constitutive) activity. Rhodopsin behaves as a simple on-off switch, 
in which a single photon fully activates the receptor. This is accompanied by 
the transition of the inverse agonist cis-retinal, bound in the 7TM domain of 
opsin, to the full agonist all-trans-retinal, followed by a series of 
conformational changes leading to the formation of  the active conformation 
metarhodopsin II (Kobilka 2007).  
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1.2.4 G protein-dependent signalling 
 
One major feature of GPCRs is their ability to bind G proteins. Upon agonist 
activation, GPCRs undergo structural changes within their 7TM domain, 
which mainly affects the conformation of the ICLs, thus uncovering G protein 
binding sites within ICL2, 3 and 4 (Hamm 2001). It is thought that receptor 
activation leads to the formation of a ternary complex consisting of agonist, 
GPCR and G protein. However, many receptors activate G protein signalling 
in the absence of an agonist, thus are constitutively active (Gether 1998).   
Conventional G proteins are heterotrimeric proteins, consisting of a Gβ/γ-
heterodimer and a Gα-subunit that binds guanosine diphosphate (GDP) and 
guanosine triphosphate (GTP) and acts as a GTPase. GDP-bound Gα tightly 
binds to Gβ/γ, leading to cell membrane association of the G protein where it 
can couple a GPCR. The GPCR acts as a guanosine nucleotide exchange 
factor (GEF), inducing the release of GDP from Gα, followed by binding of 
GTP. This, however, induces conformational changes within Gα, leading to 
the dissociation of the Gβ/γ-dimer. Both subunits, GTP-Gα and Gβ/γ, may 
activate different downstream effectors. Once GTP is hydrolysed by Gα, 
downstream signalling is terminated, since inactive Gα-GDP binds again to 
Gβ/γ. The hydrolysis of GTP is regulated by RGS (regulator of G protein 
signalling) proteins (McCudden et al. 2005; Pierce et al. 2002).  
A variety of different Gα and Gβ/γ subunits have been identified, with 16 
human Gα-genes, 5 human Gβ-genes (Gβ1-5) and 12 Gγ-genes (Gγ1-12) 
resulting in a huge number of possible combinations for the Gβγ-dimer 
(McCudden et al. 2005). Some of the Gβγ-combinations preferably target 
specific GPCRs and specifically activate certain effector proteins. The 39-
45 kDa Gα-proteins consist of a nucleotide-binding domain with homology to 
Ras-like GTPases and an α-helical domain. They can be subdivided into four 
major classes: Gs, Gq, G12, Gi. Each of the classes is composed of specific 
isotypes showing a high degree of amino acid similarities, as shown in 
table 1.1 (Simon et al. 1991; McCudden et al. 2005).  
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Table 1.1 Classification of human Gα proteins. After Simon et al. (1991). 
G protein class Isotypes within the class 
Gs Gαs, Gαolf 
Gi  Gαi1, Gαi2, Gαi3, Gαo, Gαt1, Gαt2, Gαgust, Gαz 
Gq Gαq, Gα11, Gα14, Gα16 
G12 Gα12, Gα13 
 
 
The different Gα subfamilies also activate different downstream effectors 
such as second-messenger producing enzymes or ion channels. Adenylyl 
cyclase (AC) was the first recognized effector, activated by Gαs, whereas Gαi 
was later found to inhibit AC (Ross and Gilman 1977; Hildebrandt et al. 
1983). AC hydrolyses ATP to cAMP, which activates effectors such as 
protein kinase A (PKA) or Ca2+-channels. cAMP and Ca2+ are ubiquitous 
second messengers, involved in many physiological functions. Gαi proteins 
also activate mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3K), signalling pathways that are involved in 
cell growth, proliferation and survival (Fig. 1.3) (Leurs et al. 2005). 
Gα12/13 proteins regulate Rho-family guanine nucleotide exchange factors 
(Rho-GEFs) that activate small GTPases such as RhoA, Rac1, Ras or Cdc42 
by inducing the exchange of GDP to GTP. The small GTPases in turn 
activate a wide range of effector proteins which are mainly involved in the 
organisation of the actin cytoskeleton, including the formation of stress fibers 
or focal adhesion complexes. These processes play important roles for 
biological functions such as cell adhesion and migration. Moreover, signalling 
through the small GTPases is also involved in cell cycle progression, cell 
proliferation, apoptosis or oncogenic transformation (Fig. 1.3) (Sah et al. 
2000; Chiariello et al. 2010; Schwartz 2004). 
Gq proteins activate the β-isoforms of PLC (PLCβ) that hydrolyses 
phosphatidylinositol bisphosphate to the second messengers diacylglycerol 
(DAG) and inositol triphosphate (IP3). DAG activates protein kinase C (PKC) 
and IP3 mobilises Ca2+-release from intracellular stores (Mizuno and Itoh 
2009). Similar to Gα12/13, Gq proteins initiate RhoA signalling, which is 
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independent of PLCβ. However, Gq activates different Rho-GEFs than 
Gα12/13 proteins (Fig. 1.3) (Mizuno and Itoh 2009).  
 
 
 
Figure 1.3 Examples for G protein-dependent signalling. 
Following agonist activation, GPCRs can couple to different heterotrimeric G 
proteins, inducing the dissociation of the Gβγ-subunit and the activation of the Gα-
subunit. There are four different classes of Gα proteins (Gαs, Gαi, Gαq and Gα12) 
with varying signalling abilities. Typical Gαs-signalling involves activation of adenylyl 
cyclase (AC), which converts ATP to cyclic AMP (cAMP), a second messenger that 
activates protein kinase A (PKA); Gαi-signalling inhibits AC, leading to a decrease in 
intracellular cAMP levels. Gαi can also induce phosphoinositide 3-kinase (PI3K), 
leading to activation of the PI3K/Akt/mTOR pathway; Gαq activates PLCβ, which 
hydrolyses phosphatidylinositol bisphosphate (PIP2) to the second messengers 
inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 binds Ca2+-permeable 
channels located at the endoplasmic reticulum, increasing intracellular Ca2+-levels. 
DAG activates protein kinase C (PKC), which phosphorylates several intracellular 
targets. Gαq-signalling can also lead to Rho activation; Gα12 activates Rho 
GTPases, leading to structural rearrangements of the cytoskeleton. 
Taken from Lappano & Maggiolini (2011). 
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1.2.5 Desensitisation of G protein-dependent signalling 
 
G protein-dependent signalling through GPCRs can quickly be dampened by 
a process called receptor desensitization (Ferguson 2001; Lefkowitz 1998). 
Desensitization means the loss of responsiveness of the GPCR to an 
ongoing stimulus and serves as a regulatory mechanism to protect the cell 
against acute and chronic receptor overstimulation. The process is controlled 
through the phosphorylation of GPCRs by protein kinases such as the 
second-messenger kinases PKA and PKC or G protein-coupled receptor 
kinases (GRKs). These kinases phosphorylate serines and threonines within 
ICL3 and the cytoplasmic tail of GPCRs. 
Phosphorylation by second-messenger kinases represents a negative 
feedback-loop, which leads to the disruption of the GPCR-G protein 
interaction. Protein kinase-activation by one GPCR can lead to the 
phosphorylation and subsequent desensitisation of another GPCR (Pierce et 
al. 2002). Thus, second-messenger kinases can phosphorylate GPCRs 
independently of agonist activation (Ferguson 2001). However, specific 
phosphorylation can also lead to the generation of novel G protein binding 
sites allowing coupling to a different G protein. This was shown for the Gs-
coupled β2AR, where PKA-mediated receptor phosphorylation promotes Gi 
coupling, thus promoting the activation of a different signalling pathway 
(Pierce et al. 2002; Daaka et al. 1997). 
There are seven different GPCR kinases (GRKs) expressed in human, which 
are subdivided into three groups: the retinal enzymes GRK1 (rhodopsin 
kinase) and GRK7 (cone opsin kinase), GRK2 (βAR kinase-1, βARK1) and 
GRK3 (βARK2), GRK4 (expressed in testis) and the ubiquitously expressed 
GRK5 and GRK6 (Pitcher et al. 1998; Ferguson 2001). The phosphorylation 
of GPCRs by GRKs leads to the recruitment of arrestins. There are two 
groups of arrestins each consisting of two members: visual and cone arrestin 
(also called arrestin 1 and 4), as well as β-arrestin 1 and 2 (also called 
arrestin 2 and 3). Expression of visual and cone arrestin is restricted to the 
retina, whereas the β-arrestins are expressed ubiquitously with high 
expression levels in neuronal tissue and spleen (Craft et al. 1994; Attramadal 
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et al. 1992; Ferguson 2001). The interaction of arrestins with GPCRs 
desensitises the receptor as it sterically inhibits further G protein binding, 
thus terminating G protein-dependent signalling (Pierce et al. 2002). 
Depending on the GPCR, arrestin binding sites are located in one of the 
ICLs, as well as the cytoplasmic tail (Cen et al. 2001; Cheng 2000; Wu et al. 
1997; Krupnick et al. 1994; DeGraff et al. 2002). In rhodopsin-like receptors, 
the D(/E)RY motif located in ICL2 was shown to be involved in both G protein 
and arrestin binding (Marion et al. 2006; Barak et al. 1994).  
For a long time, the dogma existed that GRKs only phosphorylate agonist-
occupied GPCRs, leading to arrestin-recruitment (Oakley et al. 2001). 
However, GRKs can phosphorylate GPCRs in the absence of ligand 
stimulation, which is likely due to the constitutive activity of certain GPCRs 
that acquire an activated conformation in the absence of agonist (Ferguson 
2001). In general, arrestins preferentially bind to agonist-activated and GRK-
phosphorylated GPCRs and visual arrestin only binds GRK-phosphorylated 
rhodopsin (Gurevich et al. 1995). However, there are exceptions, where 
arrestins bind to agonist-activated, non-phosphorylated receptors, as well as 
unliganded, but phosphorylated GPCRs. Thus, GRK-phosphorylation 
increases the affinity of arrestins for the GPCRs, but more important than 
receptor phosphorylation is a conformational change of the receptor, 
promoting the interaction with arrestins (Marion et al. 2006; Oakley et al. 
2001). 
 
1.2.6 Internalisation of GPCRs 
 
Endocytosis or internalisation of GPCRs is a very important mechanism to 
regulate GPCR activity. GPCRs can internalise via multiple endocytic 
mechanisms and receptor internalisation rates, as well as their intracellular 
trafficking routes can vary enormously (Ferguson 2001). 
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1.2.6.1 Clathrin-dependent endocytosis 
 
The processes of GPCR desensitisation, including GRK phosphorylation and 
arrestin binding, are usually followed by GPCR endocytosis. Binding of β-
arrestins to GPCRs specifically targets them to endocytosis via clathrin-
coated vesicles, as shown for the β2AR and angiotensin II type 1A receptor 
(AT1AR) (Zhang et al. 1996). β-arrestins directly interact via their cytoplasmic 
tails with proteins required for the formation of clathrin-coated pits such as 
the major adaptor protein AP-2 and other components of this machinery 
(Goodman et al. 1997; Laporte et al. 1999; Laporte et al. 2000). Monomeric 
clathrin triskelia polymerise and form a coat around the vesicles (“vesicles in 
a basket”) by binding to the adaptor proteins, but never directly to the 
membrane or the receptor (Patel et al. 2008). Vesicle budding, the next stage 
of internalisation, is mediated by the GTPase-activity of dynamin, which is 
recruited to clathrin-coated pits (Fig. 1.4). However, dynamin action is not 
restricted to clathrin-coated vesicles (McMahon and Boucrot 2011; Henley et 
al. 1998). Finally, clathrin detaches from the vesicles and is recycled, 
whereas the vesicles fuse with early endosomes. 
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Figure 1.4 Clathrin-dependent endocytosis of GPCRs. 
The cytoplasmic tail and ICL3 of agonist-activated GPCRs are phosphorylated by 
GRKs, leading to binding of β-arrestin to the phosphorylated GPCR. β-arrestin 
recruits proteins of the clathrin endocytotic machinery, such as the adapter protein 
AP-2 and clathrin itself that bind to the GPCR and form an intracellular coat. Vesicle 
budding is followed by pinching off the vesicle, which is mediated by the large 
GTPase dynamin (not shown). 
AP-2, AP-2 heterotetrameric adaptor complex; βArr, β-arrestin; H, hormone; G, 
G protein; E, enzyme; GRK, GPCR kinase; P, phosphate group; ICL3, intracellular 
loop 3. Taken from Ferguson (2001). 
 
 
1.2.6.2 Clathrin-independent endocytosis 
 
Increasing evidence for β-arrestin- and clathrin-independent endocytosis of 
GPCRs was demonstrated more recently. These mechanisms may even 
apply for receptors that are usually internalised via clathrin, at least in the 
presence of a clathrin-inhibitor like a dominant-negative β-arrestin (Zhang et 
al. 1996). This indicates that some GPCRs can switch the mode of 
internalisation depending on the cellular environment. The best described 
alternative route for clathrin-independent endocytosis is internalisation via 
caveolae. Caveolae are flask- or omega-shaped membrane invaginations 
(“little caves”) with a diameter of 50-80 nm that can be detected using 
electron microscopy (Fig. 1.5).  
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Figure 1.5 Electron microscopy image of a caveola in pulmonary artery 
smooth muscle cells (8900x). 
Taken from Patel et al. 2008, modified. 
 
 
Caveolae are present in many but not all eukaryotic cells and are marked by 
the presence of integral membrane proteins belonging to the family of 
caveolins (cav-1, -2, -3) that serve as scaffolds. Caveolae are rich in 
hydrophobic cholesterols and glycosphingolipids and are detergent-resistant, 
thus called non-planar membrane (lipid) rafts (Patel et al. 2008; Kiss and 
Botos 2009). Caveolae form in golgi and traffick to the cell membrane, where 
they are anchored to the cytoskeleton by proteins like filamin (Tagawa et al. 
2005; Mundy et al. 2002), thus forming quite immobile structures. However, 
the interaction of cav-1/caveolae with a variety of proteins like receptor 
tyrosine kinases (RTKs), ion channels or GPCRs triggers their endocytosis. 
Caveolae budding and the release from the membrane is regulated by Src-
dependent caveolin tyrosine phosphorylation (Kiss and Botos 2009). 
Caveolins assemble in oligomers and form a cytoplasmic coat located on the 
invaginations. Similar to internalisation of clathrin-coated pits, dynamin is 
required for the fission of caveolae by constricting their necks (De Camilli et 
al. 1995). Once pinched off, caveolae are transported along microtubules into 
the cytoplasm. The actin cytoskeleton needs to be re-organised, as filamin 
physically prevents detachment of caveolae from the membrane (Parton et 
al. 1994). This is achieved by temporary actin depolymerisation (Pelkmans 
and Helenius 2002). 
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Caveolae do not exclusively play a role in GPCR endocytosis, but also for 
GPCR signalling. As part of membrane rafts, caveolae enrich components for 
GPCR signalling, including GPCRs and G proteins by directly interacting with 
them. Thus, caveolae bring GPCRs and their downstream effectors into close 
proximity, facilitating signalling (Patel et al. 2008; Ostrom and Insel 2004).  
 
1.2.6.3 Endosomal sorting 
 
Once internalised, the vesicles fuse with early endosomes and their GPCR 
cargo is sorted to different endocytic pathways. It was shown that members 
of the Rab family of small GTPases play important roles in vesicle budding at 
the cell surface, their transport and fusion with endosomes (Somsel Rodman 
and Wandinger-Ness 2000). Sorting has partially occurred already at the 
plasma membrane, as the fate of the GPCR may be influenced by post-
translational modifications including phosphorylation or ubiquitination, 
interactions with proteins such as β-arrestins and the “choice” of the 
endocytic machinery (e.g. clathrin-dependent/-independent) that can deliver 
the receptor to different endocytic vesicles (Hanyaloglu and von Zastrow 
2008). Nonetheless, the main sorting seems to occur in early endosomes, 
where interactions with adaptor proteins determine whether GPCRs are 
recycled or degraded (Hanyaloglu and von Zastrow 2008; von Zastrow 2003; 
Sorkin and Von Zastrow 2002). The two traffic routes lead to opposite 
receptor fates, as GPCRs targeted to lysosomes are typically degraded, 
whereas their recycling to the cell membrane leads to rapid receptor recovery 
(resensitisation) (Pierce et al. 2002; von Zastrow 2003). Additionally, 
evidence is accumulating for the initiation of new signalling pathways from 
GPCRs that remain intact in endocytic vesicles (Fig. 1.6) (Sorkin and von 
Zastrow 2009; Irannejad et al. 2013).  
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Figure 1.6 Sorting of endocytosed GPCRs. 
Internalised vesicles containing GPCRs fuse with early endosomes, in which 
GPCRs are sorted to different intracellular compartments. Sorting to multivesicular 
bodies (MVBs) and lysosomes leads to proteolytic degradation of the GPCR, 
whereas the receptor is recycled back to the cell surface, if sorted to recycling 
endosomes. In addition, intact GPCRs can induce signalling responses from the 
endosomes. Taken from Hanyaloglu & von Zastrow 2008, modified. 
 
 
For β-arrestin-dependent internalisation, it was shown that variations in the 
persistence of the GPCR-β-arrestin association affect their intracellular fate. 
Thus, some GPCRs such as the β2AR or β1BAR quickly dissociate from β-
arrestin near the cell membrane during endocytosis, are dephosphorylated in 
endosomes and recycle back to the cell surface. These GPCRs are called 
“class A” receptors. This nomenclature must not to be confused with the 
original A-F classification scheme regarding the different GPCR families, in 
which rhodopsin-like GPCRs were called “class A GPCRs” (Kolakowski 
1994). The class A and class B receptor nomenclature in the context of 
internalisation is independent of the GPCR family and does only refer to the 
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strength of the GPCR-β-arrestin interaction, which influences the fate of the 
endocytosed receptor. 
In contrast to β2AR or β1BAR, vasopressin receptor 2 (V2R) and the AT1AR 
internalise complexed with β-arrestin in endocytic vesicles, which prevents 
GPCR recycling. Instead, the GPCRs are retained in endosomes or targeted 
to lysosomes. These so called “class B” GPCRs usually contain a cluster of 
phosphorylated serines or threonines within their C-terminal tail, which 
reduces β-arrestin dissociation, preventing recycling (Oakley et al. 1999; 
Ferguson 2001; Hanyaloglu and von Zastrow 2008; Oakley et al. 2001).  
Moreover, the intracellular fate of a GPCR changes upon prolonged agonist-
stimulation, leading to down-regulation of recycled receptors (e.g. β2AR), 
contributing to loss of drug effectiveness (von Zastrow 2001). 
The receptor-bound ligand may dissociate from the receptor within 
endosomes, probably due to the acidic milieu with pH~5, followed by 
lysosomal degradation. This is also the case if receptor and ligand are 
transported to lysosomes as a complex. However, other ligands remain 
associated with the receptor and recycle back to the cell surface in a 
receptor-ligand complex, such as transferrin and its receptor (Goldstein et al. 
1985). 
 
1.2.7 G protein-independent signalling 
 
In addition to their role in desensitisation and internalisation of GPCRs, it is 
now appreciated that β-arrestins initiate GPCR signalling in their own right. β-
arrestins serve as scaffolds and adaptors, connecting the activated and 
endocytosed GPCR with different signalling pathways (Ferguson 2001; 
Lefkowitz and Shenoy 2005). This mainly accounts for class B GPCRs, since 
they show prolonged association with β-arrestins. 
The best-studied β-arrestin-dependent signalling mechanism following GPCR 
endocytosis is activation of mitogen-activated protein kinases (MAPKs). 
Receptor-bound β-arrestins can recruit and bind non-receptor tyrosine 
kinases such as c-Src, leading to the activation of a signalling cascade 
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involving MAP kinase kinase kinases (MAP3K such as Raf) that 
phosphorylate MAP kinase kinases (MAPKKs such as MEK) which in turn 
phosphorylate MAPKs such as extracellular signal-regulated kinases (ERK1 
and ERK2). In case of class B receptors that stably associate and 
endocytose with β-arrestins, ERK signalling persists for a longer period than 
in case of class A receptors, which only transiently interact with β-arrestins. 
In endocytic vesicles, β-arrestins serve as scaffolds for the components 
involved in ERK1/2 activation, which leads to the formation of a multiprotein 
complex consisting of the endocytosed GPCR, β-arrestin, Ras, MEK and 
ERK. This prevents the translocation of ERK1/2 to the nucleus, which inhibits 
cell proliferation, but enables ERK to phosphorylate cytosolic substrates, 
inducing protein-translation and anti-apoptotic signals (Ferguson 2001; 
Lefkowitz and Shenoy 2005) (Fig. 1.7).  
 
 
Figure 1.7 G protein- and β-arrestin-dependent signalling. 
Activation of GPCRs can lead to classical G protein-dependent signalling resulting in 
the production of second messengers, which induce cellular responses. Additionally, 
activated GPCRs are phosphorylated by GRKs and bind β-arrestins, which leads to 
receptor desensitisation, thus physically interrupting G protein-dependent signalling. 
Moreover, β-arrestins induce a couple of downstream signalling pathways in their 
own right and are also involved in receptor internalisation. 
GRK, GPCR kinase; MAPK, mitogen-activated protein kinase, PI3K, 
phosphoinositide 3-kinase, EGFR, epidermal growth factor receptor. 
Taken from Rajagopal et al. (2010). 
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Following the activation of the AT1AR, concurrent recruitment of β-arrestin 1 
and activation of Gαq/11 activates RhoA, which induces stress fiber formation 
(Barnes et al. 2005).  β-arrestins can also directly interact with the inhibitor of 
NF-κB, IκBα, as well as upstream kinases that regulate the activity of IκB, 
leading to the inhibition of NF-κB activity (Witherow et al. 2004). Stimulation 
of the β2AR enhances the interaction between β-arrestin 2 and IκB and in 
that way β2AR modulates NF-κB-dependent transcription (Gao et al. 2004). 
Additionally, activation of the Gi/o-coupled receptor GPR109A by nicotinic 
acid recruits β-arrestin 1, which binds and activates cytosolic phospholipase 
A2 (Walters et al. 2009; Reiter et al. 2012). 
In addition, there are biased ligands for GPCRs that either activate G protein-
dependent or β-arrestin-dependent signalling cascades such as ERK-
activation (Lefkowitz and Shenoy 2005; Rajagopal et al. 2010). 
 
1.2.8 EGFR transactivation 
 
Agonist-activation of GPCRs can lead to the activation of the ERK/MAPK 
signalling cascade by transactivating the epidermal growth factor receptor 
(EGFR), inducing cell proliferation (Daub et al. 1996). The crosstalk between 
GPCRs and EGFR occurs in non-transformed and transformed cells. It is 
implicated in processes such as fertilisation, neurogenesis, wound healing, 
heart development, but also in diseases such as cardiac hypertrophy and 
cancer, since it promotes cellular functions such as growth, survival, 
migration and metastasis (Lappano and Maggiolini 2011; Wetzker and 
Böhmer 2003). Activation of GPCRs leads to intracellular activation of 
metalloproteinases (MPs) which cleave membrane-tethered growth factors 
such as the epidermal growth factor (EGF), heparin-binding EGF (HB-EGF), 
transforming growth factor α (TGFα) or amphiregulin (AR), which activate the 
EGFR (Fischer et al. 2003; Prenzel et al. 1999). This mechanism is also 
called “triple-membrane-passing-signalling” (TMPS), since it involves three 
signalling steps passing the cell membrane (Wetzker and Böhmer 2003). 
Activation of the EGFR induces EGFR dimerization and intracellular tyrosine 
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auto-phosphorylation by the receptor’s intrinsic kinase activity. The protease-
activated receptor 1 (PAR1), the CXC chemokine receptor type 4 (CXCR4), 
AT1R, LPA receptors or the endothelian A subtype receptor (ETAR) all 
participate in this signalling pathway (Lappano and Maggiolini 2011). MPs 
cleaving the EGF-like ligands belong to the ADAM (a disintegrin and 
metalloproteinase) family of zinc-dependent proteases, with ADAM9, 10, 12, 
15 and 17 playing a role (Werb and Yan 1998; Ohtsu et al. 2006; Werry et al. 
2005). Knockout of ADAM17 in mice is embryonic lethal and resembles mice 
lacking EGFR or TGFα, as they share the same defects in maturation and 
morphogenesis of epithelial structures (Peschon et al. 1998). GPCR-
dependent EGFR transactivation can be mediated by both G protein- and β-
arrestin-dependent signalling. However, especially the signalling mediators 
downstream of the activated GPCR controlling MP activity are not well 
characterised (Fig. 1.8). 
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Figure 1.8 GPCR-dependent EGFR transactivation (“triple-membrane-passing-
mechanism”, TMPS). 
The agonist-activated GPCR binds G proteins and is phosphorylated by GRKs, 
leading to binding of β-arrestins. Second messengers and other signalling mediators 
activated by G proteins or β-arrestins induce ADAM-activation. The ADAM cleaves 
the membrane-tethered pro-EGF-like ligand leading to its release and interaction 
with the EGFR, which is activated by ligand binding. The downstream signalling 
mechanisms activated by the EGFR induce mitogenic and anti-apoptotic cellular 
signalling responses. 
 
 
Early investigations revealed that Gq-and Gi-coupled GPCRs transactivate 
EGFR in Cos-7 (Faure et al. 1994), HEK293, U373 glioblastoma cells and 
others (Gschwind et al. 2001). Later, G13-coupled receptors were identified 
(Gohla et al. 1998; Gohla et al. 1999), while Gs-coupled receptors cannot 
transactivate EGFRs (Gschwind et al. 2001; Fischer et al. 2003). In response 
to activation of the Gi-coupled α2AARs, the dissociated Gβγ-subunit activates 
c-Src, leading to shedding of HB-EGF by an unidentified ADAM (Pierce et al. 
2001). Induction of PLC-signalling through the Gq-coupled AT1R is required 
for ADAM17-dependent shedding (Mifune et al. 2005). PKC is well known to 
activate ADAM17 (Horiuchi et al. 2007; Kveiborg et al. 2011) and AT1R-
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dependent activation of HB-EGF shedding involves PKC and Src in particular 
cell lines (Shah et al. 2004). In addition, Ca2+ and reactive oxygen species 
(ROS) are good candidates for GPCR-dependent ADAM activation (Ohtsu et 
al. 2006). Activated LPA-receptors activate ADAM-dependent shedding 
through Ras/ERK-signalling (Umata et al. 2001). 
In contrast, the β1AR transactivates the EGFR in a β-arrestin dependent 
manner. In this model, β-arrestin binds the agonist-activated β1AR, recruits 
Src which in turn activates an ADAM, inducing cleavage of HB-EGF and 
activation of the EGFR (Noma and Lemaire 2007). More recently, it was 
demonstrated that GPCR-dependent EGFR transactivation can also occur in 
the absence of agonist, due to constitutive GPCR activity. A subtype of the 
α1A-AR constitutively transactivates EGFR through β-arrestin-coupling and 
ADAM12/matrix metalloproteinase 7 (MMP7) activation, leading to cell 
proliferation (Oganesian et al. 2011). 
Besides the triple-membrane-passing-mechanism of EGFR transactivation 
outlined above, there are also some examples for a mode of transactivation 
that is independent of ADAM-mediated EGFR-ligand shedding. In these 
cases, several GPCR signalling mediators such as Src, PKC, Ca2+, Ca2+-
regulated tyrosine-kinase Pyk2, Ca2+-calmodulin-dependent kinase II 
(CaMKII) or PI3K were identified (Fischer et al. 2003; Buchanan et al. 2003; 
Ohtsu et al. 2006). The exact mechanism of transactivation varies, but often 
involves phosphorylation and activation of the EGFR by Src tyrosine kinase 
(Werry et al. 2005). Moreover, a direct association between agonist-bound 
GPCRs and EGFRs leading to second-messenger independent 
transactivation was demonstrated for AT1R and β2AR (Maudsley et al. 2000; 
Seta and Sadoshima 2003). 
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1.2.8.1 A disintegrin and metalloproteinases (ADAMs) 
 
A disintegrin and metalloproteinases (ADAMs) are membrane-anchored zinc-
dependent proteases that belong to the group of adamalysin proteases, a 
family of the metzincin superfamily. The family of adamalysins also includes 
the secreted ADAM-TS (ADAMs with thrombospondin repeats) and class III 
snake venom metalloproteinases (SVMPs). Matrix metalloproteinases 
(MMPs) and membrane-type MMPs (MT-MMPs) represent further families 
within the metzincin clan (Fig. 1.9) (Murphy 2008; Hooper 1994). 
22 different ADAMs are expressed in human, some of them are 
predominantly found in the testis and others broadly in somatic tissues, such 
as ADAM17 (Wolfsberg et al. 1995; Seals and Courtneidge 2003; Edwards et 
al. 2008). 
 
 
 
Figure 1.9 Classification of zinc metalloproteinases. Taken from Murphy (2008). 
The zinc metalloproteinases comprise 3 superfamilies: the gluzincins, metzincins 
and aspzincins. The major families within the metzincin superfamily are the matrix 
metalloproteinases (MMPs), reprolysins (also known as adamalysins, including a 
disintegrin and metalloproteinases (ADAMs) and ADAMs with thrombospondin 
repeats (ADAMTS) proteins) and the astacins. 
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1.2.8.1.1 Structure of ADAMs 
ADAMs are multidomain proteins consisting of an extracellular prodomain, a 
metalloproteinase domain, a disintegrin domain, a cysteine-rich domain and 
an EGF-like domain, a transmembrane domain and a cytoplasmic domain 
(Fig. 1.10) (Edwards et al. 2008). 
 
 
 
Figure 1.10 Domain structure of the ADAM family. Taken from Murphy (2008). 
Pro, prodomain; MP, metalloproteinase domain; DIS, disintegrin domain; CR, 
cysteine-rich domain; EGF, EGF-like domain; TM, transmembrane domain; CD, 
cytoplasmic domain; HVR, highly variable region (within cysteine-rich domain).  
 
 
The prodomain keeps the metalloproteinase domain in an inactive state by 
interacting with the active site zinc ion within the catalytic cavity. During 
maturation in the golgi, the prodomain is cleaved and released from the rest 
of the protein, which activates the ADAM. The prodomain is required for 
proper folding of ADAMs and in its absence, catalytically inactive proteases 
are formed (Seals and Courtneidge 2003). 
The metalloproteinase domain is required for the main function of ADAMs, 
which is the proteolytic shedding of substrates. It comprises the active site, 
containing the zinc-binding consensus sequence HEXGHXXGXXHD, which 
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is characteristic for the superfamily of metzincins. 13 of 22 human ADAMs 
contain this catalytic site and are predicted to be proteolytically active, 
including ADAM10 and 17 (Edwards et al. 2008; Seals and Courtneidge 
2003). 
The disintegrin domain of ADAMs shows close homology to a domain 
found in snake venom metalloproteinases (SVMPs), which inhibits integrin-
mediated adhesion of platelets to fibrinogen via an Arg-Gly-Asp (RGD) 
sequence present in a disintegrin loop of SVMPs. However, most ADAMs, 
except ADAM15, lack the RGD sequence within their disintegrin domain, but 
contain the consensus motif CRXXXXXCDXXEXC, which is thought to 
enable binding to integrins (Edwards et al. 2008). 
Information on the function of the cysteine-rich and the EGF-like domains of 
ADAMs is scarce. It was proposed that those domains mediate adhesive 
interactions (Edwards et al. 2008; Gaultier et al. 2002; Iba et al. 2000). For 
ADAM10 and 17, the cysteine-rich domain is required for shedding activity 
(Gaultier et al. 2002), whereas the EGF-like domain is absent in ADAM10 
and 17 (Edwards et al. 2008).  
The cytoplasmic tails of ADAMs have variable length and sequences. They 
contain binding sites for Src-homology region 3 (SH3) domain-containing 
proteins and phosphorylation sites for serine/threonine or tyrosine kinases. 
Therefore, the cytoplasmic domain represents an important structure for the 
intracellular signalling function of ADAMs, as it defines interactions with 
adapter molecules and/or kinases (Poghosyan et al. 2002; Seals and 
Courtneidge 2003). 
 
1.2.8.1.2 Biological functions of ADAMs 
Ectodomain (ECD) shedding of membrane-tethered growth factors, 
cytokines, receptors and adhesion molecules was demonstrated for several 
ADAMs (Edwards et al. 2008). Shedding is an important mechanism for 
cellular signalling by either releasing soluble ECDs of cytokines and growth 
factors, which then stimulate cells in an autocrine or paracrine manner, or by 
reducing the amount of membrane-tethered proteins, thus decreasing cellular 
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responsiveness to selected stimuli (Hundhausen et al. 2003). Shedding 
activity is constitutive, but can also be induced by GPCRs, PKC or Ca2+ 
ionophores (Edwards et al. 2008). 
Due to the integrin binding function of the disintegrin domain, an adhesive 
function was described for many ADAMs (Schlöndorff and Blobel 1999). 
While family members such as ADAM17 and 10 act as sheddases, others 
remain “orphan proteases”, because of their unknown functions (Seals and 
Courtneidge 2003).  
Members of the ADAM family are involved in the regulation of many 
processes such as signal transduction, cell migration, fertilisation, cell-cell 
communication or cell adhesion (Black and White 1998). Dysregulation of 
their functions can lead to pathology, including Alzheimer disease, 
rheumatoid arthritis, asthma or cancer (Kodama et al. 2004; Seals and 
Courtneidge 2003; Edwards et al. 2008). 
 
1.2.8.1.3 ADAM17 
ADAM17 or tumour necrosis factor (TNF)-α-converting enzyme (TACE) was 
the first member of the ADAM family demonstrating shedding activity towards 
the EGFR ligand TNF-α and other substrates (Blobel et al. 1992; Black et al. 
1997). It was demonstrated that ADAM17 plays a role not only for the 
activation of TNF-α, but also for signalling through the EGFR during 
development. ADAM17 knockout mice die shortly after birth and have open 
eye lids, skin and hair abnormalities, as well as defects in epithelial 
maturation and in many other organs (Peschon et al. 1998). This phenotype 
closely resembles the phenotype of mice lacking EGFR or its ligands 
heparin-binding-EGF (HB-EGF), amphiregulin or transforming growth 
factor-α (TGF-α), which are also substrates of ADAM17 (Peschon et al. 1998; 
Blobel 2005; Sternlicht et al. 2005; Jackson et al. 2003). Further ADAM17 
substrates are L-selectin adhesion molecule, TNF receptor and the amyloid 
precursor protein (APP) (Peschon et al. 1998; Buxbaum et al. 1998). The 
identification of these substrates demonstrated that there is a high variability 
of sequences cleaved by ADAM17. 
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1.2.8.1.4 ADAM inhibitors 
The four natural tissue inhibitors of metalloproteinases (TIMP1-4) regulate 
ADAM activity by interacting with their catalytic domain. TIMPs also inhibit 
MMPs, but have greater selectivity towards ADAMs (Edwards et al. 2008). 
The hydroxamate-based compounds GI254023X, which preferentially blocks 
ADAM10 but not ADAM17, and GW280264X, which inhibits both ADAM10 
and 17, were used to demonstrate that ADAM10 is involved in the 
constitutive shedding of interleukin-6 receptor and the transmembrane 
chemokine CX3CL1 from the cell surface, whereas ADAM17 mediates 
phorbol-12-myristate-13-acetate (PMA)-stimulated shedding (Hundhausen et 
al. 2003; Ludwig et al. 2005). Synthetic ADAM inhibitors represent promising 
therapeutic agents for the treatment of different diseases. ADAM10 is 
involved in shedding of the human epidermal growth factor receptor 2 
(HER2) and is an interesting target for anti-cancer therapies. Several 
selective ADAM17 inhibitors are in clinical trials for the treatment of 
rheumatoid arthritis, since ADAM17 plays a central role in TNF-α shedding 
(Moss et al. 2008; Edwards et al. 2008). Another ADAM10/17 inhibitor was 
shown to reduce tumour growth by inhibiting the shedding of the EGFR 
ligands HB-EGF, amphiregulin and TGF-α (Fridman et al. 2007).  
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1.3 Adhesion GPCRs 
 
1.3.1 Structure of adhesion GPCRs 
 
The family of adhesion GPCRs (aGPCRs) is, with 33 members, the second 
largest family of GPCRs in the human genome and can be further subdivided 
into nine groups (I-IX), based on the phylogenetic relationship between the 
7TM-domains (Fig. 1.11) (Langenhan et al. 2013). Group I contains the 
lectomedin receptors (LEC1-3) that are often called latrophilins, group II 
contains the EGF-like module containing mucin-like receptors (EMR1-3), 
GPR127 and the cell differentiation antigen receptor (CD97), group III 
contains GPR123-125, group IV contains the cadherin, EGF LAG seven-pass 
G-type receptors (CELSR1-3), group V contains GPR133 and GPR144, 
group VI contains GPR110-116, group VII contains brain angiogenesis 
inhibitor receptors (BAI1-3), group VIII contains GPR56, GPR97, GPR112, 
GPR114, GPR126, GPR128 and human epididymal gene product 6 (HE6) 
and group IX consists of the very large GPCR (VLGR1) (Bjarnadóttir et al. 
2004; Lagerström and Schiöth 2008; Langenhan et al. 2013).  
Structurally, aGPCRs contain an unusually long extracellular N-terminus that 
is linked to the 7TM-domain via a GPCR proteolytic site (GPS)-containing 
stalk region. The long N-termini are often highly glycosylated and may 
contain structural motifs such as EGF-like, immunoglobulin-like, cadherin-
like, leucine-rich or thrombospondin-like repeats that are known to be 
involved in cell-cell contacts or cell-matrix adhesion. Therefore, aGPCRs 
likely play dual roles in adhesion and signalling (Fig. 1.11) (Yona et al. 2008; 
Araç, Boucard, et al. 2012). 
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Figure 1.11 Schematic representation of the extracellular N-terminal domains 
of the 33 human adhesion GPCRs as predicted by RPS-BLAST at NCBI.  
GPS, GPCR proteolytic site; domains: EGF, epidermal growth factor; HBD, 
hormone-binding domain; Ig, immunoglobulin; OLF, olfactomedin; GBL, galactose-
binding lectin; CA, cadherin; LamG, laminin G; LRR, leucine-rich repeats, SEA, sea 
urchin sperm protein, enterokinase and arginine; TSP, thrombospondin; PTX, 
pentraxin; Numbers at the end of N-termini indicate the number of amino acids 
found in the N-termini from the predicted start at TM1.  
Taken from Bjarnadóttir et al. (2004).  
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1.3.2 GPS cleavage and the GAIN domain 
 
The GPS domain was originally identified in the calcium-independent 
receptor of latrotoxin-1, called CIRL-1, latrophilin-1, CL-1 or LEC-2 
(Krasnoperov et al. 1999; Araç, Aust, et al. 2012). The GPS domain is 
located proximal to the first TM-helix, at the end of the N-terminal 
extracellular region and is ~40 aa long. It contains conserved cysteine and 
tryptophan residues and cleavage occurs between a leucine and a threonine, 
serine or cysteine residue (H-L|T/S/C) (Araç, Boucard, et al. 2012). Self-
catalytic (cis-autoproteolytic) GPS cleavage occurs early during GPCR 
biosynthesis in the endoplasmic reticulum (ER) and produces two 
independent proteins, an N-terminal and a C-terminal domain. Recent 
investigation of the aGPCRs latrophilin-1 and brain angiogenesis inhibitor 3 
(BAI3) revealed that the GPS motif is part of a larger domain, the GPCR-
Autoproteolysis INducing (GAIN) domain, previously called stalk region 
(Araç, Boucard, et al. 2012). It is now known that the GAIN domain is 
~320 aa long, conserved in all 33 human aGPCRs and five human polycystic 
kidney disease (PKD) proteins, 11-pass membrane proteins that are not 
GPCRs.  
Experiments with latrophilin-1 mutants showed that deletion of the GAIN 
domain except for the GPS motif abolishes autoproteolysis. Therefore, the 
GPS motif is not functional by itself and is probably unfolded when expressed 
in the absence of the GAIN domain. The presence of the entire GAIN domain 
is both required and sufficient for GPCR autoproteolysis (Araç, Boucard, et 
al. 2012). Despite the cleavage event, several aGPCRs, such as latrophilin-1 
and -3 or GPR56 were shown to remain associated as heterodimers at the 
cell surface, thus the N-terminal domain does not dissociate (Araç, Boucard, 
et al. 2012; Xu et al. 2006). The GAIN domain seems to play an important 
role in this process, since it forms non-covalent interactions with the 
secondary structure comprising the GPS cleavage site, generating a tightly 
associated heterodimer. In addition to its autoproteolytic functions, the GAIN 
domain can also serve as a ligand binding domain, as shown for the GAIN 
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domain of latrophilin-1 and its binding partner α-latrotoxin (Araç, Boucard, et 
al. 2012). 
Mutations within the GAIN domain of the transmembrane protein PKD1 
abolish autoproteolysis and cause autosomal-dominant polycystic kidney 
disease (ADPKD) (Qian et al. 2002). Mutations within the GAIN domains of 
aGPCRs are associated with a variety of diseases, including bilateral 
frontoparietal polymicrogyria (BFPP) for GPR56 (Piao et al. 2004), attention-
deficit/hyperactivity disorder for latrophilin-3 (Arcos-Burgos et al. 2010), 
Usher syndrome 2 for very large GPCR-1 (VLGR1) (Ebermann et al. 2009) or 
cancer for latrophilin-1/-3 and BAI3 (Kan et al. 2010). Cancer-inducing 
mutations in the GAIN domains of latrophilin-1 and -3 do not affect 
autoproteolysis or cell surface localisation. Thus, the cancer-mutations may 
interfere with other functions of the GAIN domain, such as the regulation of 
GPCR signalling through interaction of the GAIN domain with the 7TM-
domain or ligand binding (Araç, Boucard, et al. 2012; Araç, Aust, et al. 2012) 
 
1.3.3 Physiological functions of adhesion GPCRs 
 
1.3.3.1 De-orphanised adhesion GPCRs 
 
Most aGPCRs are still considered to be orphan GPCRs, which means that 
their ligand and physiological functions are unknown. The first de-orphanised 
aGPCR was CD97, which binds the complement regulatory protein decay 
accelerating factor (CD55 or DAF) (Hamann et al., 1996; Lin et al., 2001). In 
addition, CD97 and the closely related receptor EGF-like module containing 
mucin-like receptor protein 2 (EMR2) were found to bind the extracellular 
matrix (ECM) component chondroitin sulphate, a glycosaminoglycan (Stacey 
et al., 2003; Kwakkenbos et al., 2005). Latrophilin-1 binds the neurotoxin α-
latrotoxin (Krasnoperov et al. 1997) and a splice variant of the 
transmembrane protein teneurin-2, Lasso, its endogenous ligand in rat brain 
(Silva et al., 2011). Fibronectin leucine-rich repeat transmembrane protein 3 
(FLRT3) is an endogenous ligand for latrophilin-3 (Sullivan et al. 2012). BAI1 
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expressed on macrophages binds phosphatidylserine on apoptotic cells 
(Park et al. 2007). Finally, GPR56 binds tissue transglutaminase 2 (Xu et al. 
2006) and collagen III, components of the ECM (Luo et al. 2011). 
 
1.3.3.2 Adhesion GPCRs in immunology 
 
Several aGPCRs play active roles in the immune system. The EGF-7TM 
receptors CD97 and EMR1-4 are predominantly expressed in leucocytes and 
involved in several aspects of leucocyte development and activation, which 
play a role in the activation phase of an inflammatory response (Yona et al. 
2008). Whereas expression of EMR1 in human is restricted to eosinophils, 
EMR2-4 are more ubiquitously expressed in myeloid leucocytes such as 
monocytes, neutrophils, dendritic cells and macrophages. Additionally, CD97, 
the leucocyte activation antigen, is also expressed in smooth muscle cells, as 
well as activated T and B cells. Interactions of the closely related EMR2 and 
CD97 with chondroitin sulfate play a role in myeloid cell migration during 
inflammation, whereas binding of CD97 to CD55 co-stimulates T cells during 
the adaptive immune response (Yona et al. 2008; Yona and Stacey 2010). 
BAI1 is expressed on macrophages and binds phosphatidylserine on the 
plasma membrane of apoptotic cells. This interaction induces the clearance 
of apoptotic cells by phagocytosis, which occurs during the subsequent 
resolution phase of the inflammatory response (Park et al. 2007). Other 
aGPCRs are also expressed in leucocytes such as GPR56, which is found in 
CD56+ natural killer cells (NK cells) present in peripheral blood and inflamed 
tissues, as well as GPR97 in whole blood. Thus, it is likely that more 
aGPCRs play a role in immunology then previously appreciated (Della 
Chiesa et al. 2010; Yona et al. 2008). 
 
1.3.3.3 Adhesion GPCRs in embryonic developmental  
 
The most extensively studied aGPCRs in embryonic development are the 
members of the 7TM-cadherin subfamily (Celsr/Flamingo/Starry night). 
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CELSR1-3 are found in mammals, whereas Flamingo or Starry night is the 
CELSR1 homologue in Drosophila melanogaster. The extracellular domain of 
7TM-cadherins contains nine cadherin-repeats and a combination of EGF-
like and laminin G-like domains (Hulpiau and van Roy 2009). Studies of 
Drosophila embryogenesis showed that Flamingo is involved in the formation 
of the nervous system and in the regulation of tissue polarity, which is 
important during wing and eye development. Planar cell polarity (PCP) 
describes the coordinated polarity of cells or tissue, either with neighbouring 
cells or along an embryonic axis. Flamingo functions in the PCP-signalling 
cascade and a “Flamingo bridge” model was proposed, in which Flamingo 
senses activity of the GPCR Frizzled between neighbouring cells and acts 
with Frizzled to propagate polarising information (Yona and Stacey 2010; 
Lawrence et al. 2007). Latrophilins are structurally related to the 7TM-
cadherin family and studies in C.elegans revealed a role of latrophilin-1 in the 
generation of anterior to posterior cell polarity during embryogenesis 
(Langenhan et al. 2009). Analysis of Wnt/Frizzled-signalling in C.elegans 
embryos showed that multiple parallel Wnt signals are required for the 
transmission of the polarising information and latrophilin-1 might be involved 
in the propagation of these signals (Rocheleau et al. 1997; Schlesinger et al. 
1999). 
 
1.3.3.4 Adhesion GPCRs in the CNS 
 
In rodents, 17 out of 30 aGPCRs are expressed in the central nervous 
system (CNS) and investigations showed that BAI1-3, CELSR1-3, latrophilin-
1-3, VLGR1 and GPR56 play important roles in the CNS of mice and human 
(Yona and Stacey 2010). 
Whereas latrophilin-2 is expressed more ubiquitously, latrophilin-1 and -3 are 
predominantly expressed in the brain and are associated with synaptic cell 
adhesion and cell signalling in the CNS (Matsushita et al. 1999). BAI1-3 are 
almost exclusively expressed in embryonic and adult brain, where they are 
likely involved in angiogenesis and neuronal differentiation (Kee et al. 2004; 
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Koh et al. 2001). CELSR1-3 are expressed broadly within the developing 
CNS. CELSR1 is mostly found in the ventricular zone, whereas CELSR3 is 
expressed in the cortical plate. CELSR2 is found in the entire developing 
cerebral cortex (Shima et al. 2002). CELSR2 and 3 are activated through 
homophilic interactions and it was shown that they have opposite effects 
during neurogenesis. Whereas CELSR2 enhances neurite growth, CELSR3 
suppresses it (Shima et al. 2007). During embryonal neurogenesis, VLGR1 is 
strongly expressed in the CNS (Weston et al. 2004). VLGR1 is involved in 
the normal development of auditory hair bundles and mutations in VLGR1 
are associated with Usher syndrome 2, causing blindness and deafness 
(McMillan et al. 2002).  In brain, GPR56 is expressed in the cerebral cortex, 
ventricular and subventricular zones and rostral cerebellum during CNS 
development and mutations in GPR56 are associated with the brain 
malformation BFPP, which will be discussed in detail in a later chapter (Li et 
al. 2008; Koirala et al. 2009; Piao et al. 2004; Bai et al. 2009; Jeong et al. 
2013; Iguchi et al. 2008). 
 
1.3.4 Signalling by adhesion GPCRs 
 
The large amount of orphan receptors in the aGPCR family is one reason for 
the lack of evidence of G protein-dependent signalling. Another explanation 
is the complicated structure of aGPCRs, with their variable N-termini and the 
existence of two independent proteins upon GPS cleavage, which may 
interact independently of each other and may even cross-interact with other 
aGPCRs. The 7TM of latrophilin-1 interacts not only with its own N-terminus, 
but also with that of EMR2 or GPR56 (Silva et al. 2009). Thus, binding of α-
latrotoxin to the N-terminus of latrophilin-1 could activate GPR56-dependent 
signalling, indicating the complexity of aGPCR signal transduction (Yona and 
Stacey 2010). Finally, alternative splicing of aGPCRs, such as CD97, EMRs 
and GPR56 result in naturally occurring splice variants that may activate 
different downstream signalling pathways (Kwakkenbos et al. 2004; Kim et al. 
2010). 
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For some aGPCRs, G protein-dependent signalling was demonstrated. α-
latrotoxin binds to latrophilin-1, inducing Ca2+-signalling and transmitter 
release from synaptosomes. Latrophilin-1 associates with Gαo and Gαq and it 
is likely that it induces Gαq/Gβγ-dependent PLCβ activation, leading to Ca2+-
mobilisation and neurotransmitter release (Lelianova et al. 1997; Davletov et 
al. 1998; Rahman et al. 1999). Moreover, GPR56 forms a complex with the 
tetraspanins CD81/9 and Gαq and inhibits neural progenitor signalling via 
coupling to Gα12/13 leading to RhoA activation (Little et al. 2004; Iguchi et al. 
2008). On the other hand, BAI1, GPR124 and GPR125 interact with the PDZ 
(PSD-95, Dlg, ZO-1/2)-domains of intracellular proteins via an xTxV motif in 
their cytoplasmic tails, indicating G protein-independent signalling by 
aGPCRs (Lagerström et al. 2007; Shiratsuchi et al. 1998; Yona et al. 2008). 
Moreover, binding of phosphatidylserine to BAI1 induces the interaction of 
BAI1 with the ELMO1-DOCK180 (engulfment and cell motility 1 & dedicator 
of cytokines) complex and the small GTPase Rac, promoting phagocytosis of 
apoptotic cells (Park et al. 2007). 
 
1.3.5 Adhesion GPCRs in tumorigenesis 
 
Several aGPCRs are aberrantly expressed on cancer cells and involved in 
processes such as angiogenesis, migration and invasion. GPR124, a tumour 
endothelial marker, interacts with glycosaminoglycans (GAGs) and integrin 
αvβ3, mediating endothelial survival and tumour angiogenesis (Carson-Walter 
et al. 2001; Vallon and Essler 2006). EMR2 is overexpressed in invasive 
breast cancer cells (Davies et al. 2011) and mediates adhesion and migration 
in glioblastoma cells. High expression levels of EMR2 are correlated with 
poor overall survival in glioblastoma patients (Rutkowski et al. 2011). CD97 
expression at the front of many different cancer cells is associated with 
tumour invasion. Overexpression of CD97 promotes tumour growth in 
immunodeficient mice, stimulates cell motility, increases the 
metalloproteinase activity of MMPs and the secretion of chemokines. These 
effects can increase the invasion capacity of tumours (Galle et al. 2006). 
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Additionally, CD97 acts as a pro-angiogenic factor by interacting with 
α5β1/αvβ3 integrins on endothelial cells, which promotes endothelial cell 
migration and invasion (Wang et al. 2005). BAIs are involved in the regulation 
of brain tumour progression and BAI1 inhibits angiogenesis by binding αvβ5 
integrin on endothelial cells, inhibiting their proliferation (Nishimori et al. 
1997; Koh et al. 2004; Yona et al. 2008). BAI1 expression levels are 
decreased in glioblastoma and overexpression of BAI1 impairs glioma 
angiogenesis. Therefore, BAI1 represents a biomarker for high grade gliomas 
(Kee et al. 2004; Kaur et al. 2003). GPR56 is down-regulated in highly 
metastatic melanoma cells and its expression inhibits tumour growth and 
metastases, likely through interaction with TG2 (Xu et al. 2006; Yang et al. 
2014). However, GPR56 is overexpressed in glioblastoma and might 
promote cell adhesion and signalling (Shashidhar et al. 2005). The role of 
GPR56 in cancer will be discussed in detail in one of the following sections. 
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1.4 GPR56 
 
1.4.1 Expression of GPR56 
 
The Gpr56 gene (also called TM7XN1) consists of 14 exons, is located on 
chromosome 16q13 and was initially cloned by two groups that isolated the 
gene from a human heart cDNA library (Liu et al. 1999) and a human 
melanoma metastasis model (Zendman et al. 1999), respectively. The two 
identified genes are 98% identical, but differ by an insertion of six amino 
acids in ICL1 (Terskikh et al. 2001). Thus, Zendman et al. (1999) likely 
identified the natural occurring splice variant ∆430-35-GPR56, whereas Liu et 
al. (1999) isolated the gene encoding wild type GPR56.  
GPR56 is ubiquitously expressed in human tissues, with moderate mRNA 
expression levels in kidney, prostate, testis and weak expression in bladder, 
lung, thyroid gland, uterus and brain (Zendman et al. 1999). Liu et al. (1999) 
presented slightly different results with the highest expression of GPR56 
mRNA in thyroid gland and lower expression levels in brain, heart, kidney, 
pancreas, testis and skeletal muscle. Analysis of GPR56 protein expression 
revealed very low expression levels in human lung, liver and adult brain 
(Shashidhar et al. 2005). In mouse, high levels of GPR56 protein were 
detected in kidney and pancreas, medium levels in liver, spleen, ovary, 
uterus and brain and low levels in heart and lung (Huang et al. 2008). 
 
1.4.2 Structure of GPR56 
 
GPR56 full-length protein consists of 693 amino acids, with a molecular 
weight of ~75 kDa and has a predicted three-dimensional structure typical for 
aGPCRs (Fig. 1.12). During protein maturation, GPR56 is cleaved in the ER, 
resulting in an N- and C-terminal domain. Cleavage occurs at the GPS site 
between aa382/383 that is located within the GPS domain (aa343-394). The 
long, extracellular N-terminus (aa26-382) is highly N-glycosylated at seven 
Asn-residues and contains a serine, threonine, proline (STP)-rich domain 
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(aa108-177), forming a mucin-like stalk that is ~ 65 kDa in size. The C-
terminus consists of the 7TM-domains (aa383-657) and the short, 
cytoplasmic C-terminal tail (aa658-693), resulting in a ~25 kDa protein (Xu et 
al. 2006; Jin et al. 2007; Huang et al. 2008; Chiang et al. 2011).  
 
 
 
 
Figure 1.12 GPR56 gene and schematic protein structure. 
GPR56 consists of an N-terminal domain containing two partially overlapping ligand 
binding sites for collagen III and TG2, 7 N-glycosylation sites and the GPS motif that 
separates N-GPR56 from C-GPR56 upon cleavage. C-GPR56 consists of the 7TM-
domain and the short intracellular tail. 
Taken from Singer et al. (2012), modified. 
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1.4.3 GPR56 interaction partners and potential ligands 
 
Firstly, Little et al. (2004) reported the identification of the tetraspanins CD81 
and CD9, forming a membrane-spanning complex with GPR56 that 
intracellularly couples Gαq, without performing any signalling studies. Later, 
Xu et al. (2006) demonstrated the interaction of N-GPR56 with mouse tissue 
transglutaminase (mTG2), a component of the extracellular matrix. The TG2 
binding site was identified between aa107-177 of N-GPR56 (Yang et al. 
2011). However, a potential mechanism of signal transduction due to the 
GPR56-TG2 interaction was not presented. Yang et al. (2014) showed that 
GPR56 antagonises the tumorigenic effect of exogenous TG2 in melanoma 
MC-1 cells by GPR56-dependent internalisation of TG2, likely leading to 
lysosomal degradation of both GPR56 and TG2. Additionally, an unknown 
ligand was identified in the pial basement membrane (BM) of the developing 
mouse cerebral cortex and deletion of aa93-143 in an N-GPR56-Fc probe 
completely abolished ligand binding (Li et al. 2008). This ligand was identified 
as collagen III, another component of the ECM, present in the pial BM of the 
developing brain (Luo et al. 2011). Collagen III induces GPR56-dependent 
RhoA activation and inhibits migration of neural progenitor cells (NPCs) (Luo 
et al. 2011). Further analysis of the ligand binding site revealed that collagen 
III binds to aa27-160 within N-GPR56. In addition, an N-GPR56-Fc probe 
failed to bind to Col3a1-/- mouse brains, suggesting that the ligand of GPR56 
in brain is indeed collagen III (Luo et al. 2012). 
 
1.4.4 GPR56 in brain development 
 
Although many of the known aGPCRs are expressed in the central nervous 
system (CNS), GPR56 is the only one that was associated with a 
developmental brain malformation in humans, which is called bilateral 
frontoparietal polymicrogyria (BFPP). BFPP is caused by mutations in 
GPR56 and Gpr56 knockout mice display a similar cobblestone-like cortical 
malformation (Piao et al. 2004; Li et al. 2008; Bahi-Buisson et al. 2010). 
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BFPP is an autosomal-recessive hereditary disorder and the brains of 
patients are characterised by numerous, abnormally small gyri (folds) in the 
frontal and parietal lobes, as well as hypoplasia of cerebellum and pons (Piao 
et al. 2004; Li et al. 2008; Piao et al. 2005). BFPP patients show mental 
retardation, language impairment, motor development delay, seizures, ataxia 
and severe epilepsy (Chiang et al. 2011; Jin et al. 2007; Piao et al. 2004; Li 
et al. 2008).  
25 mutations within Gpr56 associated with BFPP were identified, including 
missense, splicing and frameshift mutations (Piao et al. 2004; Quattrocchi et 
al. 2013; Singer et al. 2012; Fujii et al. 2013). 18 mutations are located in 
extracellular domains, including the N-terminus, the GPS-domain and ECLs 
of the receptor and only 7 of them are found in the 7TM-region. Similar to the 
frameshift and splicing mutations, the missense mutations located in the 
extracellular domains of GPR56 cause BFPP, indicating loss-of-function of 
the mutant receptors (Ke et al. 2008; Bahi-Buisson et al. 2010; Singer et al. 
2012; Quattrocchi et al. 2013). The two missense mutations within the GPS-
domain, W349S and C346S, impair GPS-cleavage and cause a trafficking 
defect of GPR56, as the receptors largely remain in the ER (Jin et al. 2007; 
Ke et al. 2008). This indicates the importance of GPS-cleavage for GPR56 
trafficking, as shown for other aGPCRs (Krasnoperov et al. 2002), but it is not 
the general rule as evolutionary loss of the GPS cleavage site does not affect 
the function of aGPCRs belonging to the subfamilies of EMR, CELSR or BAI 
receptors (Prömel et al. 2012). Moreover, in contrast to BAI3 endogenously 
expressed in neurons, in HEK293 cells ectopically expressed BAI3 in not 
cleaved, but still efficiently transported to the cell membrane (Araç, Boucard, 
et al. 2012). However, the N-terminal GPR56 missense mutations (R38Q, 
R38W, Y88C, C91S) result in reduced cell surface expression caused by 
protein misfolding and impaired intracellular trafficking (Jin et al. 2007; 
Chiang et al. 2011).  
A crucial event for the development of a cobblestone cortex, as observed in 
BFPP patients, is a defective pial basement membrane (BM), a specialised 
extracellular matrix (ECM) overlying the surface of the developing brain. This 
is accompanied by abnormal neural migration. Although GPR56 expression 
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is almost undetectable in adult brain (Shashidhar et al. 2005), GPR56 is 
highly expressed in neural stem and progenitor cells, localised in the 
ventricular and subventricular zones of the developing mouse and human 
fetal brain (Piao et al. 2004; Iguchi et al. 2008; Bai et al. 2009). During 
development and differentiation, the neural stem and progenitor cells lose 
GPR56 expression (Bai et al. 2009). In mice, GPR56 is expressed at the cell 
surface of neural progenitor cells (NPCs) from embryonic day 13 till postnatal 
day 7 (Iguchi et al. 2008; Piao et al. 2004). GPR56 overexpression inhibits 
NPC migration from neurospheres. In NIH/3T3 cells, GPR56 overexpression 
induces Rho-dependent F-actin reorganisation and stress fiber formation. 
Additionally, GPR56 overexpression in HEK293 cells activates transcription 
through SRE- and NF-κB-responsive elements in a Gα12/13 and Rho-
dependent manner, which is elevated by treatment with anti-N-GPR56 
antibody (Iguchi et al. 2008). In summary, GPR56 negatively regulates 
migration of NPCs by activating Rho signalling via Gα12/13. 
During cortical development, NPCs migrate along radial glial fibers from the 
ventricular zone to the cortical plate, a process called radial migration. Thus, 
inhibition of NPC migration mediated by GPR56 might be involved in brain 
development, since terminating signals in radial migration are important for 
proper lamination of the cortex (Iguchi et al. 2008). 
The ECM component collagen III was identified as the major ligand for 
GPR56 in the developing mouse brain that is present in meningeal 
fibroblasts, the meninges and pial BM (Luo et al. 2011). Col3a1-/- mice 
develop cobblestone lissencephaly as observed in Gpr56-/- mice (Jeong et al. 
2012). Additionally, collagen III treatment inhibits migration of NPCs. 
Collagen III activates RhoA in a GPR56- and Gα12/13-dependent manner in 
NIH/3T3 cells and NPCs (Luo et al. 2011), similar to what was shown for the 
anti-N-GPR56 antibody (Iguchi et al. 2008).  
Taken together, GPR56 likely plays an important physiological role in the 
regulation of the pial BM integrity by binding collagen III in the ECM during 
cortical development, thus regulating the migration of NPCs and neurons.  
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1.4.4.1 GPR56 knockout mice 
 
Analysis of Gpr56-/- mice showed that loss of GPR56 expression results in a 
disruption of the pial BM accompanied by neuronal progenitors migrating 
through the breaches in the defective BM during early brain development, 
causing the cobblestone-like brain malformation observed in BFPP patients 
(Li et al. 2008). GPR56 is expressed in NPCs in murine fetal forebrain. Radial 
glial cells, a special type of neural progenitors, attach via their end feet to the 
pial BM. GPR56 is expressed at the cell surface of these end feet and binds 
to collagen III in the pial BM (Li et al. 2008; Luo et al. 2011). The defects in 
the pial BM observed in Gpr56-/- mice lead to an abnormal anchorage of the 
radial glial end feet that extend beyond the pial surface, which is 
accompanied by overmigrating neurons (Li et al. 2008). 
Analysis of the brain defects in adult Gpr56-/- mice revealed a malformation of 
the rostral cerebellum that becomes evident at perinatal age and only in 
regions where GPR56 is normally expressed (Koirala et al. 2009). At this 
stage of development, GPR56 expression is restricted to developing rostral 
granule cells, including precursors and young postmitotic neurons. Due to 
Gpr56 knockout, these cells lose the ability to adhere to ECM molecules such 
as laminin-1 and fibronectin, present in the pial BM. However, despite loss of 
GPR56 expression, granule cells show normal proliferation in vivo or 
migration and neurite outgrowth in vitro. As observed by Li et al. (2008), loss 
of GPR56 expression causes breaches in the pial BM, through which the 
granule cells migrate outward (Koirala et al. 2009).  
Defects in integrins and their ligand laminin are associated with pial BM 
breakdown and neuronal overmigration. Since rostral granule cells from 
Gpr56-/- mice lose the ability to adhere to laminin-1 (Koirala et al. 2009), 
Jeong et al. (2013) investigated a potential interaction between α3β1-integrin 
and GPR56. Loss of α3β1-integrin in NPCs attenuates the inhibitory effect of 
collagen III treatment on migration from neurospheres, similar to what was 
observed before in Gpr56-/- mice. Moreover, α3β1-/- Gpr56-/- double knockout 
mice display a more severe cortical phenotype than Gpr56-/- single knockouts 
with defects in the pial BM that appear earlier in development, suggesting a 
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potential interaction between the two cell surface receptors. GPR56 and 
α3β1-integrin colocalise in rostral granule cells and neurons, however, α3β1-
integrin does not bind directly to collagen III. Thus, GPR56 and α3β1-integrin 
function together in cortical development, likely via an unknown mediator 
(Jeong et al. 2013). 
The only phenotype in Gpr56-/- mice outside the CNS was reported by Chen 
et al. (2010), showing that GPR56 is involved in the regulation of mouse 
testis development and fertility. Interestingly, the authors reported that TG2 
co-localises with laminin-1 in mouse testes and that the distribution pattern of 
TG2 is altered in Gpr56-/- mice. However, Tg2-/- mice do not show any 
defects in testis development, indicating that TG2 might not be the ligand for 
GPR56 during testes development or that there is compensation by another 
ligand (Chen et al. 2010). 
 
1.4.5 GPR56 and cancer 
 
1.4.5.1 GPR56 as a tumour suppressor 
 
Zendman and colleagues (1999) originally isolated GPR56 from human 
melanoma cells where they demonstrated that GPR56 mRNA expression 
levels decrease with increasing potential of the melanoma cells to form 
metastases in the lung. This was later confirmed by Xu et al. (2006), showing 
down-regulation of GPR56 mRNA and protein in highly metastatic melanoma 
cells. Experiments using a xenograft tumour model indicated that 
overexpression of GPR56 in MC-1 melanoma cells results in reduced cell 
growth and fewer lung metastases. However, high GPR56 expression levels 
do not affect proliferation in vitro, suggesting that GPR56 interacts with a 
factor in the microenvironment in vivo, which was identified as TG2.  
However, Xu et al. (2010) themselves later demonstrated that GPR56 
actually does not influence endogenous melanoma progression by crossing 
Gpr56-/- mice with mice from a melanoma model expressing GPR56. In their 
study, all of the offspring (Gpr56+/+, Gpr56+/- and Gpr56-/- mice) develop 
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melanoma, but tumour progression does not differ among the animals. These 
results indicated that GPR56 has no effect on endogenous melanoma 
progression, which is in contrast to the results obtained with the xenograft 
tumour model (Xu et al. 2006).  
Nonetheless, analysis of tumour sections from MC-1 melanoma cells 
overexpressing GPR56 by Yang et al. (2011) showed reduced amounts of 
blood vessels and much lower vascular endothelial growth factor (VEGF) 
concentrations in cell supernatants when compared to vector control MC-1 
cells, thus expression of GPR56 inhibits melanoma angiogenesis. On the 
other hand, knockdown of TG2 by shRNA does not result in increased levels 
of VEGF in GPR56-positive MC-1 cells, indicating that TG2 does not mediate 
inhibition of VEGF secretion by GPR56 (Yang et al. 2011).   
A recent report by (Yang et al. 2014) confirmed previous observations made 
by Xu et al. (2006) regarding a reduction in tumour growth following the 
interaction of GPR56 with TG2. Injection of GPR56-overexpressing MC-1 
cells into Tg2+/+Rag2-/- mice results in reduced tumour weight when 
compared to control MC-1 cells (low endogenous GPR56 expression). 
Moreover, injection of TG2-ablated MC-1 cells into Tg2-/-Rag2-/- mice causes 
a reduction in tumour weight, indicating that TG2 itself promotes melanoma 
growth. The tumour weight is not further reduced, when TG2-ablated MC-1 
cells overexpressing GPR56 are injected into Tg2-/-Rag2-/- mice, indicating 
that TG2 mediates the inhibitory effect of GPR56. 
In addition to highly metastatic melanoma cells, GPR56 protein expression is 
down-regulated in human pancreatic cancer cell lines, despite high GPR56 
mRNA levels. The down-regulation, however, is not due to proteasomal 
degradation of GPR56, thus GPR56 expression is likely suppressed at the 
translational level (Huang et al. 2008). 
 
1.4.5.2 GPR56 as a tumour promoter 
 
GPR56 mRNA is up-regulated in human esophageal squamous cell 
carcinoma (ESCC) tissue and cell lines, whereas it is undetectable in normal 
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esophageal tissues (Sud et al. 2006). GPR56 protein expression is up-
regulated in human glioma tumours and cell lines (Shashidhar et al. 2005). In 
these cells, GPR56 is believed to play a role for cell adhesion, since it is 
expressed at the front of migrating cells. Moreover, GPR56 overexpression in 
HEK293 cells activates TCF (T-cell factor), PAI-1 (plasminogen activator 
inhibitor-1) and NF-κB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) responsive elements (Shashidhar et al. 2005), which is in 
line with the report from Iguchi et al. (2008). Kim et al (2010) demonstrated 
increased promoter activities of COX2 (cyclooxigenase 2), iNOS (inducible 
nitric oxide synthase) and VEGF genes following GPR56 overexpression. 
Moreover, GPR56 mRNA is up-regulated in many other cancer types outside 
the CNS such as ovarian, pancreatic, colon, breast, brain and non-small cell 
lung cancers, suggesting a general role of GPR56 in tumorigenicity (Ke et al. 
2007). GPR56 expression is also associated with the transformation 
phenotype in HeLa cells. ShRNA-mediated silencing of GPR56 in several 
cancer cell lines induces apoptosis, suggesting that GPR56 normally 
prevents intrinsic apoptosis of cancer cells.  Moreover, GPR56-silenced 
A2058 melanoma cells display impaired adhesion to fibronectin in vitro and 
partially dephosphorylated ERK, indicating a role for GPR56 in adhesion 
signalling (Ke et al. 2007). The same authors presented opposing results to 
Xu et al. (2006) regarding the effect of GPR56 expression on tumour 
progression, using a similar melanoma xenograft model. In their model, 
shRNA-mediated down-regulation of GPR56 in A2058 melanoma cells 
results in inhibition of tumour growth, demonstrating the oncogenic properties 
of GPR56 (Ke et al. 2007). This was also observed by others, when GPR56- 
and TG2-ablated MC-1 melanoma cells were injected into Tg2-/-Rag2-/- mice, 
leading to a complete inhibition of melanoma tumour growth. The result 
indicated that GPR56 itself has tumour promoting functions in the absence of 
TG2, as tumour growth is not entirely ablated when MC-1 control cells with 
low endogenous GPR56 expression and ablated TG2 expression are injected 
into the same mice (Yang et al. 2014).  
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The discrepancies between the different reports highlight that GPR56 is 
either a tumour suppressor or promoter and it is likely that additional ligands 
and therefore functions may be discovered in the future.  
 
1.4.6 GPR56 in immune cells 
 
GPR56 is a marker of cytotoxic natural killer cells (NK cells) and cytotoxic T 
lymphocytes (Della Chiesa et al. 2010; Peng et al. 2011). GPR56 expression 
is down-regulated upon activation of NK cells by cytokines such as 
interleukins. GPR56 down-regulation is regulated at the transcriptional level 
and does not include retention of the protein in the cytoplasm (Della Chiesa 
et al. 2010). The role of GPR56 in these cells remains completely unknown, 
however overexpression of GPR56 in a cytotoxic NK cell line reduces 
migration dramatically in vitro (Peng et al. 2011). Thus, GPR56 might 
regulate migration of cytotoxic lymphocytes, which would concur with reports 
on the regulation of migration in NPCs. 
 
1.4.7 The role of N-GPR56 in GPR56 activation 
 
Like other aGPCRs, GPR56 is cleaved into two independent proteins, N-
GPR56 and C-GPR56, which remain non-covalently associated at the cell 
surface (Xu et al. 2006; Jin et al. 2007; Huang et al. 2008). In addition to its 
ligand binding ability (Xu et al. 2006; Luo et al. 2011), several results 
indicated that N-GPR56 serves as an endogenous antagonist for C-GPR56. 
In contrast to wild type GPR56, overexpression of an N-terminal deletion 
mutant (“C-GPR56”) in MC-1 melanoma cells results in a significant induction 
of melanoma growth and angiogenesis in vivo, whereas addition of N-
GPR56-Fc reduces GPR56-dependent VEGF-production (Yang et al. 2011). 
These data indicated an antagonistic relationship between C- and N-GPR56, 
in which N-GPR56 inhibits GPR56 activity. Deletion of the TG2-binding site 
(aa108-177), a motif rich in serines, threonines and prolines (STP), results in 
induction of tumour growth and angiogenesis, indicating that the STP-region 
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is required for the inhibitory effect of N-GPR56. It was speculated that the 
deletion of the STP-domain results in a conformational change of N-GPR56, 
thus it is unable to inhibit GPR56 activity (Yang et al. 2011). 
Overexpression of another N-terminally truncated GPR56 mutant (“∆NT”) in 
HEK293 cells actives RhoA (Paavola et al. 2011). The high degree of GPR56 
ubiquitination, increased co-localisation with β-arrestin-2 and cytotoxicity is 
caused by prolonged expression of ∆NT. This was associated with high auto-
activity of truncated ∆NT, confirming the inhibitory function of N-GPR56.  
In a co-culture system, trans-trans N-terminal interactions (interactions of the 
same receptor type on adjacent cells) between full-length GPR56 expressed 
on the surface of HEK293 base cells and N-GPR56 or full-length GPR56 
expressed in the co-cultured HEK293 cells, induce GPR56-dependent Rho 
activation in the base cells. This result indicated that GPR56 trans-trans or 
potential ligand-GPR56 interactions could lead to the removal of N-GPR56 or 
induce a conformational change within N-GPR56, resulting in the activation 
of the receptor as seen with truncated ∆NT (Paavola et al. 2011). 
 
1.4.8 Natural splice variants 
 
Four natural splice variants of GPR56 were reported by Kim et al (2010). 
Variant 1, ∆430-35-GPR56, results from alternative splicing in exon 10 and 
lacks six amino acids in ICL1. Variant 2 is similar to ∆430-35-GPR56, but 
additionally contains five amino acids surrounding the region of the signal 
peptide cleavage site. Compared to wild type GPR56, overexpression of 
variant 1 and 2 in HEK293 cells increases SRE-mediated transcription, 
indicating that the 6 amino acid deletion in the first intracellular loop might 
facilitate activation of the Rho signalling pathway (Kim et al. 2010). Variant 3 
lacks 170 amino acids (∆38-208) within N-GPR56, but has an intact signal 
peptide and variant 4 lacks the first 175 amino acids (∆1-175) including the 
signal peptide. Overexpression of variants 3 and 4 result in reduced promoter 
activities, including the VEGF promoter (Kim et al. 2010). These findings 
contradict the hypothesis that N-terminal deletion mutants are constitutively 
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more active than wild type GPR56 (Yang et al. 2011; Paavola et al. 2011). 
However, folding and trafficking defects resulting in impaired cell surface 
expression levels might explain the result, as observed for BFPP-mutants 
(Jin et al. 2007) and another N-terminally truncated GPR56 variant before 
(Iguchi et al. 2008). 
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1.5 Transglutaminases 
 
Transglutaminases (TGs) are a family of structurally and functionally related 
proteins. The human genome encodes nine TGs that belong to the 
structurally related papain-like superfamily of cysteine proteases (Lorand and 
Graham 2003). Eight of the TGs found in man, TG1-7 and FXIIIa, are 
catalytically active (Lorand and Graham 2003; Thomas et al. 2013). One 
member of the TG family, erythrocyte band 4.2, is catalytically inactive and 
has scaffolding functions. Enzymatically active TGs catalyse a variety of 
post-translational protein modifications that are involved in biological 
processes such as blood coagulation or ECM assembly (Lorand and Graham 
2003). However, TGs also contribute to auto-immune reactions, where TG2-
modified gliadin peptides are immunogenic and cause coeliac disease (Sollid 
2002). 
The human TGs are expressed in different tissues and recognize various 
substrates for their enzymatic reactions. However, all catalytically active TGs 
require Ca2+ to perform post-translational protein modifications. Interestingly, 
even extracellular TGs such as FXIIIa and TG2 lack a signal sequence and it 
remains elusive how they are secreted (Aeschlimann and Paulsson 1994).  
The human TGs share a high degree of sequence conservation and they all 
have a similar tertiary structure consisting of 4 domains: the N-terminal β-
sandwich, the α/β-catalytic core and the C-terminal β-barrels 1&2 (Fig. 1.13). 
All of the catalytically active TGs share a common catalytic site containing a 
catalytic triad (Cys-His-Asp). In addition, TG1 and FXIIIa exist as pro-
enzymes with an N-terminal sequence that is cleaved to generate active 
enzymes (Fig. 1.13 A) (Iismaa et al. 2009). 
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Figure 1.13 Genomic organisation, protein domains and tertiary structure of 
human TGs. 
(A) FXIIIa and TG1 consist of 15 exons (numbered) and 14 introns, whereas exon 1 
is non-coding and exon 2 encodes an N-terminal pro-peptide. TG2-7 and 
erythrocyte band 4.2 consist of 13 exons and 12 introns. All TGs are composed of 4 
structural domains: N-terminal β-sandwich, α/β-catalytic core and β-barrels 1&2. 
(B) Crystal structure of GDP-bound TG2.  
Orange, α1B-adrenergic receptor binding site; red, phospholipase Cδ1-recognition 
domain; balls and sticks, catalytic residues (Cys277, His335, Asp358) and key GTP-
binding residues (Phe174, Arg478, Val479, Arg580,Tyr583). 
Taken from Lorand & Graham (2003) and Iismaa et al. (2009), modified. 
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1.6 Tissue transglutaminase (TG2) 
 
1.6.1 Expression of TG2 in the human body 
 
The TGM2 gene is localised on chromosome 20q11-12 and encodes an 
~80 kDa protein. In contrast to the other TGs that show a restricted 
expression pattern in specific organs and tissues, TG2 is ubiquitously 
expressed is the human body. However, its physiological role remains 
elusive (Lorand and Graham 2003). TG2 is expressed in cells of different 
lineages including mesenchymal, epithelial and hematopoietic and is 
constitutively expressed in endothelial cells, smooth muscle cells and 
fibroblasts (Iismaa et al. 2009). TG2 localises intracellularly in the cytoplasm, 
nucleus and mitochondria, as well as extracellularly in the ECM or at the cell 
surface in association with the ECM (Nurminskaya and Belkin 2012).  
Amino acid sequence alignments of all human TGs revealed a close 
relationship between TG2, TG3, TG5, TG6, TG7 and band 4.2, which belong 
to one phylogenetic lineage (Grenard et al. 2001). TG2 was the first 
recognized member of the TG family (Sarkar et al. 1957). 
 
1.6.2 Enzymatic activities of TG2  
 
Like other members of the TG family, TG2 catalyses several post-
translational modifications of proteins, which are Ca2+- and thiol-dependent. 
Essential for the reactions is the presence of the catalytic triad located within 
the catalytic core domain, consisting of Cys277, His335 and Asp358, as well as 
two stabilizing tryptophans (Iismaa et al. 2009; Lorand and Graham 2003). 
The three main reactions catalysed by TG2 will be briefly explained in the 
following section: transamidation, hydrolysis and esterification. All of these 
reactions involve an initial acylation step, where a Gln-containing peptide or 
protein, the first substrate, reacts with the active site Cys of TG2. As a result, 
the substrate is covalently bound to the active site Cys, forming a γ-
glutamylthioester, known as the acyl-enzyme intermediate (Fig. 1.14). This 
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initial step is followed by the nucleophilic attack of the thioester bond by a 
second substrate, leading to the cleavage of the thioester bond of the 
intermediate. Depending on the nature of the second substrate, the following 
step may be a transamidation (amine attacks) or esterification (alcohol 
attacks) reaction. In the absence of a second substrate, water can drive a 
hydrolysis reaction (Fig. 1.15).  
If the amino-group of a Lys within another protein (second substrate) serves 
as the attacking nucleophile, a transamidation reaction occurs. The most 
important and best studied transamidation reaction is protein cross-linking 
(Fig. 1.14 & 1.15). During the reaction, the Gln of the first substrate is cross-
linked to the Lys of the second substrate, forming an Nε(γ-glutamyl)lysyl 
isopeptide bond (Iismaa et al. 2009). The crosslinking reaction is unique for 
the family of TGs (Lorand & Graham, 2003; Pinkas et al. 2007). Another 
transamidation reaction is amine incorporation into the Gln of the first 
substrate (Fig. 1.15).  
Esterification of the Gln in the first substrate occurs if a suitable alcohol 
serves as the second substrate. Hydrolysis reactions occur in the absence of 
a second substrate and result in the replacement of the –NH2 group of Gln in 
the first substrate by an –OH group. This hydrolysis reaction is called 
deamidation and converts the Gln into a Glu. Peptides present in glutenins 
and gliadins, two major components of wheat gluten proteins, which are 
deamidated by TG2, are the dominant epitopes for activating T cells and 
cause coeliac disease (Lorand and Graham 2003; Sollid 2002). Hydrolysis 
can also follow the crosslinking of two peptides and reverse the crosslinking 
reaction by cleavage of the isopeptide bond. (Fig. 1.15) (Iismaa et al. 2009; 
Lorand and Graham 2003). 
. 
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Figure 1.14 Mechanism of post-translational protein modifications catalysed 
by TG2.  
The initial acylation step is similar for all post-translational modifications catalysed 
by TG2 and involves the reaction of a Gln-containing first substrate with TG2. The 
reaction results in the formation of a covalent bond between the substrate and the 
TG2 active site Cys, forming a γ-glutamylthioester, the acyl-enzyme intermediate. 
The following reactions depend on the nature of nucleophile donor that is present, in 
this case a Lys-containing second substrate. Nucleophilic attack of the thioester 
bond of the acyl-enzyme intermediate by the amine group of the Lys results in 
cleavage of the thioester group. This causes the release of the crosslinked product, 
followed by regeneration of TG2. Taken from Iismaa et al. (2009), modified. 
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Figure 1.15 Reactions catalysed by TG2. 
The three main categories of Ca2+-dependent post-translational modifications 
catalysed by TG2 are transamidation reactions including protein crosslinking (a), 
amine incorporation (b) and acylation (c); esterification reactions (d); hydrolysis 
reactions including deamidation (e) and isopeptidase cleavage (f). The type of 
reaction that is catalysed by TG2 depends on the nature of the nucleophile donor.  
Blue rectangle, first substrate containing acceptor-Gln; purple ellipse, second substrate with 
Lys donor residue; R, side chain of a primary amine; R’, Gln-containing peptide; 
R’’, a ceramide (sphingolipid); R’’’ & R’’’’, side chains in branched isopeptides. 
Taken from Lorand & Graham (2003), modified. 
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1.6.3 Biological functions of TG2-mediated transamidation 
 
TG2 catalyses the formation of intra- and intermolecular crosslinks. 
Extracellular TG2 generates intramolecular crosslinks that mainly affect 
protein conformations and interactions (Nemes et al. 2009). Intermolecular 
crosslinking of ECM proteins such as fibronectin, collagen or fibrinogen leads 
to the formation of covalently linked, highly stable polymers (Barsigian et al. 
1988; Collighan and Griffin 2009). TG2 also crosslinks itself to these ECM 
proteins (Barsigian et al. 1991). Crosslinking of ECM proteins contributes to 
the stabilisation and the resistance of the ECM to proteolytic degradation. In 
addition, it unmasks binding sites for cell surface receptors such as integrins, 
promoting cell-ECM adhesion (Belkin et al. 2005).  
ECM crosslinking plays an important role in the process of wound healing 
and angiogenesis (Aeschlimann and Thomazy 2000; Iismaa et al. 2009; 
Nurminskaya and Belkin 2012). However, inappropriate crosslinking of the 
ECM by TG2 leads to fibrosis (Jones et al. 2006).  
Intracellularly, protein crosslinking is involved in apoptosis. Moreover, 
cytosolic TG2 stimulates inflammation by crosslinking IκBα, resulting in the 
activation of NFκB signalling (Iismaa et al. 2009). 
Amine incorporation to small GTPases such as RhoA, Rab4A, Rab3A, 
Rab27a or Rac1 by intracellular TG2 was shown to alter their activities. In 
case of RhoA, this modification leads to its constitutive activation and 
enhanced degradation, which activates AKT1 and inhibits contractility in 
vascular smooth muscle cells (Guilluy et al. 2007). 
 
1.6.4 Regulation of the transamidation activity 
 
The transamidation activity of TG2 is Ca2+-dependent. Activation of TG2 by 
Ca2+-binding, however, is inhibited by binding of GTP to TG2 and vice versa. 
Intracellularly, GTP concentrations are high and Ca2+-concentrations are low, 
thus TG2 is bound to GTP and exists in a compact, “closed” conformation, 
with the active site buried (Fig. 1.16 A).  
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In the closed conformation, TG2 acts as a G protein, but lacks 
transglutaminase activity (Nakaoka et al. 1994). Activation of TG2 requires 
the binding of at least two Ca2+-ions, inducing a large conformational change 
of the enzyme by moving the two β-barrels away from the catalytic core (Fig. 
1.16 B) (Pinkas et al. 2007). 
 
 
 
 
Figure 1.16 Crystal structures and schematics of TG2 closed and open 
conformations. 
(A) GDP-bound, “closed”, catalytically inactive conformation of TG2. 
(B) Inhibitor-bound, catalytically arrested, “open” conformation of TG2. Accessible 
motifs that were buried in the closed conformation are marked red in the schematic. 
(C) Conformational change during enzymatic activation of TG2. 
Blue, N-terminal β-sandwich; green, catalytic core domain; yellow, C-terminal β-
barrel 1; red, β-barrel 2. 
Taken from Pinkas et al. (2007), modified. 
 
 
It is thought that TG2 can be activated intra- and extracellularly upon 
increased Ca2+-levels (Pinkas et al. 2007). Although extracellular Ca2+-
concentrations are relatively high under normal physiological conditions, 
extracellular TG2 is mostly inactive. Therefore, it was investigated how TG2 
activity is regulated.  Pinkas et al. (2007) speculated that externalised TG2 
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remains in a closed, inactive conformation, which results from guanine 
nucleotide- and/or integrin-binding. Chemical injury however, might activate 
TG2 rapidly. Others showed that the oxidative state of the extracellular milieu 
regulates TG2 activity, as oxidation leads to disulphide bond formation and 
TG2 inactivation (Stamnaes et al. 2010). Moreover, it was speculated that 
Ca2+ is not the only trigger for TG2 activation and there might be additional 
factors such as conformational changes due to interacting proteins on the cell 
surface and in the ECM that stabilize TG2 in an active conformation 
(Nurminskaya and Belkin 2012). 
In addition, it remains elusive as to which conformation Ca2+-activated TG2 
acquires, due to the lack of a crystal structure of the Ca2+-bound form (Király 
et al. 2011). The inhibitor-bound, open conformation was presented as the 
prototypical structure of catalytically active TG2 (Pinkas et al. 2007), but 
others speculated that it might represent one of the transition states occurring 
during the enzymatic reaction (Király et al. 2011). 
 
1.6.5 TG2 as a GTPase and G protein  
 
Besides the enzymatic functions described above, TG2 can act as a GTPase 
by hydrolysing GTP, which is independent of its transamidating activity 
(Achyuthans and Greenberg 1987). Intracellular TG2 functions as a Gα 
protein and mediates GPCR signalling by coupling to several GPCRs such 
as α1B- and α1D-ARs, thromboxane A2, oxytocin and follicle stimulating 
hormone receptors, where it induces PLC signalling (Nakaoka et al. 1994; 
Chen et al. 1996; Nurminskaya and Belkin 2012). However, TG2 shows no 
structural homology to the Gα subunits of other heterotrimeric G proteins or 
small GTPases. Whereas Gαq proteins induce PLCβ-signalling, TG2 
specifically interacts with PLCδ1 (Nakaoka et al. 1994; Kang et al. 2002). The 
Ca2+-binding protein calreticulin acts as the Gβ-subunit for intracellular TG2 
and inhibits the GTPase- and transamidating-activities of TG2 by keeping the 
protein in its inactive, GDP-bound conformation, ready for the initiation of 
GPCR signalling. Intracellular TG2 is activated and deactivated similar to Gα 
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subunits of heterotrimeric G proteins (Mhaouty-Kodja 2004). The agonist-
activated GPCR induces the exchange of GDP to GTP and TG2 dissociates 
from calreticulin (Gβ). TG2 is deactivated by GTP-hydrolysis and 
reassociates with calreticulin  (Nurminskaya and Belkin 2012).  
In its function as a GTPase, TG2 is involved in several other signalling 
pathways. α1-AR dependent activation of intracellular TG2 induces 
hypertrophy in cardiomyocytes by inducing ERK signalling (Lee et al. 2003) 
and proliferation in hepatocytes (Wu et al. 2000). Intracellular TG2 can 
promote or inhibit cell migration. GTPase activity of TG2 promotes cell 
migration of fibroblasts by activating PKCα signalling and phosphorylation of 
focal adhesion kinase (FAK), which is required for the turnover of focal 
adhesions (Stephens et al. 2004). On the other hand, the α1B-AR-induced 
interaction of intracellular TG2 with the cytoplasmic tails of integrins inhibits 
migration of smooth muscle cells (Kang et al. 2004).  
Although the GTPase activity of TG2 was shown to activate several signalling 
pathways, their pathophysiological implication remains elusive. However, 
signalling mediated by intracellular TG2 seems to have rather pro-survival 
effects, since the GTPase activity of intracellular TG2 protects NIH/3T3 and 
HeLa cells against apoptosis (Datta et al. 2007). 
 
1.6.6 Non-enzymatic functions of extracellular TG2 and their 
physiological roles 
 
Besides ample enzymatic functions, several non-covalent interactions with 
numerous binding partners in the nucleus, cytoplasm, cell surface and ECM 
have been identified that promote signalling and/or adaptor/scaffolding 
functions of TG2. Often, these interaction partners also serve as 
transamidating substrates for TG2. 
Extracellular TG2 interacts with matrix metalloproteinase 2 (MMP2) and cell 
surface receptors such as integrins, syndecan-4, platelet-derived growth 
factor receptor, GPR56 and others (Belkin et al. 2004; Akimov et al. 2000; 
Zemskov et al. 2009; Xu et al. 2006).  
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In addition to stabilising the ECM by crosslinking, extracellular TG2 also 
interacts with the ECM independently of its enzymatic functions. Thus, TG2 
interacts with fibronectin (FN) (Turner and Lorand 1989), mediating the 
assembly of FN fibrils, which does not require TG2’s transamidating activity, 
but promotes the deposition of soluble FN into the ECM (Akimov and Belkin 
2001). Moreover, TG2 acts as a bridge between integrins and FN, promoting 
cell-ECM adhesion and cell migration (Akimov et al. 2000; Zemskov et al. 
2006). Independently of FN, TG2-integrin complexes enhance the formation 
of focal adhesion complexes and stress fibers by activating FAK, as well as 
RhoA. Taken together, the TG2-integrin interactions affect cellular processes 
including adhesion, migration and spreading (Stephens et al. 2004; 
Nurminskaya and Belkin 2012). 
 
1.6.7 TG2 and cancer 
 
The role of TG2 in cancer progression is controversial and there are several 
reports demonstrating either down- or up-regulation of TG2 in this process 
(Kotsakis and Griffin 2007; Mehta et al. 2010). It was shown that TG2 is 
down-regulated in primary tumours from breast (Ai et al. 2008), liver (Barnes 
et al. 1985) and prostate (Birckbichler et al. 2000) and that its expression 
level and activity decrease with tumour progression. In breast cancer, the 
expression of TG2 might be reduced by epigenetic gene silencing in primary 
tumours (Ai et al. 2008). Down-regulation of TG2 promotes matrix 
destabilisation and degradation, which is accompanied with tumour cell 
invasion. In secondary metastatic tumours, however, TG2 is highly 
overexpressed and promotes cell survival (Kotsakis and Griffin 2007). 
In contrast, analysis of drug-resistant cancer cells obtained from 
glioblastoma, melanoma, as well as breast, lung, pancreatic and ovarian 
carcinoma show increased TG2 expression levels (Han and Park 1999; 
Mehta 1994; van Groningen et al. 1995; Mehta et al. 2010). Cells derived 
from metastases show even higher TG2 expression levels when compared to 
their primary tumours. It is believed that TG2 expression levels positively 
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correlate with the potential of tumours to metastasise (Mehta et al. 2010; 
Chen et al. 2002).  
The resistance of cancer cells to apoptosis is a property that allows them to 
metastasise and to develop drug-resistance (Kerbel et al. 1994). Increased 
expression of TG2 can prevent apoptosis and prolong cell survival. TG2 
down-regulates the tumour suppressor protein phosphatase and tensin 
homolog (PTEN) and constitutively activates the pro-survival factors NF-κB 
and Akt, which is associated with cancer progression, including 
chemoresistance and metastasis (Wang et al. 2012; Mann et al. 2006; Verma 
and Mehta 2007; Cao et al. 2008). Down-regulation of TG2 by siRNA or 
inhibition of TG2 by small molecule inhibitors in various cancer cell types 
increases their sensitivity to chemotherapeutics and inhibits invasion in vitro 
and in vivo (Verma and Mehta 2007).  
Integrins influence the ability of cells to proliferate, migrate and undergo 
apoptosis and mediate processes such as invasion and metastasis (Giancotti 
and Ruoslahti 1999). TG2 associates with β1, β3 and β5 integrins, which 
enhances the adhesion of ovarian cancer cells to FN and induces directional 
migration of these cells, promoting cell invasion (Satpathy et al. 2007). 
Moreover, TG2 up-regulates anti-apoptotic and pro-survival signalling 
pathways, rendering cancer cells drug-resistant (Mehta et al. 2010). Thus, 
association of TG2 with integrins increases binding of breast cancer cells to 
FN, leading to FAK-activation, which initiates downstream signalling by 
PI3K/Akt, Ras/Erk or Crk/Dock180/Rac. These downstream pathways are 
pro-survival and increase the invasive properties of cancer cells (Mehta and 
Eckert 2005; Levental et al. 2009).  
 
1.6.8 TG2 knockout mice 
 
Despite numerous cellular functions of TG2, Tg2-/- mice are viable and 
develop and reproduce normally. The ECM structure and composition, as 
well as the onset of apoptosis are unaltered (De Laurenzi and Melino 2001). 
The lack of a lethal phenotype can be partially explained by compensation of 
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TG2 functions by other TGs. However, clearance by phagocytosis seems to 
be altered in the thymus and the liver in these mice and they develop 
inflammatory and autoimmune reactions (Szondy et al. 2003). In the late 
phase of apoptosis, crosslinking by TG2 normally stabilizes the structure of a 
dying cell prior to phagocytosis, preventing the release of intracellular 
components and inflammatory responses (Chhabra et al. 2009). Moreover, 
Tg2-/- mice display defects in wound healing, which is associated with 
impaired adherence of fibroblasts to the ECM (Nanda et al. 2001). Tg2-/- 
mouse embryonic fibroblasts show impaired cell migration, which can be 
partially rescued by addition of exogenous TG2, confirming the critical role for 
extracellular TG2 in wound repair (Mehta and Eckert 2005; Telci and Griffin 
2006). 
Studies with Tg2-/- mice have also shown that TG2 activity contributes to the 
autosomal-dominant neurodegenerative disorder Huntington’s disease (HD). 
HD is associated with extensive apoptosis of neuronal cells in the cerebral 
cortex, resulting in progressive motor dysfunction and dementia. The disease 
is caused by the expansion of CAG repeats, encoding glutamine, within the 
gene encoding the cytosolic protein huntingtin (htt) (MacDonald et al. 1993). 
Originally, insoluble aggregates of htt proteins, which result from non-
covalent hydrogen bond interactions, were thought to cause HD (MacDonald 
et al. 1993). However, more recently it was shown that the soluble complexes 
of mutant htt are neurotoxic (Ruan and Johnson 2007). Crossing of Tg2-/- 
mice and HD R6/1 transgenic mice resulted in reduced cell death and 
improved motor function, but increased formation of htt aggregates, 
indicating that TG2 might inhibit aggregate formation (Mastroberardino et al. 
2002). Therefore, it was suggested that TG2 increases the formation of 
soluble high-molecular weight htt complexes, which cause HD, by 
crosslinking insoluble, poly-glutamine htt-aggregates, thus increasing their 
solubility (Lai et al. 2004).  
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1.7 Glioblastoma multiforme  
 
Glioblastoma multiforme (GBM) is the most aggressive and most common 
type of primary brain tumour in humans. The origin of the cells that give rise 
to glioblastomas is still under investigation. However, it was proposed that 
neural stem and progenitor cells can transform into glioblastoma cells, as 
well as mature glia (astrocytes and oligodendrocytes) that de-differentiate 
due to multiple genetic mutations (Hadjipanayis and Van Meir 2009a; 
Hadjipanayis and Van Meir 2009b; Bachoo et al. 2002). According to the 
classification of the World Health Organisation, which clinically distinguishes 
four classes of gliomas, GBM is a grade IV astrocytoma, thus the highest 
grade glioma tumour and most malignant astrocytoma (Holland 2000; Zhang 
et al. 2003). Histologically, the presence of necrotic cells in the tumour centre 
and the increase of blood vessels around the tumour distinguishes GBM from 
lower grade gliomas (Salcman 2012). In general, glioblastomas are 
considered to be one of the most vascularised tumours, which enables them 
to grow extremely fast and which makes them highly invasive (Shashidhar et 
al. 2005). With respect of the genetics of GBM, there are diverse 
modifications such as gene deletions, amplifications or point mutations. 
Mutations of the phosphatase and tensin homolog (PTEN), normally 
regulating the PI3K-pathway involved in cell proliferation, loss of the tumour 
suppressors p16 and p19 (also called Ink4a-ARF) and amplification of the 
EGFR gene are associated with primary (de novo) GBM. In addition, 
rearrangements of the EGFR gene such as an in-frame deletion result in the 
expression of a truncated EGFR, showing constitutive tyrosine kinase activity 
(Sehgal 1998; Nagane et al. 2001). Moreover, platelet-derived growth factor 
receptor (PDGFR) amplification and p53 mutations often occur in secondary 
glioblastomas that develop from lower grade astrocytomas (Sehgal 1998; 
James and Olson 1996; Geevimaan and Babu 2013). 
The Cancer Genome Atlas (TCGA) is a project that analyses expression 
profiles and genetic data of cancer. The analysis of primary GBM tumours led 
to a subdivision of grade IV glioblastomas into four groups (classical, 
mesenchymal, neural and proneural) (Fig. 1.17). Comparison of the gene 
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profiles of the 4 glioblastoma subtypes with neurons and glia in vitro suggests 
different cell origin for the GBM subtypes (Van Meir et al. 2010).  
 
 
 
 
Figure 1.17 Subdivision of GBM into 4 subgroups, based on genetic 
alterations and gene expression profiles. Taken from Meir et al. (2010) 
Normal brain cells of different origin undergo genetic alterations, leading to a cell 
population of tumour-initiating cells (TIC). This cell population can accumulate 
further genetic and epigenetic changes and become a brain cancer-propagating cell 
(BCPC) population, leading to the formation of GBM. Based on different genetic 
alterations, 4 different subgroups of GBM can be distinguished: the classical, 
mesenchymal, neural and proneural types of GBM. 
GBM, glioblastoma multiforme; EGFR, epidermal growth factor receptor; PDGFR, 
platelet-dervied growth factor receptor, PTEN, phosphatase and tensin homolog; 
TNF, tumour necrosis factor; IDH, isocitrate dehydrogenase; PI3K, phosphoinositide 
3-kinase; HIF, hypoxia-inducible factor.  
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The “classical” subtype has a typical genetic profile of highly proliferative 
cells and shows gene amplification of EGFR and loss of PTEN. Neural 
precursors and stem cell markers, as well as Notch- and Sonic hedgehog-
signalling mediators are up-regulated. The “mesenchymal” subtype is 
characterised by an expression profile associated with angiogenesis and 
mesenchyme and expresses astrocytic markers. NF1, TP53 and PTEN 
tumour suppressor genes are often mutated or lost. The “proneural” subtype 
expresses oligodendrocytic and proneural developmental marker genes. 
Overexpression or amplification of PDGFR and TP53 mutations are typical. 
Mutations in the IDH1 (isocitrate dehydrogenase 1) gene that are usually 
found in lower grade gliomas suggest that secondary glioblastomas belong to 
this subtype. The “neural” subtype is poorly defined, but shows gene 
expression profiles similar to differentiated cells in normal brain tissue with 
expression of neuronal markers.  
It must be noted that despite a classification into 4 subgroups may help to 
treat the different tumours more efficiently, all subgroups of GBMs 
demonstrate inactivation of the tumour suppressors p53 and Rb and 
activation of receptor tyrosine kinase pathways (Van Meir et al. 2010). 
About 50% of all gliomas are GBMs, which can occur in any age group, but 
they are most commonly observed in 50-70 years old adults. The standard 
therapy of GBM includes surgical resection of the tumour, followed by 
radiation therapy, often in combination with chemotherapy. In many cases, 
however, tumour recurrences occur even outside of the region of prior 
resection and it is impossible to remove all tumour cells. Glioblastoma cells 
often migrate away from the primary tumour and form metastases within the 
brain, however they rarely spread outside the brain to distinct regions in the 
body (Salcman 2012). Due to the complex character of GBM and the non-
efficient therapies, most of the patients have a poor prognosis and die of the 
disease within 14 months of diagnosis (Holland 2000; Zhang et al. 2003; Van 
Meir et al. 2010). 
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1.8 Aims of the thesis 
 
GPR56 is a member of the novel family of adhesion G protein-coupled 
receptors. GPR56 plays a role during early brain development and mutations 
or loss of Gpr56 expression result in a severe malformation of the brain.  
The role of GPR56 in cancer is controversial, as the receptor can act as a 
tumour suppressor or promoter, depending on the cancer type and stage (Xu 
et al. 2006; Ke et al. 2007; Huang et al. 2008; Sud et al. 2006; Shashidhar et 
al. 2005). In highly invasive glioblastoma, GPR56 may act as a tumour 
promoter, as it is overexpressed and involved in adhesion signalling 
(Shashidhar et al. 2005). However, downstream signalling pathways induced 
by GPR56 are poorly understood and an activation of GPR56 by its potential 
ligand TG2 was not demonstrated to date. Understanding the signalling 
pathways induced by GPR56 and the potential role of the GPR56-TG2 
interaction in cancer may provide valuable information for novel anti-cancer 
therapies, since GPCRs represent very interesting drug targets. 
The main aim of this project was to characterise the interaction between TG2 
and GPR56 and to investigate GPR56 downstream signalling. In order to 
achieve this aim, the following questions were addressed: 
 
 Does TG2 activate GPR56-dependent signalling? 
 Does GPR56 activation require specific domains or the catalytic 
activity of TG2? 
 Are there other putative ligands for GPR56 among the family of 
transglutaminases?  
 How do GPR56 mutations or domain deletions affect GPR56 activity 
and the interaction with TG2? 
 What downstream signalling proteins are activated by GPR56? 
 Is GPR56 internalised? 
 Is TG2 internalised in a GPR56-dependent manner? 
 What is the mechanism of GPR56 internalisation? 
 What happens to endocytosed GPR56 and TG2? 
 What is the role of GPR56 in glioblastoma? 
  
 
 
 
 
 
CHAPTER 2: 
Materials and methods
 68 
 
2 Material and methods 
 
The formulations of the used solutions and buffers are summarised in 
Appendix I, the used chemicals are listed in Appendix II, as well as the 
consumables and laboratory equipment in Appendix III.  
 
 
2.1 DNA manipulation  
 
2.1.1 Agarose gel electrophoresis 
 
Plasmid DNA was mixed with 6x DNA loading buffer (Promega) and loaded 
onto a 1 % (w/v) agarose gel containing 0.1 mg/ml ethidium bromide (Sigma-
Aldrich) in 1x TAE buffer (40 mM Tris acetate, 1 mM EDTA). The DNA 
fragments were separated at a voltage of 100 V for 20-30 mins and 
visualized under UV light. 1 kb plus DNA marker (Invitrogen) was used to 
estimate the size and amount of DNA analysed. To purify DNA from agarose 
gels, the QIAquick gel extraction kit (QIAGEN) was used according to 
manufacturer’s instructions. 
 
2.1.2 Restriction digest 
 
2-5 μg plasmid DNA was mixed with 1 μl (20 U) of each restriction enzyme 
(New England Biolabs (NEB) or Promega) using the recommended NEB 
buffer and double distilled water to reach a final volume of 50 µl. The 
restriction mixtures were incubated at 37 °C for 1 h, separated by agarose 
gel electrophoresis and extracted from the gel as outlined in 2.1.1.  
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2.1.3 Ligation 
 
5 µl of purified vector DNA, 4 µl of purified insert DNA fragment, 1x rapid 
ligation buffer (Promega) and 3 U of T4 DNA ligase (Promega) was mixed 
and incubated for 1 h at room temperature to perform ligation (20 µl reaction 
volume). 
 
2.1.4 Transformation 
 
5 µl of the ligation mixture was added to 100 µl frozen NovaBlue GigaSingles 
competent E.coli (Novagen, MerckKGaA) and incubated for 10 mins on ice. 
Heat shock transformation was performed at 37 °C for 1 min and cells were 
put back on ice immediately for 2 mins. Bacteria were streaked at varying 
dilutions on LB plates containing 50 µg/ml carbenicillin (Melford) using 
several plates and incubated overnight at 37 °C.  
 
2.1.5 Identifying positive clones  
 
Single colonies were picked using a sterile pipette tip and transferred into 
3 ml LB medium containing 50 µg/ml carbenicillin. Bacteria were incubated at 
37 °C and 220 rpm overnight. 1.5 ml of overnight bacterial culture was 
centrifuged at 4,000 rpm for 10 mins. The supernatants were discarded and 
the plasmid DNA was purified from the bacterial pellets using the QIAprep 
Spin MiniPrep Kit (QIAGEN) according to manufacturer’s instructions.  
5 µl of purified plasmid DNA was cleaved with the same restriction enzymes 
that were used to generate complementary restriction sites within the vector 
and the insert DNA fragment (2.1.2), followed by agarose gel electrophoresis 
(2.1.1). A positive clone was identified as it contained a DNA insert fragment 
of the right size and was sent for dideoxy sequencing (MWG Operon). 
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2.1.6 Plasmid DNA midiprep 
 
To amplify large amounts of DNA, a positive E.coli clone was grown 
overnight in 100 ml LB medium containing 50 µg/ml carbencillin at 37 °C and 
220 rpm agitation. The bacterial suspension was centrifuged at 4,500 rpm for 
20 mins to pellet E.coli. DNA was extracted from the pellet using the 
GenElute HP Plasmid Midiprep Kit (Sigma-Aldrich) according to 
manufacturer’s instructions. 
 
 
2.2 DNA mutagenesis 
 
2.2.1 PCR reactions 
 
In order to replace potential serine (S684, S685, S687, S689, S690, S691) 
and threonine (T688) phosphorylation sites in the C-terminal tail of GPR56 by 
alanine, three reverse primers were designed (Table 2.1).  The wild type 
GPR56-pOTP7-CA plasmid was used as a template for the production of the 
T688-A GPR56 mutant. To generate the ∆684-91S-A-GPR56 mutant, the 
∆687/689S-A-GPR56 plasmid served as a template (generated by Dr. Vera 
Knäuper). The generated ∆684-91S-A-GPR56 mutant was used as a template 
for the production of the ∆684-91S/T-A-GPR56 mutant. For all PCR reactions 
the forward primer GPR56for was used.  
The results of cloning the T688-A GPR56, ∆684-91S-A-GPR56 and ∆687/689S-A-
GPR56 mutants are discussed in Chapter 5.2.1. 
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Table 2.1 Oligonucleotides used for PCR mutagenesis 
Reverse primer Primer sequence  
Primer #1  
(T688-A) 
5’AAATCTAAGATGCGGCTGGACGAGGCGCTGCCCGAGC
TGATGGGGAG3’ 
Primer #2 
(∆687/689S-A) 
5’AAATCTAGAGATGCGGGCGGCAGCGGTGGCGCCAGC
ACCGATGGGGAGCCTGGC3’ 
Primer #3 
(∆687/689S/T-A) 
5’AAATCTAGAGATGCGGGCGGCAGCGGCGGCGCCAGC
ACCGATGGGGAG3’ 
Forward primer Primer sequence  
GPR56for 5’AAAAGATCTAAAATGACTCCCCAGTCGCTGCTGCAGA3’ 
 
 
Primers were synthesised by MWG Operon and the PCR reactions were 
carried out using a 96-well thermal cycler (VWR). Table 2.2 outlines the 
composition of the PCR master mixes and table 2.3 the programmes used to 
amplify the DNA. 
 
 
Table 2.2 Composition of PCR master mixes (50 µl reaction volume) 
Component 
1x Herculase II reaction buffer (Agilent Technologies) 
300-700 ng Template DNA  
(GPR56-pOTP7-CA, ∆687/689S-A-GPR56 or ∆684-91S-A GPR56) 
1 mM dNTP mix (Agilent Technologies) 
0.5 µM Reverse primer (#1, #2 or #3) 
0.5 µM Forward primer (GPR56for) 
1 U Herculase II Fusion DNA Polymerase (Agilent Technologies) 
2% DMSO (Agilent Technologies) 
Double distilled water up to a total volume of 50 µl 
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Table 2.3 PCR cycling parameters 
Segment 
Number of 
cycles 
Stage Temperature Duration 
1 1 Initialization step 95 °C 2 mins 
2 20 
Denaturation 95 °C 30 sec 
Annealing 63 °C 30 sec 
Elongation 72 °C 2 mins 
3 1 Final elongation 72 °C 3 mins 
4 --- Storage 4 °C --- 
 
To remove primers, nucleotides, polymerases and salts from the PCR 
sample, the QIAquick PCR Purification kit (QIAGEN) was used according to 
manufacturer’s instructions.  
 
2.2.2 Generating an intermediate GPR56 expression vector 
 
A GPR56 fragment (GPR56f) lacking the C-terminal residues 564 to 693 was 
created by cleaving the wild type GPR56 expression vector pcDNA4-
GPR56/V5-His with BamH I and Hind III (2.1.2). The cleaved DNA fragment 
GPR56f was purified using a 1 % agarose gel (2.1.1) and ligated into BamH I 
and Hind III cleaved pcDNA4/V5-His (Invitrogen). The resulting intermediate 
expression vector pcDNA4-GPR56f/V5-His was amplified as described above 
(2.1.4-2.1.6).    
 
2.2.3 Restriction digest of PCR reactions 
 
In order to reconstitute the C-terminal tail of GPR56f, the 800 bp long, 
purified PCR products (2.2.1) were cleaved with Xba I/BamH I/Xho I 
restriction enzymes (NEB) at 37 °C overnight, as PCR products need 
prolonged incubation times to ensure a complete digest. Xho I was added to 
the mixture to distinguish between wanted and unwanted fragments, as a 
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digest with Xba I/BamH I alone would result in the generation of two 
fragments of the same size (400 bp).  
 
2.2.4 Purification of cleaved PCR products 
 
The cleaved PCR products were separated using a 1% agarose gel (2.1.1). 
Due to the addition of Xho I to the digestion mixture, three fragments, one of 
400 bp and two of 200 bp were produced. The 400 bp fragment was 
extracted from the gel and purified as described before (2.1.1). 
 
2.2.5 Cloning of C-terminal GPR56 phosphorylation mutants 
 
In order to extend the C-terminal end of truncated GPR56f with mutant PCR 
products (2.2.4), the intermediate pcDNA4-GPR56f-V5/His construct was 
cleaved with BamH I and Xba I restriction enzymes (NEB) to generate 
complementary restriction sites. The cleaved DNA vector was purified from a 
1% agarose gel (2.1.1). Cleaved vector and PCR fragments were ligated 
(2.1.2). The final products, pcDNA4-T688A-GPR56/V5-His, pcDNA4-∆684-91S-
A-GPR56/V5-His and pcDNA4-∆684-91S/T-A-GPR56/V5-His were amplified in 
E.coli (2.1.4-2.1.6) and sent for dideoxy sequencing to MWG operon.  
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2.3 Cell culture 
 
All plastic ware used in tissue culture was obtained from Sarstedt Ltd., unless 
otherwise stated. Foetal bovine serum (FBS), Opti-MEM and advanced 
DMEM culture media, MEM non-essential amino acids, 
Penicillin/Streptomycin and trypsin/EDTA were purchased from Gibco, 
EMEM and DMEM culture media from Lonza, Hygromycin B and Blasticidin 
from Invitrogen and poly-L-lysine solution from Sigma-Aldrich.  
 
2.3.1 Cell lines 
 
Culture conditions for the cell lines used are outlined in table 2.4. 
In general, cell lines were maintained at 37 °C in humidified air containing 
5 % CO2, and passaged every 4-5 days or upon confluency. Cells were 
washed once with PBS (without Ca2+ and Mg2+), followed by incubation with 
1 ml trypsin/EDTA per 75 cm2 tissue culture flask for 5 mins at 37 °C. Trypsin 
activity was stopped by adding 7 ml of DMEM/10% FBS. Cells were collected 
by centrifugation for 5 mins at 1,500 rpm, medium removed and cells 
resuspended in growth medium and diluted in a ratio of 1:5 to 1:10, 
respectively. 
  
 75 
 
Table 2.4 Culture conditions for cell lines. 
 
2.3.1.1 HEK293 model system 
 
The HEK293 Flip-In cell line was purchased from Invitrogen. The stable 
HEK293 N-Strep/HA-GPR56/V5 cell line inducibly expressing GPR56 was 
established by Dr Vera Knäuper. Briefly, full-length GPR56 cDNA was cloned 
into pcDNA5-FRT-TO (Invitrogen), followed by transfection and selection of 
the TET-on HEK293 Flp-In cell line according to the manufacturers’ 
instructions (Invitrogen).  
 
2.3.1.2 HCA2 fibroblasts 
 
Stably transfected HCA2 cell lines were obtained from Prof. Daniel 
Aeschlimann. Briefly, the HCA2 strain of normal diploid fibroblasts was 
immortalised by stable transfection with amphotrophic retrovirus pBABE-
hTERT (human telomerase). Immortalised HCA2 cells were then transfected 
with different expression constructs for stable expression of TG2 mRNA: one 
Cell line Origin Medium 
HEK293 Flip-In 
Human embryonic 
kidney 
90% DMEM, 10% FBS 
HEK293  
N-Strep/HA-
GPR56/V5 
Human embryonic 
kidney 
90% DMEM, 10% FBS, 15 µg/ml 
blasticidin, 100 µg/ml hygromycin 
U373 
Human brain tumour 
(glioblastoma) 
89% DMEM, 10% FBS, 1 % MEM 
non-essential amino acids 
U373 shGPR56 
(stably transfected) 
Human brain tumour 
(glioblastoma) 
89% DMEM, 10% FBS, 1 % MEM  
non-essential amino acids,  
200 µg/ml hygromycin B 
HCA2  
TG2 sense (S) Human fibroblasts 
89% DMEM, 10% FBS, 1% 
Pen/Strep, 400 µg/ml geneticin 
HCA2 TG2 
antisense (As) Human fibroblasts 
89% DMEM, 10% FBS, 1% 
Pen/Strep, 400 µg/ml geneticin 
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construct with the coding sequence for TG2 inserted in sense (TG2 
overexpression) and the other construct with the coding sequence in 
antisense orientation (TG2 null). Stably transfected cells were isolated and 
maintained in selection medium containing 400 µg/ml geneticin (Stephens et 
al. 2004). 
 
2.3.1.3 Glioblastoma cell line 
 
The glioblastoma cell line U373 was purchased from the American Type 
Culture Collection (ATCC). U373 glioblastoma cells are human brain tumour 
cells derived from a grade IV glioblastoma. GPR56 is highly expressed in 
glioblastoma cells compared to non-tumourigenic brain tissue (Shashidhar et 
al. 2005) and therefore U373 cells were chosen as a model cell line to 
generate GPR56 knockdown cell lines. 
 
2.3.1.3.1 Generating GPR56 knockdown cells 
Two SureSilencing shRNA plasmids targeting GPR56 mRNA and a non-
coding shRNA plasmid (negative control) were purchased from 
SABiosciences (QIAGEN) in order to stably transfect the glioblastoma cell 
line U373.  The DNA sequences encoding the shRNAs are outlined in 
Appendix IV. 
 
2.3.1.3.2  Linearization of shRNA plasmid DNA 
2 µg of each shRNA plasmid DNA was cleaved with Nae I restriction enzyme 
(NEB) for 3 h at 37 °C as described in 2.1.2. Nae I was inactivated by 
incubation for 20 mins at 65 °C. 
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2.3.1.3.3  Phenol-chloroform extraction of shRNA plasmid DNA 
The linearized shRNA plasmid DNA was diluted in double distilled water to a 
final volume of 500 μl. An equal amount of phenol:chloroform:isoamyl alcohol 
(25:24:1 v/v, Promega) was added and vortexed to mix the organic and water 
phases. The mixture was centrifuged for 3 mins at 13,000 rpm and the top 
aqueous phase containing the DNA was removed and transferred into a new 
microcentrifuge tube. 1/10 volume of 3 M sodium acetate (pH 5.5) and 
2 volumes 100 % ethanol was added to the DNA and incubated at - 20 °C for 
1 h. Precipitated DNA was collected by centrifugation for 30 mins at 
13,000 rpm and 4 °C. The ethanol supernatant was carefully removed and 
the pellet dried for 30 mins at 37 °C. The linearized, purified DNA was 
resuspended in 40 μl double distilled water and stored at - 20 °C. 
 
2.3.1.3.4  Stable transfection of cells 
Cells were stably transfected using the reverse transfection protocol supplied 
by SABiosciences. 100 µl of serum-free Opti-MEM was pipetted into each 
well of a 24-well plate. 0.4 µg of linearized shRNA plasmid DNA was added 
and mixed by gently rocking the plate. FuGENE 6 Transfection Reagent 
(Promega) was pre-diluted 1:2 in fresh Opti-MEM, and 2.4 µl of the mixture 
was added to each well (1:3 ratio DNA:FuGENE 6), mixed by rocking the 
plate and incubated for 30 mins at room temperature to allow DNA-FuGENE-
complex formation. 
U373 glioblastoma cells were resuspended in culture medium to a density of 
1.6x106 cells/ml and 500 µl the cell suspension was added to the wells 
containing the FuGENE-DNA-complexes (8x105 cells/well). Cells were 
incubated for 24 h as they already reached confluency. 
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2.3.1.3.5  Hygromycin kill curve of U373 cells 
In order to select for stably transfected cells, the hygromycin concentration 
killing all non-transfected cells was determined. 5x104 non-transfected U373 
cells were plated at a low density (~ 10 % confluence) in a 6-well plate 
containing growth medium supplemented with hygromycin B (Invitrogen) at 
final concentrations ranging from 0-800 µg/ml. Medium was changed every 
two days and cells were allowed to grow until the hygromycin-free cells 
reached confluency. The effective hygromycin concentration was determined 
at 200 µg/ml. 
 
2.3.1.3.6 Selection of stably transfected cells 
ShRNA transfected cells were re-plated onto 24-well plates at 10% 
confluency in growth medium containing 200 µg/ml hygromycin B. The 
medium was changed every 5-7 days, until small single cell colonies 
appeared. 
 
2.3.1.3.7  Isolating single cell colonies 
To lift single cell clones, the selection medium was taken off and cells were 
washed twice with PBS. Sterile cloning cylinders (internal diameter: 4.7 mm, 
height: 8 mm; Sigma-Aldrich) were placed over single colonies and sealed by 
dropwise adding 1 % (w/v) low-melting point agarose (Gibco-BRL) around 
the cylinders. 50 µl of accutase (Millipore) was dispensed into the cloning 
cylinders and incubated for 5 mins at 37 °C. According to the size of the 
colony, the cells were then transferred to individual wells of either 24- or 6-
well plates containing selection medium that was changed every two days. 
Upon confluency, cells were transferred into bigger plates or tissue culture 
flasks.  
  
 79 
 
2.4 Alkaline phosphatase-Amphiregulin (AP-AR) shedding 
assay 
 
2.4.1 Transient transfection of HEK293 cells 
 
Cells were seeded onto poly-L-lysine coated wells of a 24-well plate at a 
density of 1x105 cells/well in 0.5 ml DMEM/10 % FBS and grown for 24 h. To 
co-transfect one well, 0.5 µg of a GPR56 expression construct and 0.25 µg of 
Alkaline Phosphatase-tagged Amphiregulin (AP-AR) were mixed with 2.25 µl 
FuGENE 6 transfection reagent (Promega) in 200 µl serum-free Opti-MEM. 
The mixture was incubated for 20 mins at room temperature to allow 
formation of DNA-FuGENE 6 complexes and added dropwise to the cells. 
After rocking the plate gently, the cells were incubated at 37 °C, 5% CO2 for 
48 h. 
 
2.4.2 Inhibition of ADAM10 and ADAM17 
 
ADAM inhibitors targeting ADAM10 (GI254023x) and ADAM10/17 
(GW280264x) were obtained from Dr. Amour, GlaxoSmithKline (GSK). 
Cells were transfected with wild type GPR56 and AP-AR as outline in 2.4.1. 
and 48 h later the experiments were started. 
When ADAM inhibitors were used at a final concentration of 10 μM, cells 
were serum starved for 1 h in DMEM containing 10 μM ADAM inhibitor or 
DMSO solvent control. Medium was removed and cells were washed 1x with 
250 µl serum-free Opti-MEM prior to incubation in serum-free, gassed Opti-
MEM for 30 mins at 37 °C. 
When ADAM inhibitors were used at a final concentration of 1 μM, cells were 
washed 1x with warm, serum-free advanced DMEM, followed by serum-
starvation in advanced DMEM containing 1 μM ADAM inhibitor or DMSO 
solvent control for 1 h. The medium was removed and cells were stimulated 
with 20 μg/ml C230-A TG2 or buffer control in the presence of ADAM inhibitors 
or DMSO solvent control in advanced DMEM for 1 h at 37 °C. 
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For experiments using an inhibitory ADAM17 antibody (Prof. G. Murphy, 
Cambridge, UK), cells were washed 1x with advanced DMEM and serum 
starved in the presence of 100 nM D1A12 ADAM17 inhibitory antibody or 
human IgG control for 1 h. Medium was removed and cells were treated with 
20 μg/ml C230-A TG2 or buffer control in advanced DMEM in the presence of 
100 nM D1A12 ADAM17 inhibitory antibody or human IgG control for 1 h at 
37 °C.  
 
2.4.3 Treatment with potential ligands for GPR56 
 
Cells were washed 1x with warm, serum-free advanced DMEM, followed by a 
serum-starvation step for 1 h in advanced DMEM. Medium was removed and 
cells were treated with different transglutaminases (Table 2.5) or collagen III 
in advanced DMEM for 1 h at 37 °C at the indicated final concentrations.  
 
 
Table 2.5 Transglutaminases and their storage buffers. 
Transglutaminase Buffer 
C230-A TG2 20 mM Tris-HCl (pH 7.5), 300 mM NaCl, 1mM EDTA 
TG2 10 mM Tris-HCl (pH 7.5), 300 mM NaCl, 1mM EDTA 
OC-TG2 10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM EDTA 
C277-S TG2 20 mM Tris-HCl (pH 7.5), 300 mM NaCl, 1mM EDTA 
TG6 10 mM Tris-HCl (pH 7.8), 500 mM NaCl, 10 mg/ml sucrose 
TG7 50 mM Tris-HCl (pH 8.0), 10 mM reduced glutathione 
∆FXIII 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 15 % glycerol 
 
 
2.4.4 Measurement of AP-activity in the medium 
 
At the end of the stimulation period, medium was collected and transferred 
into 1.5 ml tubes, followed by centrifugation for 3 mins at 13,000 rpm to 
remove cells. 50 µl of AP-AR containing supernatant was placed in 
duplicates in a 96-well plate. Alkaline phosphatase substrate solution 
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(2 mg/ml p-NPP; Sigma-Aldrich) was prepared by mixing 600 µl of 50 mg/ml 
p-NPP with 15 ml AP buffer (100 mM Tris-HCl (pH 9.5), 100 mM NaCl, 
20 mM MgCl2). 150 µl of substrate solution was added to the supernatants in 
the plate (final concentration of p-NPP on 96-well plate was 1.5 mg/ml) and 
AP-activity was determined. The hydrolysis of p-NPP to p-nitrophenol was 
measured at 405 nm every 10 to 30 mins over a period of several hours 
using a microplate reader (OMEGA plate reader, BMG Labtech). 
 
2.4.5 Statistical analysis 
 
The GraphPad Prism software was used to analyse data by One-way Anova 
with Tukey post-test. P values below 0.05 (95 % confidence interval) were 
considered significant. For the final analysis of every experiment, at least 3 
independent shedding assays were performed, with usually 4 repeats per 
condition and construct in each assay (n=12). Data are shown as mean 
+/- SEM.  
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2.5 Protein analysis by Western Blotting 
 
2.5.1 Production of cell lysates 
 
A “GPCR lysis buffer” containing 50 mM HEPES (pH 7.5), 10 mM NEM, 
100 µM benzamidine, 0.5 % Nonident P-40, 250 mM NaCl, 2 mM EDTA, 
10% (v/v) glycerol was produced. For the production of cell lysates, 10 µl of a 
protease inhibitor cocktail (#P8340 from Sigma-Aldrich; final concentrations: 
1.04 mM AEBSF, 0.8 µM aprotinin, 40 µM bestatin, 14 µM E-64, 20 µM 
leupeptin, 15 µM pepstatin A) and 5 µl Na3VO4 (final concentration = 1.5 mM; 
Sigma-Aldrich) were added to 1ml of the buffer. 
After removing the medium, the cell monolayer was lysed with 35 µl lysis 
buffer per well of a 24-well plate and incubated for 30 mins on ice. Cell 
lysates were transferred into 1.5 ml microcentrifuge tubes and centrifuged at 
13,000 rpm for 5 mins to remove cell debris. The supernatants were stored at 
- 80 ˚C to avoid protein degradation. 
 
2.5.2 Protein concentration assay (DC assay) 
 
Protein concentrations were determined using the colorimetric DC protein 
assay (Bio-Rad). A protein standard curve was created by analysing different 
BSA concentrations ranging from 0.2 - 1.5 mg/ml for each assay. 5 µl of each 
protein standard and sample were pipetted in duplicates into a 96-well plate, 
then 25 µl of Reagent A’ (20 µl Reagent S in 1 ml Reagent A) and 200 µl of 
Reagent B was added per well. The plate was gently mixed by rocking and 
incubated for 15 mins at room temperature. The absorbance was measured 
at 570 nm and protein concentrations determined from the standard curve. 
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2.5.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
50 µg of cell lysate or 25 µl of cell supernatant was diluted 1:2 using 2x SDS 
reducing sample buffer. To denature proteins, the mixtures were incubated at 
95 °C for 5 mins. To analyse C-GPR56 by western blotting, the samples were 
incubated for 10 mins at room temperature in order to avoid induction of 
aggregation by boiling. Samples were then centrifuged for 1 min at 
13,000 rpm, followed by separation using 4 % stacking and 10 %, 11 % or 
12.5 % resolving SDS polyacrylamide gels at 50-100 mA (max 250 V) until 
the dye front reached the bottom of the gel. 
 
2.5.4 Western blotting 
 
Polyvinyliden-difluorid (PVDF) membranes (Thermo Fisher Scientific) were 
activated for 20 sec in methanol, followed by equilibration in transfer buffer in 
conjunction with the SDS polyacrylamide gels. Proteins were then transferred 
to the PVDF membrane at 75 V for 1 h or at 15-20 V overnight (at least 16 h) 
in a transfer cell (Bio-Rad) containing transfer buffer and a cooling block. 
Non-specific protein binding sites of the membrane were blocked by 
incubating the membrane for 1 h with 5 % skimmed milk dissolved in TBST 
using a shaker. The membrane was incubated for 4 h or overnight with the 
primary antibody diluted in 5 % skimmed milk/TBST on a rotator plate. 
Membranes were washed 3x 5 mins in 1x TBST and incubated for 1 h at 
room temperature with the secondary antibody diluted in 5 % skimmed 
milk/TBST on a rotator plate. All primary and secondary antibodies used for 
Western Blotting are outlined in Table 2.6. Membranes were washed 4x 
10 mins with 1x TBST on a shaker. Membranes were removed and 1 ml EZ-
ECL reagent (Solution A:Solution B 1:2; Geneflow) was added and incubated 
for 1 min. Membranes were exposed to ECL hyperfilms (Amersham 
Bioscience) and developed in a CURIX 60 automated developer (Agfa 
HealthCare GmbH).  
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Table 2.6 Antibodies used for Western Blotting 
 Primary antibodies 
Antibody 
Working  
dilution 
Working 
concentration 
Manufacturer 
Sheep anti-GPR56 1:1,000 200 ng/ml R&D Systems 
Mouse anti-V5 1:5,000 20 ng/ml Invitrogen 
Mouse anti-TG2 
(CUB) 1:1,000 200 ng/ml Thermo Scientific 
Mouse anti-GAPDH 1:5,000 12.5 ng/ml Sigma-Aldrich 
 Secondary antibodies 
Antibody 
Working  
dilution 
Working 
concentration 
Manufacturer 
Donkey anti-sheep-
HRP 
1:5,000 20 ng/ml 
Jackson 
ImmunoResearch 
Donkey anti-mouse-
HRP 
1:5,000 16 ng/ml 
Jackson 
ImmunoResearch 
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2.6 Immunofluorescence 
 
All primary and secondary antibodies used for immunofluorescence are 
outlined in table 2.7. Cells were analysed using a Leica SP5 confocal 
microscope (Leica Microsystems). Images were acquired with a 63x oil 
immersion objective, using the 488, 543 and 633 laser lines, respectively.  
 
Table 2.7 Antibodies used for immunofluorescence 
Primary antibodies 
Antibody 
Working 
dilution 
Working 
concentration 
Manufacturer 
Sheep anti-N-GPR56 1:200 1 μg/ml R&D Systems 
Mouse anti-V5 1:500 1 μg/ml Invitrogen 
Mouse anti-Flag M2 1:200 1 μg/ml Sigma-Aldrich 
Rabbit anti-LAMP1 1:200 5 μg/ml Sigma-Aldrich 
Mouse anti-LAMP2 1:200 5 μg/ml DSHB 
Mouse anti-TG2 
(CUB7402) 1:200 1 μg/ml Thermo Scientific 
Rabbit anti-Caveolin-1 1:200 5 μg/ml Abcam 
Secondary antibodies 
Antibody 
Working 
dilution 
Working 
concentration 
Manufacturer 
Donkey anti-sheep AF 568 1:500 4 μg/ml Invitrogen 
Donkey anti-mouse AF 594 1:500 4 μg/ml Invitrogen 
Donkey anti-mouse AF 488 1:500 4 μg/ml Invitrogen 
Donkey anti-rabbit AF 488 1:500 4 μg/ml Invitrogen 
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2.6.1 Immunodetection of GPR56 in eukaryotic cells 
 
2.6.1.1 Endogenous GPR56 expression in U373 cells as detected with 
N-GPR56 antibody 
 
U373 parental or stable GPR56 knockdown cells were plated onto poly-L-
lysine coated glass coverslips in 24-well plates at a density of 
0.1x105 cells/well in 0.5 ml DMEM/10% FBS. Detection of endogenously 
expressed GPR56 was performed 72 h after seeding. Cells were washed 
using PBS and fixed with 4% paraformaldehyde (PFA)/PBS for 5 mins. Cells 
were washed 3x with PBS for 5 mins, blocked for 30 mins in 1% BSA/PBS 
prior to incubation with primary sheep anti-N-GPR56 antibody (1 μg/ml) for 
2 h in a humidified chamber. Cells were washed 3x with PBS, incubated for 
1 h with secondary donkey anti-sheep Alexa Fluor 568 antibody (4 μg/ml) in 
blocking buffer and washed 3x with PBS for 5 mins. Nuclei were counter 
stained with DAPI-containing vectashield mounting medium (Vector 
Laboratories). 
 
2.6.1.2 GPR56 expression in transiently transfected HEK293 cells 
 
Cells were plated onto poly-L-lysine coated glass coverslips in a 24-well plate 
at a density of 0.3x105 cells/well in 0.5 ml DMEM/10% FBS. The next day, 
cells were transfected. To transfect one well, 0.5 µg of a GPR56 expression 
construct was mixed with 1.5 µl FuGENE 6 transfection reagent (Promega) in 
200 µl serum-free Opti-MEM. The mixture was incubated for 20 mins at room 
temperature to allow the formation of DNA-FuGENE complexes. 200 µl was 
then added dropwise to the cells. Two days post-transfection, the 
extracellular N-terminus of GPR56 was detected on fixed cells as described 
in 2.6.1.1. 
The C-terminal domain of GPR56 was detected via the V5 epitope-tag. 
Therefore, fixed cells were permeabilised for 10 mins using 0.5% 
saponin/PBS. Cells were washed 3x with PBS and blocked with 1% 
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BSA/PBS for 30 mins. Primary mouse anti-V5 antibody (1 μg/ml) was 
incubated for 2 h in a humidified chamber prior to the appropriate wash 
steps. Donkey anti-mouse Alexa 594 (4 μg/ml) was used as secondary 
antibody and incubated for 1 h. Cells were washed 3x with PBS and nuclei 
stained with DAPI.  
 
2.6.2 Immuno-colocalisation of GPR56 and TG2 in stable HEK293 cells  
 
HEK293 cells inducibly expressing GPR56 were seeded at 0.3x105 cells per 
well onto poly-L-lysine coated glass coverslips in a 24-well plate in 0.5 ml 
DMEM/10% FBS without antibiotics. The next day, GPR56 expression was 
induced in half the wells by adding DMEM/10% FBS medium supplemented 
with 10 μg/ml doxycycline. The second half of the plate was cultured in 
DMEM/10% FBS alone and was used as a GPR56 negative control. After 
48 h, cells were washed with serum-free advanced DMEM and serum 
starved for 1 h at 37 °C prior to C230-A TG2 treatment (20 μg/ml) for 5 sec, 
15 mins and 30 mins at 37 °C. Cells were fixed as described in 2.6.1.1. In 
order to follow internalisation of N-GPR56, cells were also permeabilised as 
outlined in 2.6.1.2. Following a blocking step for 30 mins in 1% BSA/PBS, 
TG2 and GPR56 were stained using the primary mouse anti-TG2 CUB7402 
antibody at 1 μg/ml and the primary sheep anti-N-GPR56 at 1 μg/ml for 2 h in 
a humidified chamber. Donkey anti-mouse Alexa 488 and donkey anti-sheep 
Alexa 568 secondary antibodies were used at 4 μg/ml dilution and incubated 
for 1 h. Coverslips were washed 3x with PBS and mounted onto slides using 
vecta shield containing DAPI.  
 
2.6.3 SNAP-tag staining of GPR56 in HEK293 cells 
 
Cells were plated onto poly-L-lysine coated glass coverslips in a 24-well plate 
at a density of 0.3x105 cells/well in 0.5 ml DMEM/10% FBS. The next day, 
four wells were transfected with 2 µg SNAP-GPR56/V5 (or SNAP-β2-
adrenergic receptor as control) as described in 2.4. 48 h post-transfection, 
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cells were washed with serum-free advanced DMEM and serum starved for 
1 h at 37 °C in advanced DMEM. In the meantime, 1 µl of 1 mM SNAP-
surface substrate (in DMSO; NEB) was diluted in 1 ml advanced DMEM. 
Medium was removed from the cells, 250 µl of 1 µM SNAP-substrate solution 
was added and incubated for 15 mins at 37 °C or 4 °C, as indicated. SNAP-
tag surface substrates 488, 549 or 647 were used. Cells were washed 3x 
with 0.5% BSA/advanced DMEM to remove excessive SNAP-tag surface 
substrate, followed by 1x wash in serum-free advanced DMEM. Cells were 
then ready for further treatments as outlined below. 
 
2.6.3.1 Immunolocalisation of TG2  
 
SNAP-surface label 647 (NEB) was used to stain SNAP-GPR56 for 15 mins 
at 4 °C (2.6.3), followed by pulse-treatment with 20 μg/ml C230-A TG2 for 
5 sec. Medium was removed and cells fixed immediately to investigate cell 
surface co-localisation of GPR56 and TG2. In order to follow receptor 
internalisation, cells were incubated in serum-free medium for up to 1 h at 
37 °C following TG2 treatment. Cells were fixed, permeabilised and blocked 
as described above. TG2 was detected using the mouse anti-TG2 CUB7402 
antibody at 1 μg/ml as described in 2.6.2. Either donkey anti-mouse Alexa 
488 or donkey anti-mouse Alexa 594 secondary antibodies were used at 
4 μg/ml dilution.  
 
2.6.3.2 Immuno-colocalisation of TG2 and lysosomes or caveolae 
 
Cells were stained with SNAP-surface substrate 647 (NEB) and treated with 
C230A-TG2 as described in 2.6.3.1 and cells were incubated in serum-free 
medium for up to 6 h prior to fixation (2.6.1). For visualization of late 
endosomes/early lysosomes, fixed and permeabilised cells were stained with 
rabbit anti-LAMP1 (5 µg/ml) or mouse anti-LAMP2 (5 µg/ml) antibodies for 
2 h in a humidified chamber. For caveolae staining, a rabbit anti-Cav1 
antibody (5 µg/ml) was used and incubated for 2 h. In both cases, donkey 
 89 
 
anti-rabbit Alexa 488 served as secondary antibody conjugate and was 
incubated for 1 h. Cells were co-stained for TG2 as described in 2.6.2. All 
wash steps were carried out as explained in 2.6.1.1. 
 
2.6.3.3 Co-staining of transferrin receptors  
 
SNAP-GPR56 transfected cells were serum starved for 1 h. Transferrin 
receptor/Transferrin-488 complexes were formed by incubating cells with 
10 µg/ml Transferrin-488 (Molecular probes, Invitrogen) for 30 mins at 4 °C in 
cold advanced DMEM. Cells were washed 3x in ice-cold PBS, prior to 
staining with SNAP-surface substrate 647 for 15 mins at 4 °C, as described 
in 2.6.3. Cells were pulse treated with 20 µg/ml C230-A TG2 for 5 sec, fixed 
directly with 4% PFA/PBS or incubated in serum free medium for 15 mins 
prior to fixation. Cells were washed 3x with PBS and nuclei stained with 
DAPI.  
 
2.6.3.4 Inhibition of endocytosis with sucrose  
 
Following serum starvation for 30 mins in 0.45 M sucrose in advanced 
DMEM, cells were stained with SNAP-surface substrate 647 (NEB) for 
15 mins at 4 °C (2.6.3) and pulse treated with 20 µg/ml C230-A TG2 for 5 sec. 
Cells were either fixed with 4% PFA/PBS immediately, or incubated in 
advanced DMEM in the presence or absence of 0.45 M sucrose for 30 mins 
prior to fixation, followed by permeabilisation in 0.5 % saponin/PBS. Cells 
were blocked as described above in 1% BSA/PBS and TG2 was detected 
using mouse anti-TG2 CUB7402 antibody at 1 μg/ml and incubated for 2 h. 
Donkey anti-mouse Alexa 594 secondary antibody was used at 4 μg/ml 
dilution and incubated for 1 h. Coverslips were washed 3x with PBS and 
mounted onto slides using vecta shield containing DAPI. 
  
 
 
 
 
 
CHAPTER 3: 
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3 Investigations of GPR56 downstream signalling 
using an AP-AR shedding assay 
 
3.1 Introduction 
 
Adhesion GPCRs (aGPCRs) are the second biggest family of GPCRs, but 
they are by far the most poorly understood. Most of aGPCRs are still 
considered orphan receptors with no known ligands. Therefore, aGPCRs are 
difficult to study. 
In recent years, the major approach to de-orphanise aGPCRs was to use 
soluble, recombinant protein probes, consisting of the ligand binding N-
terminal ectodomain (ECD) of the aGPCR fused to a truncated Fc-fragment 
with an optional C-terminal biotinylation signal sequence (Lin et al., 2009; Lin, 
et al., 2005). These Fc-fusion proteins are used to isolate binding partners of 
the aGPCR.  
 
In order to de-orphanise GPR56, this “ligand fishing” approach was applied 
by several groups using different N-GPR56-Fc probes. Xu and colleagues 
(2006) used mGPR56N-hFc to identify an ~80 kDa ligand from extracted 
mouse lungs, which was identified as TG2.  
Li et al. (2008) used an mGPR56N-mFc probe to find potential ligands for 
GPR56 in mouse brain. The probe bound to the pial basement membrane 
(BM) in the cerebral cortex and this interaction was entirely lost or 
discontinuous on brain sections from Gpr56-/- mice. The results indicated a 
GPR56-dependent expression of the putative ligand and partial breakdown of 
the pial BM due to GPR56 depletion. The nature of the potential ligand was 
not characterised in this study (Li et al. 2008), but was later identified in 
meningeal fibroblasts (MFs) as the ECM component collagen III (Luo et al. 
2011).  
Chiang et al. (2011) identified a third potential ligand for GPR56, which was 
not TG2. Using an hGPR56-mFc fusion protein, the unknown binding partner 
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was detected in several cell lines. It was described as a trypsin-sensitive cell 
surface protein and the interaction with GPR56 was EDTA- and EGTA-
sensitive, but was restored by the addition of Ca2+ or Mg2+. However, its 
identity remained elusive to date. The identified binding partner might be an 
integrin, as their receptor function is dependent on the presence of Ca2+ and 
Mg2+ (Leitinger et al., 2000). Moreover, Jeong et al. (2013) revealed a link 
between GPR56 and α3β1-integrin, as double knockout mice showed an even 
more severe cortical malformation than Gpr56-/- single knockout mice. 
However, α3β1-integrin does not bind to the GPR56 ligand collagen III and it 
was not shown whether α3β1-integrin may directly interact with GPR56. Thus 
it is not clear, how the two transmembrane receptors function together. 
Moreover, TG2 was shown to interact with β1-, β3-, and β5-integrins and acts 
as a co-receptor for ECM proteins (Iismaa et al. 2006; Akimov et al. 2000). 
Thus, the binding partner identified by Chiang et al. (2011) might be a TG2-
bound integrin. 
Using Co-IP experiments, Little et al. (2004) identified the tetraspanin CD81 
in a complex with CD9 as interacting partners of GPR56. A complex 
formation between CD81/9, GPR56 and Gαq/11-proteins was described, but a 
signalling outcome as a result of the protein association was not shown.  
 
The first real evidence for a GPR56-dependent signalling response was 
presented by Shashidhar et al. (2005), who showed that overexpression of 
GPR56 increased the activity of NF-κB, PAI-I and TCF response elements, 
all of which have been implicated in tumorigenesis and adhesion. Iguchi et al. 
(2008) then showed that the GPR56-dependent transcription through 
activation of NF-κB and SRE responsive elements was mediated by Gα12/13 
and Rho signalling. However, co-expression of TG2 did not increase SRE-
mediated transcriptional activity.  
Kim et al. (2010) also showed an increased transcriptional activity of SRE, 
E2F, NFAT response elements and COX2, iNOS, VEGF promoters following 
GPR56 overexpression. These signalling pathways are involved in cell 
proliferation, invasion, angiogenesis and tumour growth, respectively. 
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Regarding ligand-induced responses mediated through GPR56, Iguchi et al. 
(2008) demonstrated for the first time that treatment of GPR56-expressing 
cells with a self-made, polyclonal anti-N-GPR56 antibody elevated Rho 
activation and GPR56-mediated transcriptional activity of NF-κB and SRE 
responsive elements. Additionally, anti-N-GPR56 treatment inhibited 
migration of neural progenitor cells (NPCs). Luo and colleagues (2011) then 
showed that treatment of NIH/3T3 cells as well as NPCs derived from 
Gpr56+/-, but not Gpr56-/- mice, with recombinant human collagen III also 
activated Rho signalling. GPR56-KD by shRNA, as well as the expression of 
a dominant negative mutant of Gα13 ablated GPR56-dependent activation of 
RhoA by collagen III. Supporting evidence for the inhibition of migratory 
signals following the interaction between collagen III and GPR56 was 
presented from neurosphere migration assays. Collagen III treatment of 
neurospheres derived from Gpr56+/- mice, but not Gpr56-/- mice, inhibited 
migration, again indicating that GPR56 expression was required (Luo et al. 
2011).  
 
This chapter introduces a shedding assay that enables the investigation of 
GPR56 signalling. A very similar approach was described by Inoue et al. 
(2012) who tested 116 different GPCRs with known ligands using a TGF-α 
shedding assay, by measuring GPCR activation as ectodomain (ECD) 
shedding of a membrane-tethered proform of Alkaline Phosphatase-tagged 
TGF-α (AP-TGF-α). Likewise, the principle of the assay used in this project is 
based on GPR56-induced shedding of pro-AP-Amphiregulin (AP-AR) and 
quantification of the released AP-AR ECD in the conditioned medium.  
Among the 116 GPCRs tested by Inoue et al. (2012), 75 were active in their 
assay. Interestingly, GPCRs known to couple Gα12/13 and Gαq induced potent 
AP-TGFα shedding, whereas Gαi- and Gαs-coupled receptors induced only 
weak shedding. The results indicated that the TGF-α shedding assay, which 
relies on the same principle as the AP-AR shedding assay used here, 
represented a very useful and sensitive tool to measure signalling of Gα12/13- 
and Gαq-coupled receptors such as GPR56. 
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In this project, the AP-AR shedding assay was thus used to investigate the 
signalling capacity of GPR56 in non-stimulated and stimulated conditions. 
The assay was also used to identify potential downstream pathways involved 
in AP-AR shedding. HEK293 cells were chosen as a model cell line, as they 
are easy to culture and transfect. Moreover, as shown by Inoue and 
colleagues (2012) who compared 6 different cell lines, HEK293 cells showed 
low endogenous AP-activity, the highest expression of the ADAM substrate 
chosen (AP-TGF-α) and showed the most potent shedding response of AP-
TGF-α to TPA-stimulation. 
 
 
3.1.1 Aims of the chapter 
 
 To establish a sensitive and reliable, cell-based assay in order to 
investigate GPR56 signalling in response to treatment with potential 
ligands. 
 To identify the metalloproteinase involved in GPR56-dependent shedding 
of amphiregulin. 
 To identify signalling pathways downstream of GPR56. 
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3.2 Results 
 
3.2.1 Principle of the AP-AR shedding assay 
 
Investigating migration of keratinocytes from spheroids placed on TG2-
containing fibroblast matrices, Edwards (2010) showed that extracellular TG2 
activates ADAM17-mediated cleavage of EGF-like ligands in keratinocytes. 
This led to activation of the EGFR and subsequent keratinocyte migration 
and proliferation. It was speculated that GPR56, expressed on the 
keratinocyte cell surface, might represent the missing link as a binding 
partner for matrix TG2, activating the intracellular signalling cascades that 
lead to EGFR transactivation (Edwards 2010). 
In order to investigate signalling through GPR56, a shedding assay was 
established based on the idea that GPR56 would activate a 
metalloproteinase leading to cleavage of an EGFR ligand (Inoue et al. 2012; 
Edwards 2010) (Fig. 3.1 A). Shedding was measured by monitoring the 
activity of released alkaline phosphatase-tagged amphiregulin (AP-AR), as 
an example of an ADAM substrate (Sahin et al. 2004). 
The first step in order to optimise the assay was to investigate whether 
GPR56 was constitutively active in non-stimulated conditions. Therefore, 
HEK293 cells were co-transfected with AP-AR and GPR56 or the negative 
control N-GPR56, consisting of the ECD up to the GPS cleavage site of 
GPR56 (aa1-382). Two days post-transfection, GPR56-dependent activation 
of ADAM(s), leading to the release of AP-AR ECD, was determined by 
measuring changes in OD405nm due to hydrolysis of the AP substrate p-NPP.  
The example in figure 3.1 B&C shows a single representative 
shedding assay, in which cells were serum starved for 1 h, followed by 
incubation in serum-free medium for 1 h. This combination of serum 
starvation and subsequent incubation (or ligand treatment) was found to be 
optimal, ensuring that the release of AP-AR from the cell membrane was 
assayed in the linear range prior to substrate depletion (data not shown). It is 
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also in good agreement with the experimental regimen used by Inoue et al. 
(2012). 
As shown in figure 3.1 C, p-NPP hydrolysis was 2.8-fold higher in non-
stimulated, GPR56 co-transfected cells compared to N-GPR56 expressing 
cells. This result indicated that overexpression of GPR56 in HEK293 cells 
leads to AP-AR shedding, reflecting a high auto-activity of the receptor in this 
assay. This is in good agreement with previous literature reports for GPR56 
(Iguchi et al. 2008; Shashidhar et al. 2005) and other adhesion GPCRs being 
auto-active (Simundza and Cowin 2013). 
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Figure.3.1 Principle of AP-AR shedding assay and data analysis. 
(A) Schematic of the assay. GPR56 induces ADAM-dependent shedding of 
membrane-bound AP-AR. Release of AP-AR ECD was quantified by collecting 
conditioned medium and measuring AP-activity based on p-NPP hydrolysis 
(production of yellow p-NP).  
(B) Exemplary analysis of p-NPP hydrolysis in conditioned medium. HEK293 cells 
expressing GPR56 and AP-AR were serum starved for 1 h, followed by incubation in 
serum-free medium for 1 h. Conditioned medium was transferred into a 96-well pate, 
p-NPP substrate added and AP-activity measured by monitoring the colorimetric 
reaction of AP (OD405nm) using an optical plate reader. Linear regression of the 
change in absorbance over time was performed using GraphPad Prism.  
(C) The calculated slopes of the hydrolysis reaction shown in (B) represent the 
p-NPP hydrolysis rates (OD405nm/hour) due to AP-AR ECD activity released into 
medium. A single representative experiment with 4 repeats for each construct is 
shown (n=4) and data are presented as mean +/- SEM.      
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3.2.2 Validation of the GPR56 signalling response 
 
3.2.2.1 C230-A TG2 activates GPR56 
 
The section above outlined the principle of the shedding assay used to 
investigate signalling through GPR56 in transiently transfected cells. The first 
experiments using this assay already indicated that GPR56 was auto-active 
(Fig. 3.1 C). The next step was to investigate whether GPR56 activity could 
be further stimulated by treatment with its potential ligand TG2.  
As the cell-based shedding assay was performed in an extracellular, 
oxidative environment, an oxidation-resistant cysteine-to-alanine mutant TG2 
(C230-A TG2) was used in most of the assays. At this stage it was unclear, 
whether catalytic activity of TG2 and therefore a certain conformation would 
be relevant for binding and activation of GPR56. The C230-A TG2 mutant was 
used, as it is less prone to oxidation and disulfide bond formation, hence 
catalytic inactivation (Stamnaes et al., 2010).  The catalytic activity of C230-A 
TG2 under the experimental conditions of the shedding assay was 
demonstrated using a real-time fluorescence assay, which measures TG-
dependent isopeptidase activity. These experiments showed that the activity 
of C230-A TG2 was comparable to WT-TG2 (Adamczyk 2013; data not 
shown).  
Figure 3.2 shows the final analyses of experiments in which HEK293 cells 
co-transfected with N-GPR56 and AP-AR or GPR56 and AP-AR were 
compared.  
Two days post-transfection, cells were serum starved and treated with 
20 µg/ml C230-A TG2 for 1 h. In order to overcome variance resulting from 
differences in transfection efficiencies between the single experiments, the p-
NPP hydrolysis rate of each experimental repeat was normalised to 1 for the 
non-stimulated GPR56 transfection control. The relative ratios between 
experimental conditions and controls were thus determined, allowing for 
inter-assay comparisons and subsequent statistical evaluation of results. 
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When compared to N-GPR56, the p-NPP hydrolysis rate in medium of cells 
expressing GPR56 was ~70 % higher when treated with control buffer, 
indicating activation of shedding by GPR56 (Fig. 3.2). Thus, the data 
confirmed that GPR56 had a high basal activity. Shedding was further 
increased by about 45 % in GPR56 transfected cells upon C230-A TG2 
stimulation, whereas N-GPR56 transfected cells showed no response to 
C230-A TG2 treatment. The endogenous AP-activity measured in non-
transfected cells was negligible.  
These experiments indicated that GPR56 overexpression activates shedding 
of amphiregulin in transiently transfected HEK293 cells due to the high basal 
activity of the receptor and the data showed that C230-A TG2 acts as an 
agonist for GPR56. 
 
 
 
Figure 3.2 Overexpression of GPR56 activates shedding of AP-AR which is 
further increased by C230-A TG2 treatment. 
Cells were co-transfected with GPR56 and AP-AR or N-GPR56 and AP-AR, or left 
non-transfected (NT). 48 h later, cells were serum starved for 1 h, followed by 
treatment with 20 µg/ml C230-A TG2 or control buffer for 1 h.  
Data presented show mean of 3 to 6 independent experiments with 4 repeats each 
+/- SEM (n=12 to 24). Statistical significance denoted as follows: ***, p<0.001; 
ns, non-significant.  
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In order to verify that GPR56 and N-GPR56 were expressed in co-
transfected cells, total lysates of the cells used for the AP-AR shedding assay 
were analysed by western blotting. The expression of N-GPR56 and GPR56 
in cell lysates was compared using anti-N-GPR56 (Fig. 3.3 A), anti-V5 (Fig. 
3.3 B) and anti-TG2 (Fig. 3.3 C) antibodies.  
Analysis using anti-N-GPR56 antibody showed a banding pattern for wild 
type GPR56 consisting of 4 main bands running at approximately 60, 65, 70 
and 75 kDa. The latter band likely represents uncleaved full-length GPR56. 
The lower running bands probably reflect variation in posttranslational 
modifications of cleaved N-GPR56, as there are 7 N-glycosylation sites 
present in the ECD and in addition those N-linked sugars can carry several 
sialic acid moieties (Jin et al. 2007). This banding pattern is in good 
agreement with previous reports from the literature (Chiang et al., 2011; Jin 
et al., 2007; Paavola et al., 2011).  
Cells expressing N-GPR56 showed one major band running between 60-
65 kDa and a high molecular weight band at ~180 kDa, probably 
representing polyubiquitinated or multimeric protein. It must be noted that this 
band was only detected, when lysates were analysed using non-boiling 
conditions. Treatment with C230-A TG2 did not influence the banding pattern 
detected with anti-N-GPR56 antibody, indicating no crosslinking of proteins 
by TG2, although I cannot preclude that a small amount of crosslinking 
occurs. 
Staining with anti-V5 antibody (Fig. 3.3 B) showed 3 major bands for GPR56 
running at ~ 27, 50 and 75 kDa. The latter band most likely represents full 
length GPR56, as it was the same band detected with the anti-N-GPR56 
antibody (Fig. 3.3 A). The bands running at 27 and 50 kDa probably 
represent monomeric and dimeric C-GPR56. Again, this banding pattern is in 
good agreement with reports from the literature (Chiang et al. 2011). Note 
that detection of C-GPR56, especially the monomeric isoform, required that 
protein samples were incubated in SDS sample buffer without heat treatment 
in order to avoid protein aggregation, as shown by others (Chiang et al. 
2011). Interestingly, expression levels of dimeric C-GPR56 were reduced in 
GPR56 expressing cells following treatment with C230-A TG2, potentially 
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indicating elevated receptor internalisation and degradation. Lysates of N-
GPR56 expressing cells were negative for anti-V5 staining, as N-GPR56 
carries a C-terminal Flag-tag (Fig. 3.3 B).  
Analyses of cell lysates using the anti-TG2 antibody showed that N-GPR56 
and GPR56 expressing cells were negative for endogenous TG2 expression, 
as shown for HEK293 cells by others (Cho et al. 2010; D’Eletto et al. 2012). 
In lysates treated with C230-A TG2, a major band running at ~80 kDa for 
monomeric TG2, as well as higher molecular weight bands running between 
~180-260 kDa were present, probably representing crosslinked dimeric and 
multimeric TG2, respectively. It must be noted that prior to preparation of the 
cell lysates, the supernatants were just removed and cells were not washed 
extensively, thus TG2 was found in lysates of GPR56 as well as N-GPR56 
expressing cells treated with C230-A TG2. In addition, TG2 could potentially 
be matrix bound and soluble ECM proteins may be present in the cell lysates. 
However, confocal analysis of GPR56-expressing HEK293 cells treated with 
C230-A TG2 showed that TG2 was only cell surface-associated (see Chapter 
6). 
The supernatants used in the AP-AR shedding assay were also analysed by 
western blotting for GPR56 secretion and TG2 using anti-N-GPR56 (Fig. 3.3 
D) and anti-TG2 (Fig. 3.3 E) antibodies, respectively. Staining of conditioned 
medium with anti-N-GPR56 showed a specific band running at 78 kDa in N-
GPR56 transfected cells, whereas GPR56 expressing cells were negative, 
irrespective of TG2 treatment (Fig. 3.3 D). Using anti-TG2 antibody, a major 
band at 80 kDa for monomeric TG2, a band at 180 kDa representing dimeric 
TG2 and a faint band at 55 kDa likely representing TG2 lacking the β-barrel 
domains was found in supernatants of cells treated with C230-A TG2. 
 
 
 101 
 
 
 
Figure 3.3 Expression of N-GPR56 and GPR56 in transiently transfected 
HEK293 cells. 
Cells were co-transfected with GPR56 and AP-AR or N-GPR56 and AP-AR. Two 
days post-transfection, cells were serum starved for 1 h, followed by treatment with 
20 µg/ml C230-A TG2 or control buffer for 1 h. Total cell lysates were prepared and 
separated in 10% resolving gels, blotted onto PVDF membranes and stained with 
(A) anti-N-GPR56, (B) anti-V5 or (C) anti-TG2 antibodies. Anti-GAPDH staining 
served as loading control. Conditioned medium of the same cells was analysed 
using (D) anti-N-GPR56 and (E) anti-TG2 antibodies.  
Data are representative for 6 independent experiments. 
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3.2.2.2 Comparison of wild type TG2, C230-A TG2 and an anti-N-GPR56 
antibody  
 
In order to verify that stimulation of GPR56 by TG2 was specific, an anti-N-
GPR56 antibody (R&D Systems) was compared in the shedding assay with 
the TG2 response. Iguchi et al. (2008) had previously shown that a different 
anti-N-GPR56 antibody activated GPR56, inducing Rho responses using a 
neurosphere migration model as the readout. Therefore it was likely that the 
polyclonal anti-N-GPR56 antibody used in this project potentially acts as a 
ligand for GPR56. This hypothesis was examined using the AP-AR shedding 
assay.  
Figure 3.4 shows the analysis of GPR56 and AP-AR co-expressing cells 
treated with 5 µg/ml anti-N-GPR56 antibody or sheep IgG control for 1 h. 
Treatment with the antibody led to a comparable stimulation of GPR56-
dependent AP-AR shedding when compared to 20 µg/ml C230A-TG2. 
Additionally, wild type TG2 was tested in parallel. As shown in Figure 3.4, 
C230-A TG2 or 20 µg/ml wild type TG2 stimulated the release of AP-AR into 
the medium by ~40 % when compared to control buffer treatment. 
These data showed for the first time that TG2, C230-A TG2 and anti-N-GPR56 
activated GPR56-dependent AP-AR release, confirming Inoue et al.’s (2012) 
observation that GPCR activity can be assayed using this methodology. 
Thus, aGPCR signalling can be assessed using this experimental approach. 
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Figure 3.4 Wild type TG2 and an anti-N-GPR56 antibody stimulate GPR56 in a 
comparable manner to C230-A TG2. 
GPR56 and AP-AR co-transfected cells were serum starved for 1 h and treated with 
either 5 µg/ml sheep anti-N-GPR56 antibody (R&D Systems) or 20 µg/ml of TG2 or 
C230-A TG2 for 1 h.  
Data presented show mean of 3 to 7 independent experiments with 4 repeats each 
+/- SEM (n=12 to 28). Statistical significance denoted as follows: ***, p<0.001.    
 
 
 
3.2.2.3 The putative ligand collagen III 
 
The results described above revealed that TG2, the first discovered 
extracellular binding partner of GPR56 (Xu et al. 2006), was able to stimulate 
GPR56-dependent AP-AR shedding. The next step was to investigate 
whether the second potential ligand, collagen III, also activated the receptor 
using the same assay. Cells co-expressing N-GPR56 and AP-AR or GPR56 
and AP-AR were treated with collagen III for 1 h. To keep the experiments 
comparable to those using TG2 for stimulation, collagen III was used at the 
same molarity as TG2, 250 nM (≡ 75 µg/ml). Collagen III (Abcam, ab73160) 
was stored in 10 mM HCl, which was used as the buffer control. Figure 3.5 
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shows that treatment with collagen III did not stimulate basal GPR56-
dependent shedding, which was in contrast to the treatments with TG2, 
C230-A TG2 and anti-N-GPR56 antibody. 
These data suggested that collagen III does not act as an agonist for GPR56-
dependent AP-AR shedding. 
 
 
 
 
 
Figure 3.5 Collagen III does not activate GPR56. 
Cells were co-transfected with N-GPR56 and AP-AR or GPR56 and AP-AR. Two 
days post-transfection, cells were serum starved for 1 h, followed by treatment with 
250 nM collagen III (≡ 75 µg/ml) or buffer control for 1 h. 
Data presented show mean of 3 independent experiments with 4 repeats each 
+/- SEM (n=12). Statistical significance denoted as follows: ns, non-significant. 
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3.2.3 Identification of the metalloproteinase involved in GPR56-
dependent AP-AR shedding 
 
Initial experiments demonstrated that activation of GPR56 leads to AP-AR 
shedding, which is further stimulated by TG2 or an agonistic anti-N-GPR56 
antibody. The next set of experiments aimed to identify the metalloproteinase 
responsible for GPR56-dependent cleavage of AP-AR. Therefore, two ADAM 
inhibitors from GlaxoSmithKline were selected. One inhibits both ADAM10 
and ADAM17 equally well (GW280264x, ADAM10/17 inhibitor) and the other 
specifically inhibits ADAM10 with a ~100-fold increased potency when 
compared to ADAM17 (GI254034x, ADAM10 inhibitor) (Hundhausen et al. 
2003).  
N-GPR56 or GPR56 and AP-AR expressing cells were serum starved in the 
presence or absence of the inhibitors, followed by incubation in medium in 
their presence or absence, which was optionally combined with C230-A TG2 
treatment. 
Initially, both ADAM inhibitors were used at a 10 µM dose in the absence of 
ligand. At this dose, both inhibitors blocked ADAM10 and ADAM17 activity 
leading to significantly reduced p-NPP hydrolysis rates in GPR56 transfected 
cells in comparison to the DMSO solvent control (Fig. 3.6). Both the ADAM10 
and ADAM10/17 inhibitor had no effect on the background shedding of AP-
AR seen in N-GPR56 transfected cells, suggesting that this does not require 
these enzymes. 
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Figure 3.6 GPR56-dependent AP-AR shedding requires metalloproteinase 
activity. 
Cells were co-transfected with GPR56 and AP-AR or N-GPR56 and AP-AR. Two 
days later, cells were serum-starved for 1 h in 10 µM ADAM10 or ADAM10/17 
inhibitor or DMSO solvent control containing medium. Cells were incubated in 
Opti-MEM for 30 mins.  
Data presented show mean of 3 independent experiments with 4 repeats each 
+/- SEM (n=12). Statistical significance denoted as follows: ***, p<0.001.    
 
 
Inhibitors were then used at a 1 µM dose and only the ADAM10/17 inhibitor 
blocked GPR56-dependent AP-AR shedding (Fig. 3.7 A). Moreover, in the 
presence of 1 µM ADAM10/17 inhibitor, C230-A TG2 lost its stimulating effect 
on GPR56, whereas shedding in the presence of the ADAM10 inhibitor was 
comparable to DMSO control. This result indicated that ADAM17 and not 
ADAM10 is involved in the reaction. 
In order to confirm the specific involvement of ADAM17, an inhibitory 
ADAM17 antibody (Prof. G. Murphy) was used at a concentration of 100 nM 
during the serum starvation and ligand treatment period, to see whether this 
also ablated signalling. The results obtained show a highly significant 
reduction in shedding in the presence of the inhibitory antibody (Fig. 3.7 B), 
similar to what was seen using the ADAM10/17 inhibitor (Fig. 3.7 A).  
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The results shown in this section revealed that ADAM17 is required for 
GPR56-dependent shedding of amphiregulin.  
 
 
 
 
 
Figure 3.7 ADAM17 is required for GPR56-dependent AP-AR shedding. 
Cells were co-transfected with GPR56 and AP-AR and experiments were started 
48 h post-transfection with 1 h serum starvation. 
(A) Cells were serum-starved in medium containing 1 µM ADAM10 or ADAM10/17 
inhibitor or DMSO solvent control, followed by 1 h treatment with control buffer or 
20 µg/ml C230-A TG2 in the presence or absence of the same inhibitor.  
(B) Cells were serum-starved and stimulated for 1 h with 20 µg/ml C230-A TG2 in the 
presence of 100 nM ADAM17 inhibitory antibody or human IgG control.  
Data presented show mean of 3 independent experiments with 4 repeats each 
+/- SEM (n=12). Statistical significance denoted as follows: *, p<0.05; ***, p<0.001; 
ns, non-significant.    
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3.2.4 Identifying mediator proteins downstream of GPR56 
 
Experiments illustrated in the previous sections identified TG2 as an agonist 
for GPR56 activating ADAM17. In order to further characterise GPR56 
signalling, the next step was to identify signalling mediators acting 
downstream of GPR56. Work here focussed on downstream mediators of Gq- 
and G12/13-pathways, as they have been implicated in GPR56 signalling 
(Iguchi et al. 2008; Little et al. 2004; Luo et al. 2011; Yang et al. 2011). 
 
 
3.2.4.1 Interfering with the Protein kinase C (PKC) / Phospholipase C 
(PLC) pathway  
 
To address the question whether GPR56-dependent AP-AR shedding was 
mediated via Gαq/11-proteins leading to activation of the PKC/PLC signalling 
pathway, the shedding assay was used as outlined before. Cells were serum 
starved in the presence or absence of different inhibitors blocking either PLC, 
PKC or IP3-receptors prior to C230-A TG2 stimulation in their presence or 
absence. 
In order to investigate whether Phospholipase C was activated downstream 
of GPR56, the aminosteroid and PLC inhibitor U73122 and an inactive 
control compound, U73343 (Merck Millipore), were used. U73122 is known to 
inhibit GPCR-induced activation of PLC, ablating the production of IP3 and 
release of Ca2+ from intracellular stores into the cytoplasm (Bleasdale and 
Fisher 1993). As shown in figure 3.8 A, treatment of cells with 5 µM of the 
PLC inhibitor U73122 stimulated basal shedding 2-fold. Additionally, C230-A 
TG2 induced GPR56 activity was further elevated to 3-fold above solvent 
control. In contrast, U73343 did not affect p-NPP hydrolysis rates and they 
were equal to DMSO solvent control (Fig. 3.8 A). 
 
The non-competitive IP3-receptor antagonist, 2-aminoethoxydiphenyl borate 
(2-APB), was used to look at effects of abolishing the release of intracellular 
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Ca2+. 2-APB inhibits the release of Ca2+ from intracellular stores such as the 
ER, without affecting binding of IP3 to its receptors (Maruyama et al., 1997). 
Treatment of GPR56-expressing cells with 5 µM 2-APB had no effect on 
GPR56-dependent AP-AR shedding and was comparable to DMSO solvent 
control (Fig. 3.8 B). 
 
The PKCα/β inhibitor, the indolocarbazole Gö6976 (Merck), was used in 
order to investigate whether PKC activity was involved in GPR56-induced 
AP-AR shedding. Gö6976 was reported to interfere with the Ca2+-dependent 
PKC isozymes α and β1, whereas it does not inhibit any of the Ca2+-
independent PKC subtypes (δ, ε, ζ) even at high concentrations (Martiny-
Baron et al. 1993). Figure 3.8 C shows that treatment with 1 µM Gö6976 
stimulated basal GPR56-activity leading to shedding of AP-AR. However, the 
TG2 response was ablated. 
 
In summary, interfering with the PKC/PLC-signalling pathway did not inhibit 
basal GPR56-induced shedding of AP-AR by ADAM17. However, treatment 
with the PKC-inhibitor Gö6976 abolished TG2 stimulation.  
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Figure 3.8 Inhibition of the PKC/PLC signalling pathway does not block basal 
GPR56-induced shedding of AP-AR by ADAM17. 
Two days post-transfection, GPR56 and AP-AR co-transfected cells were serum 
starved for 1 h in the presence of DMSO solvent control or (A) 5 µM PLC inhibitor 
U73122 or 5 µM negative control U73343, (B) 5 µM IP3-receptor antagonist 2-APB 
or (C) 1 µM PKCα/β inhibitor Gö6976. Cells were treated with 20 µg/ml C230-A TG2 
for 1 h in the presence of DMSO solvent control or the same compounds.  
Data presented show mean of 3 independent experiments with 3 to 4 repeats each 
+/- SEM (n=10 to 12). Statistical significance denoted as follows: ***, p<0.001; 
*, p < 0.05; ns, non-significant.    
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In order to investigate whether the stimulating effect of PLC inhibition on 
GPR56-dependent AP-AR shedding was due to increased GPR56 surface 
expression levels, an experiment using confocal microscopy was performed 
to assess cell surface expression levels of GPR56 (Fig. 3.9). Cells were 
transfected with SNAP-GPR56 and 48 h post-transfection serum starved. 
SNAP-GPR56 (shown in red) was stained using SNAP-surface substrate 647 
(NEB) at 4 °C for 15 mins. Cells were stimulated with C230-A TG2 in the 
presence of U73343 negative control compound (Fig. 3.9 A) or U73122 PLC 
inhibitor (Fig. 3.9 B) for 1 h. As shown in figure 3.9, SNAP-GPR56 was 
internalised to the same amount in the presence of both compounds, 
indicating that the PLC inhibitor U73122 did not block internalisation of 
GPR56 (the SNAP-tag technology and its application in experiments using 
confocal microscopy is explained in detail in Chapter 6). 
Therefore, the stimulating effect of U73122 regarding GPR56-dependent AP-
AR shedding cannot be explained with elevated GPR56 cell surface levels. 
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Figure 3.9 The PLC inhibitor U73122 does not stabilise cell surface expression 
levels of GPR56. 
Cells were seeded onto poly-L-lysine coated glass coverslips and the next day 
transfected with SNAP-GPR56. Two days later, cells were serum starved for 1 h. 
SNAP-GPR56 (shown in red) was stained at 4 °C for 15 mins using SNAP-surface 
substrate 647 (NEB). Cells were treated with control buffer or 20 µg/ml C230-A TG2 
for 1 h in (A) 5 µM U73343 or (B) 5 µM U73122 containing medium. 
White arrow heads, internalised GPR56 stained with SNAP-surface substrate 647 (red). 
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3.2.4.2 Inhibition of the RhoA signalling mechanism 
 
The following experiments were performed to investigate whether stimulation 
of GPR56 with C230-A TG2 leads to activation of RhoA. For this purpose, the 
Rho-associated protein kinase (ROCK) inhibitor Y-27632 (Sigma-Aldrich) 
was used in the shedding assay. GPR56 and AP-AR co-transfected cells 
were serum starved and treated with C230-A TG2 in the presence or absence 
of 2 µM Y-27632. Figure 3.10 shows that treatment with the ROCK inhibitor 
reduced basal GPR56-activity, leading to loss of basal AP-AR shedding to 
almost half of the value of untreated control. Stimulation of GPR56 with C230-
A TG2 did not lead to a significant increase of p-NPP hydrolysis rates in the 
presence of the inhibitor, when compared to the buffer control. 
These data demonstrated that stimulation of GPR56 with C230-A activated 
RhoA and that this signalling pathway must be involved in GPR56-dependent 
shedding of AP-AR.  
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Figure 3.10 The ROCK inhibitor Y-27632 blocks GPR56-dependent shedding of 
AP-AR and ablates stimulation of GPR56 with C230-A TG2. 
Cells were transfected with GPR56 and AP-AR and 48 h later serum starved for 1 h 
in the presence of 2 µM ROCK inhibitor Y-27632 or serum-free medium control. 
Cells were then treated with 20 µg/ml C230-A TG2 for 1 h in the presence or absence 
of the same inhibitor.  
Data presented show mean of 3 independent experiments with 4 repeats each 
+/- SEM (n=12). Statistical significance denoted as follows: ***, p<0.001; ns, non-
significant.    
 
  
 115 
 
3.2.4.3 Inhibition of the epidermal growth factor receptor (EGFR) 
 
Previous results demonstrated that activation of GPR56 led to shedding of 
the EGFR-ligand amphiregulin by ADAM17. In order to test whether EGFR 
itself was involved directly or indirectly in GPR56-dependent AP-AR 
shedding, the EGFR inhibitor AG1478 was used in the shedding assay. 
AG1478 inhibits the intrinsic tyrosine kinase activity of EGFR and prevents 
the induction of EGFR-dependent downstream signalling. 
GPR56 and AP-AR co-transfected cells were first serum starved, then 
stimulated with C230-A TG2 in the presence of 5 µM AG1478 or DMSO 
solvent control. Treatment with AG1478 decreased basal GPR56 activity 
compared to DMSO solvent control (Fig. 3.11). However, the presence of the 
EGFR inhibitor did not influence the stimulating effect of C230-A TG2 on AP-
AR shedding. This result indicated that AG1478 does not block the TG2 
response significantly.  
The data implied that the activity of EGFR is important for the cross-talk 
between GPR56 and EGFR, thus GPR56-dependent shedding of AP-AR.  
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Figure 3.11 Basal GPR56-dependent AP-AR shedding is reduced in the 
presence of the EGFR inhibitor AG1478. 
48 h post-transfection, GPR56 and AP-AR transfected cells were serum starved for 
1 h in the presence of 5 µM EGFR inhibitor AG1478 or DMSO solvent control, 
followed by treatment with 20 µg/ml C230-A TG2 for 1 h in the presence or absence 
of 5 µM AG1478.  
Data presented show mean of 3 independent experiments with 4 repeats each 
+/- SEM (n=12). Statistical significance denoted as follows: ***, p<0.001.    
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3.3 Discussion 
 
This chapter introduced a sensitive shedding assay, representing a tool to 
assess GPCR activation, as shown by others (Inoue et al. 2012). In order to 
define the signalling activity of GPR56, the assay described by Inoue et al. 
(2012) was modified regarding the ADAM substrate used. Instead of AP-
TGF-α, AP-tagged amphiregulin was used in this project as an example for 
an EGF-like ligand (Fig. 3.1 A), as substrate depletion was reached much 
faster with AP-TGF-α than with AP-AR when cells were co-transfected with 
GPR56 (data not shown).  
Using this assay, it was demonstrated that GPR56 had a high ligand-
independent, basal activity indicating constitutive activation of the receptor 
(Fig. 3.1 & 3.2). This phenomenon was described for other GPCRs like the 
histamine H1 receptor (H1R) using the TGF-α shedding assay (Inoue et al. 
2012) and GPR56 specifically, using reporter assays as well as RhoA 
pulldown assays (Shashidhar et al. 2005; Iguchi et al. 2008; Kim et al. 2010). 
Moreover, work performed in this project demonstrated for the first time an 
agonistic TG2-GPR56 relationship, since AP-AR shedding was further 
increased by treatment with C230-A TG2 (Fig. 3.2). This finding is in contrast 
to a report from Chiang et al. (2011), who claimed that human TG2 was not 
an endogenous binding partner. However, experiments performed by 
Andreas Heil in the Aeschlimann laboratory clearly showed an interaction 
between human N-GPR56-Fc and human TG2 in solution (data not shown). 
In addition, Yang et al. (2014) just recently confirmed our results by co-IP 
experiments using MC-1 human melanoma cells overexpressing GPR56, as 
well as experiments demonstrating pulldown of hTG2-GST with hGPR56N-
Fc. 
 
Western blot analysis of the cells used in the shedding assays confirmed that 
HEK293 cells were negative for endogenous GPR56 and TG2 expression, 
therefore these cells are a good choice to evaluate signalling by GPR56 (Fig. 
3.3). Western blot analysis for N-GPR56 revealed a typical banding pattern 
for wild type GPR56, consisting of the major bands running between ~60 and 
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75 kDa, representing differentially glycosylated N-GPR56 forms, as well as 
full-length receptor, respectively (Fig. 3.3 A). The banding pattern is in line 
with several reports from the literature (Jin et al. 2007; Chiang et al. 2011; 
Luo et al. 2011; Paavola et al. 2011), however the detected bands do not 
correspond to the predicted size for N-GPR56, which should be much smaller 
(~40 kDa). As shown by Jin et al. (2007) and Chiang et al. (2011), N-GPR56 
carries 7 N-glycosylations and 5-15 moieties of sialic acid. Therefore, the 
protein ladder between 60 kDa to 75 kDa likely corresponds to N-GPR56 
decorated with carbohydrate chains added in ER and golgi. In general, N-
glycosylations are important for proper protein folding, as well as trafficking, 
cell surface expression and secretion. As a result, mutations within GPR56, 
affecting proper glycosylation and cell surface expression, were shown to 
cause the brain malformation BFPP (Jin et al. 2007). 
Due to a lack of GPR56 antibodies, the V5-epitope tag was used to detect 
the C-GPR56 domain, consisting of the 7TM-domain and the cytoplasmic tail. 
Western blot analysis using anti-V5 antibody showed a banding pattern for 
wild type GPR56 consisting of bands running at ~27 kDa (monomer), 50 kDa 
(dimer) and 75 kDa (Fig. 3.3 B), the latter most likely representing full-length 
GPR56, as this band was also recognised with the anti-N-GPR56 antibody. 
Others speculated that this might be a trimeric C-terminal receptor form 
(Chiang et al. 2011). In general, the banding pattern is in good agreement 
with other reports (Jin et al. 2007; Xu et al. 2006; Paavola et al. 2011). 
However, the band for monomeric C-GPR56 (~27 kDa) is smaller than its 
predicted size, likely due to the hydrophobic nature of the C-terminal 
fragment which includes the 7TM-region (Jin et al. 2007). Interestingly, the 
only difference between control buffer and C230-A TG2 treatment was a 
reduction in the expression level of the dimeric receptor form, running at 
~50 kDa following TG2-treatment. This finding points toward increased 
receptor internalisation and probably degradation, as investigated in 
Chapter 6. In addition, it indicates that the dimer is the receptor form mainly 
expressed at the cell surface, as shown by others for GPR56 using a surface 
biotinylation approach (Paavola et al. 2011) and for different GPCRs 
(Terrillon and Bouvier 2004; Milligan 2004). 
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In conditioned media, secreted GPR56-ECD was only found in N-GPR56 
transfected cells, but not in medium from wild type GPR56-transfected cells 
(Fig. 3.3 D). This is in contrast to observations by Chiang and colleagues 
(2011) who detected secreted N-GPR56 in medium of cells transfected with 
wild type GPR56 and several receptor mutants carrying missense mutations 
in the N-terminal domain and ECLs. They demonstrated that there must be 
an additional cleavage event independent of GPS proteolysis, mediated by 
MMPs or ADAMs, as release was abolished by the metalloproteinase 
inhibitor GM6001 (Chiang et al. 2011). In addition, Jin and colleagues (2007) 
could also detect wild type N-GPR56 in conditioned medium. It must be 
noted that conditioned media were tested for GPR56 expression after 1 h 
incubation in this project, whereas Jin and colleagues (2007) left cells for 
48 h. Thus, there may be small amounts of GPR56 present in the medium 
after 1 h, which is below detectable levels. 
 
Using the shedding assay, it was shown that TG2 and C230-A TG2 activate 
GPR56-dependent AP-AR shedding. This result was validated by showing 
the same degree of receptor activation with an agonistic anti-N-GPR56 
antibody (Fig. 3.4). These findings expand the understanding of TG2-GPR56 
interactions, as they upgrade TG2 from a binding partner (Xu et al. 2006) to 
an agonistic ligand for GPR56.  
A receptor-ligand response was previously shown for collagen III and 
GPR56, whereas collagen III negatively regulated neural progenitor migration 
through stimulation of GPR56-dependent Rho activation (Luo et al. 2011). 
The results presented in this chapter showed that collagen III did not activate 
GPR56. However, it must be noted that Luo et al. (2012) mentioned 
variations regarding the biological function of different collagen III batches 
(Abcam), which they tested before performing their experiments. It is likely 
that the collagen III used in my project was inactive due to fibril formation and 
thus did not activate GPR56. 
 
In this project, ADAM17 was identified as a mediator of GPR56 signalling, 
which is involved in GPR56-dependent and TG2-induced cleavage of AP-AR 
 120 
 
(Fig. 3.7). In the past, Gschwind et al. (2003) demonstrated the involvement 
of ADAM17 in GPCR-dependent shedding of amphiregulin and subsequent 
EGFR activation in squamous cell carcinoma. Moreover, Inoue et al. (2012) 
identified ADAM17 as the main ADAM involved in GPCR-dependent 
cleavage of TGFα, as siRNA-mediated knockdown of ADAM17 abolished 
GPCR-induced shedding for almost all receptors tested. This thesis is the 
first report showing activation of ADAM17 by GPR56 or an adhesion GPCR. 
 
In order to investigate potential downstream signalling pathways induced by 
GPR56, inhibitors were tested that interfere with the PLC/PKC signalling 
pathway, which is downstream of GPCRs coupling to Gαq-proteins (Rebecchi 
and Pentyala 2000; Inoue et al. 2012). GPR56 itself was shown to bind to 
Gαq/11 (Little et al. 2004). Moreover, using PKC inhibitors as well as a 
dominant negative mutant of PKCα, Yang et al. (2011) demonstrated that the 
inhibitory effect of GPR56 on melanoma growth and angiogenesis is 
mediated by PKCα. 
Active PLC generates two second messengers, diacylglyerol (DAG) and 
inositol triphosphate (IP3). DAG activates PKC, which in turn phosphorylates 
a variety of proteins. IP3 binds to receptors located in the membrane of the 
ER, leading to release of intracellular Ca2+, which itself controls multiple 
cellular processes (Bootman et al. 2001).  
Treatment with the PLC inhibitor U73122 led to a significant increase in basal 
shedding of AP-AR (Fig. 3.8 A). Gαq-PLC-PKC signalling might compete with 
other pathways induced by different Gα-proteins, thus inhibiting PLC could 
promote the initiation of other signalling pathways leading to AP-AR 
shedding. A similar effect was described by Inoue et al. (2012) as “shunting 
of Gα coupling”, since they observed increased TGFα shedding for some 
GPCRs due to increased Gαq-/Gα12/13-signalling when they inhibited Gαs and 
Gαi. However, they could not observe this effect with the same PLC inhibitor 
used in my project. 
On the other hand, U73122 was shown to have opposing, unspecific effects 
such as increasing the release of intracellular Ca2+ (Mogami et al. 1997), 
including IP3-mediated release of Ca2+. Interestingly, coupling of the agonist-
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activated AT1-receptor to Gq was shown to activate PLC, leading to 
mobilisation of Ca2+ and production of reactive oxygen species (ROS), which 
promotes ADAM17-dependent shedding of HB-EGF (Mifune et al. 2005). 
Thus, a direct effect of elevated Ca2+ levels on ADAM17 activity due to 
U73122 treatment, resulting in increased basal shedding cannot be excluded. 
A good example for a direct effect of compounds on ADAM17 activity are the 
results obtained with the ADAM10/17 inhibitor and the inhibitory ADAM17 
antibody (Fig. 3.7), resulting in decreased AP-AR shedding.  
The normal TG2 response in the presence of the PLC inhibitor, however, can 
be explained by the GPR56-dependent activation of ADAM17, as observed 
with DMSO solvent control (Fig. 3.8 A). 
 
Treatment with the PKC inhibitor Gö6976 significantly increased basal 
shedding when compared to DMSO control (Fig. 3.8 C). PKC activates 
GPCR kinase 2 (GRK2) by phosphorylation, resulting in binding of GRK2 to 
GPCRs, followed by their internalisation (Winstel et al. 1996). In addition, 
PKC was also shown to directly phosphorylate GPCRs, leading to their 
internalisation and attenuation of G protein signalling (García-Sáinz et al. 
2000). Thus, inhibition of PKC by Gö6976 could inhibit internalisation of 
GPR56, leading to enhanced cell surface levels of GPR56, resulting in 
increased basal shedding of AP-AR. As discussed above, treatment with the 
PLC inhibitor U73122 also increased basal shedding dramatically, when 
compared to cells treated with the negative control U73343 (Fig. 3.8 A). 
Since PKC is activated downstream of PLC, inhibition of PLC would also 
impair PKC activity, which might result in inhibition of GPR56 internalisation. 
Therefore, it was tested whether the PLC-inhibitor elevated GPR56 cell 
surface expression levels. Confocal analysis of cells treated with U73122 did 
not indicate elevated cell surface expression levels of GPR56 (Fig. 3.9). 
Nonetheless, it must be noted that approaches like flow cytometry or 
biotinylation of cell surface proteins represent better tools to quantify GPR56 
present in the cell membrane. Thus, it cannot entirely be excluded that the 
increase in basal shedding observed in the presence of the PLC and PKC 
inhibitors is due to elevated cell surface expression levels of GPR56.     
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On the other hand, PKC inhibition by Gö6976 could also directly interfere 
with ADAM17 activity, independent of GPR56. It was demonstrated by Ghosh 
et al. (2004) that inhibition of PKC by Gö6976 stimulates extracellular signal-
regulated kinase (ERK)-phosphorylation. Activated ERK, in turn, 
phosphorylates ADAM17, leading to trafficking of ADAM17 to the cell surface 
and induction of its catalytic shedding activity (Fan and Derynck 1999; Soond 
et al. 2005; Bell and Gööz 2010).  
In addition, PKC is known to directly activate ADAM17 resulting in increased 
substrate shedding, as shown for TGF-α (Dang et al. 2011; Kveiborg et al. 
2011). Thus, inhibition of PKC could directly interfere with ADAM17 
activation, which may explain the fact that TG2 addition did not lead to a 
stimulation of AP-AR shedding in wells treated with PKC inhibitor. 
 
Experiments using the IP3-receptor inhibitor 2-APB showed that inhibition of 
Ca2+-release from the ER had no effect on basal and TG2-induced AP-AR 
shedding (Fig. 3.8 B). The results implicate that Ca2+ does not play a role for 
shedding of AP-AR, which is supported by the finding that ADAM10, but not 
ADAM17 is activated by Ca2+-flux, inducing TGF-α and AR shedding 
(Horiuchi et al. 2007). In addition, the result indicates that GPR56’ 
constitutive and TG2-stimulated activity do not induce Ca2+-flux, thus GPR56 
likely does not signal via Gq. Using luciferase reporter assays looking at 
GPR56-dependent signalling, Dr. Vera Knäuper could show that GPR56 
does not couple Gq (data not shown). These findings are in line with a report 
from Inoue et al. (2012) demonstrating that not only Gαq-, but especially 
Gα12/13-dependent pathways were involved in TGFα shedding, which may 
also account for GPR56-dependent shedding of AP-AR. 
 
Data presented in this project show that Rho-signalling is activated by 
GPR56 and that ROCK-activity is required for GPR56-induced shedding by 
ADAM17 (Fig. 3.10). These findings confirm previous reports, demonstrating 
RhoA activation by GPR56 overexpression (Iguchi et al. 2008; Luo et al. 
2011; Kim et al. 2010). In addition, Luo et al. (2011) showed elevated RhoA 
signalling following collagen III treatment, resulting in inhibition of migratory 
 123 
 
signals observed in their neurosphere assays. Using a ROCK inhibitor, it was 
demonstrated for the first time that GPR56-induced Rho signalling is also 
stimulated by TG2. RhoA is usually associated with Gα12/13- and in a few 
cases with Gq-coupled receptors (Chikumi et al. 2002). Kim and colleagues 
(2010) used the same ROCK inhibitor Y-27632 and demonstrated that 
GPR56-dependent SRE-activity was mediated through Gα12/13 and Rho, 
pointing toward an involvement of Gα12/13 in GPR56-dependent shedding of 
AP-AR.  
 
Another GPCR signalling mechanism that plays a critical role for cell 
proliferation and migration, is the transactivation of epidermal growth factor 
receptors (EGFR) (Daub et al. 1996; Prenzel et al. 1999). GPCR-dependent 
cleavage of EGF-like ligands by metalloproteinases leads to activation of 
EGFRs. Gq-, Gi- and G13-proteins were reported to be involved in this 
signalling pathway (Daub et al. 1997; Gohla et al. 1998; Gohla et al. 1999), 
as well as β-arrestins (Noma and Lemaire 2007). The shedding assay used 
to measure GPR56 activity in this project is an indicator for GPR56-
dependent EGFR transactivation, as amphiregulin is one of the known EGFR 
ligands. Activation of the EGFR leads to EGFR dimerization and 
phosphorylation, resulting in the activation of several downstream mediator 
proteins like mitogen-activated protein kinases (MAPKs) (Daub et al. 1997). 
Experiments using the EGFR inhibitor AG1478 showed that basal AP-AR 
shedding was decreased in the presence of inhibitor (Fig. 3.11). This result 
indicates that there might be a positive feedback loop from downstream 
signalling pathways activated by EGFR to ADAM17. ERK is phosphorylated 
downstream of EGFR and was shown to activate ADAM17, as discussed 
above (Fan and Derynck 1999; Soond et al. 2005; Bell and Gööz 2010). 
Thus, inhibiting EGFR activation may result in decreased ADAM17 shedding 
activity, independent of GPR56. In addition, the result could also reflect a 
direct interaction between GPR56 and EGFR, as shown for somatostatin 
receptors 1 and 5 with EGFR (Watt et al. 2009), leading to activation of 
ADAM17. However, stimulation of shedding by TG2 was not affected in the 
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presence of the AG1478, indicating that GPR56-dependent ADAM17 
activation was not inhibited. 
In summary, results presented in this chapter showed that GPR56 activation 
can be measured by ADAM17-mediated AP-AR shedding. GPR56 has a high 
constitutive activity and is further activated by its agonist human TG2 or an 
agonistic anti-N-GPR56 antibody. The signalling mechanism is likely to be 
Gα12/13-dependent, requiring ROCK activity. Figure 3.12 summarises the 
discussion of this chapter. 
 
Figure 3.12 Potential downstream signalling pathways involved in GPR56-
dependent ADAM17-activation. 
Constitutive and TG2-induced GPR56 activity leads to RhoA and ROCK activation, 
which induces ADAM17-dependent shedding of AP-AR shedding, as shown by 
treatments with ADAM17 and ROCK inhibitors. Experiments using inhibitors for 
PLC, PKC, IP3-receptors and EGFR could not entirely exclude an involvement of 
PKC-, calcium- and ERK1/2-signalling in GPR56-dependent ADAM17 activation, 
which needs further evaluation.  
  
 
 
 
 
 
CHAPTER 4: 
Characterisation of  
GPR56-TG interactions
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4 Characterisation of GPR56-TG interactions 
 
4.1 Introduction 
 
Having established that TG2 activated GPR56, the next step was to 
characterise sequence and domain requirements of TG2 involved in receptor 
activation. 
TG2 consists of 4 main domains: the N-terminal β-sandwich, a catalytic core 
and two C-terminal β-barrels. Regarding the interaction with GPR56, Xu et al. 
(2006) demonstrated that the β-barrel domain was indispensable for binding 
of GPR56. Their findings indicated that the two β-barrels alone would be 
sufficient to bind and potentially activate GPR56. However, activation of 
GPR56 by TG2 or its β-barrels was not demonstrated in their study. 
The best studied catalytic function of TGs is the post-translational 
modification of proteins by crosslinking of a glutamine to a lysine residue. 
The reaction is highly Ca2+-dependent and can be inhibited by guanine 
nucleotides (Király et al. 2011; Pinkas et al. 2007). It is unclear whether the 
catalytic activity of TG2 is required for GPR56 activation. Moreover, non-
enzymatic functions of extracellular TG2, including direct interactions with 
ECM components and cell surface proteins, were associated with cellular 
processes like cell adhesion, migration and signalling (Nurminskaya and 
Belkin 2012). Thus, it is likely that the catalytic activity of TG2 is not essential 
for the activation of GPR56. This hypothesis was tested by using two 
catalytically inactive TG2 variants. 
The C277-S TG2 mutant lacks transglutaminase activity such as crosslinking, 
as it carries a mutation in the catalytic triad (Cys277-His335-Asp358) located 
within the core domain of TG2, essential for its catalytic activity (Lee et al. 
1993).  
Open Conformation-TG2 (OC-TG2, Open-TG2) is stabilized in an extended 
conformation by an irreversible inhibitor that binds to the catalytic site 
cysteine, making the TG2 active site inaccessible for substrates and forcing 
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the inactivation of the enzyme. Due to the conformational change of inhibitor-
bound Open-TG2, usually buried residues are accessible for potential 
interacting partners and the catalytic site is exposed (Pinkas et al. 2007).  
In order to identify critical structural domains for GPR56-activation, the 
related TG, human Factor XIII (FXIII) lacking the two C-terminal β-barrels, 
was tested. FXIII can be found intracellularly as well as extracellularly in the 
plasma, where it functions in the blood coagulation system by stabilising 
fibrin clots (Mehta and Eckert 2005). 
Moreover, TG6 and TG7 were used in order to address the question whether 
other TGs activate GPR56. 
TG6 is expressed in the central nervous system, testis and lung, but its main 
function and whether it causes disease is unknown (Mehta and Eckert 2005). 
However, TG6 autoantibodies were associated with the development of 
coeliac disease with epilepsy and cerebral calcifications (CEC) (Johnson et 
al. 2013). Neuronal transglutaminase represents an interesting candidate for 
a GPR56 ligand, as GPR56 ablation leads to the developmental brain 
disease BFPP (Piao et al. 2004). 
TG7 is ubiquitously, but predominantly expressed in testis and lung, however 
its physiological function and potential role in disease remains elusive 
(Grenard et al. 2001). Like TG6, TG7 is closely related to TG2 and sequence 
alignments showed a high level of sequence identity regarding the core 
domain (~50%) (Grenard et al. 2001). 
 
4.1.1 Aims of the chapter 
 
 To investigate whether the enzymatic activity of TG2 is required for the 
activation of GPR56. 
 
 To identify specific domains within TGs required for the interaction and 
activation of GPR56. 
 
 To identify new GPR56 ligands using the shedding assay.  
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4.2 Results 
 
4.2.1 GPR56 activation by TG2 is independent of transglutaminase 
activity  
 
Results of the previous chapter showed that TG2, C230-A TG2 and an anti-N-
GPR56 antibody stimulate GPR56-dependent AP-AR shedding. Wild type 
and C230-A TG2 are both catalytically active under the experimental 
conditions as evaluated using a real-time fluorescence assay which 
measures TG-dependent isopeptidase activity (Adamczyk 2013; and data not 
shown).  
In order to test whether the catalytic activity of TG2 was needed to activate 
GPR56, two catalytically inactive TG2 variants, C277-S TG2 and Open-TG2, 
were tested using the shedding assay.  
 
Figure 4.1 shows the analysis of p-NPP hydrolysis of GPR56 and AP-AR co-
transfected cells treated with C277-S TG2 and OC-TG2 (purchased from 
Zedira GmbH, Darmstadt) or C230-A TG2. Treatment with C277-S TG2 
activated GPR56 by >30 % compared to buffer control. Treatment with Open-
TG2 led to an increase in GPR56 activity of about ~37 % above controls. 
Thus, both catalytically inactive TG2 variants activated GPR56 to a similar 
extend as active C230-A TG2 (Fig. 4.1). 
 
These data showed that the catalytic activity of TG2 is dispensable for the 
stimulation of GPR56-mediated signalling. 
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Figure 4.1 Catalytically inactive tissue transglutaminases activate GPR56. 
Cells were transfected with GPR56 and AP-AR. Two days post-transfection, cells 
were serum starved for 1 h, followed by treatment with 20 µg/ml C230-A TG2, C277-S 
TG2 or Open-TG2 for 1 h.  
Data presented show mean of 4 to 7 independent experiments with 4 repeats each 
+/- SEM (n=16-28). Statistical significance denoted as follows: ***, p<0.001.    
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4.2.2 Other TG isoenzymes 
 
Previous results showed that TG2, C230-A TG2 as well as two catalytically 
inactive TG2 variants, C277-S TG2 and OC-TG2, activated GPR56-mediated 
shedding. Next, other members of the TG family were tested in order to 
identify novel potential GPR56 ligands. 
 
 
4.2.2.1 Neuronal transglutaminase (TG6, TGY) induces GPR56-
dependent AP-AR shedding  
 
To test TG6 as a potential ligand for GPR56, GPR56 and AP-AR co-
transfected cells were treated with TG6 or C230-A TG2 for comparison (Fig. 
4.2). Treatment with TG6 led to an increase in p-NPP hydrolysis of ~30 % 
compared to buffer control. Treatment with TG6 buffer alone resulted in a 
35 % increase when compared to the C230-A TG2 buffer control. Thus, the 
TG6 buffer had a similar stimulating effect as treatment with C230-A TG2. This 
was most likely caused by the presence of 10 mg/ml sucrose in the TG6 
buffer. In contrast to TG2, TG6 tends to aggregate and precipitate, which is 
prevented by the addition of sucrose to the buffer (personal communication 
with Zedira GmbH, Darmstadt). Sucrose is known to inhibit receptor 
internalisation and could therefore enhance the cell surface expression levels 
of GPR56, facilitating shedding of AP-AR. TG6 and C230-A TG2 both 
stimulated GPR56-dependent shedding when compared to their buffer 
controls.  
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Figure 4.2 TG6 activates GPR56-induced shedding of AP-AR. 
Cells were transfected with GPR56 and AP-AR. 48 h post-transfection, cells were 
serum starved for 1 h, followed by treatment with 20 µg/ml C230-A TG2 or TG6 for 
1 h.  
Data presented show mean of 4 independent experiments with 4 repeats each 
+/- SEM (n=16). Statistical significance denoted as follows: ***, p<0.001. 
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4.2.2.2 Transglutaminase 7 (TG7, TGz) activates GPR56 
  
The next member of the transglutaminase family tested was TG7. Cells co-
transfected with GPR56 and AP-AR where treated with TG7 or C230-A TG2 
and AP activity was analysed in the medium (Fig. 4.3). Treatment with TG7 
caused an increase of ~30 % when compared to buffer control. The 
stimulating effect of TG7 was therefore comparable to that of C230-A TG2. 
The presence of reduced glutathione in the TG7 buffer did not influence 
GPR56-dependent shedding of AP-AR. 
 
 
 
 
Figure 4.3 TG7 activates GPR56-dependent AP-AR shedding. 
Cells were transfected with GPR56 and AP-AR. Two days after transfection, cells 
were serum starved for 1 h, followed by treatment with 20 µg/ml C230-A TG2 or TG7 
for 1 h.  
Data presented show mean of 4 independent experiments with 4 repeats each 
+/- SEM (n=16). Statistical significance denoted as follows: ***, p<0.001. 
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4.2.2.3 A transglutaminase lacking the β-barrel domains fails to 
activate GPR56 
 
Next, the involvement of the TG2 β-barrels in GPR56 signalling was tested, 
as these domains were shown to mediate binding to N-GPR56 (Xu et al. 
2006). Unfortunately, a TG2 mutant lacking those domains was not available 
for the study, but a mutant isoform of the related TG, human factor XIII, solely 
consisting of the β-sandwich and core domain (∆FXIII; purchased from 
Zedira GmbH, Darmstadt) was used to investigate whether the two C-
terminal β-barrels of TGs were required to activate GPR56. 
GPR56 and AP-AR co-transfected cells were treated with ∆FXIII or C230-A 
TG2 and AP-activity was analysed in the medium (Fig. 4.4). In contrast to 
C230-A TG2, treatment with ∆FXIII did not significantly increase p-NPP 
hydrolysis when compared to the buffer controls. Unfortunately, full-length 
FXIII was not available for control experiments in order to evaluate its ability 
to activate GPR56. 
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Figure 4.4 Truncated ∆FXIII does not activate GPR56-dependent AP-AR 
shedding. 
Cells were transfected with GPR56 and AP-AR. 48 h post-transfection, cells were 
serum starved for 1 h, followed by treatment with 20 µg/ml C230-A TG2 or ∆FXIII for 
1 h.  
Data presented show mean of 3 independent experiments with 4 repeats each 
+/- SEM (n=12). Statistical significance denoted as follows: ***, p<0.001; ns, non-
significant.    
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4.2.2.4 The β-barrel domains of TG2 are sufficient to activate GPR56 
 
Cells transfected with GPR56 and AP-AR were treated with the β-barrels of 
TG2 or full-length C230-A TG2 and AP activity was analysed in conditioned 
medium (Fig. 4.5). Treatment of cells with the β-barrels increased AP-AR 
shedding significantly when compared to buffer control. However, the 
stimulation was not as effective as with full-length C230-A TG2. 
 
 
 
 
 
 
Figure 4.5 The β-barrel domains of TG2 activate GPR56. 
Cells were transfected with GPR56 and AP-AR. 48 h post-transfection, cells were 
serum starved for 1 h, followed by treatment with 20 µg/ml C230-A TG2 or β-barrels 
of TG2 for 1 h.  
Data presented show mean of 6 independent experiments with 4 repeats each 
+/- SEM (n=24). Statistical significance denoted as follows: ***, p<0.001; *, p<0.05.    
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4.3 Discussion 
 
The results presented in this chapter demonstrated that the transglutaminase 
activity of TG2 is dispensable for activating GPR56. Two catalytically inactive 
isoforms of TG2, C277-S TG2 and Open-TG2 were used in the shedding 
assay and both activated GPR56 (Fig. 4.1).  
The catalytic site of TG2, crucial for transglutaminase activities including 
crosslinking, is present in the core domain. This domain is located between 
the N-terminal β-sandwich and the two C-terminal β-barrels (Fig. 4.6). The 
catalytic triad within the core domain consists of cysteine277 (mutated in 
C277-S TG2), a histidine and an aspartate, as well as a conserved tryptophan 
that stabilizes the transition state of TG2, in which the enzyme is catalytically 
active (Iismaa et al. 2009).  
 
 
 
Figure 4.6 Crystal structure of Open-TG2. 
Expanded form of enzymatically inactive, irreversible peptide inhibitor-bound TG2. 
Motifs additionally accessible for GPR56-binding in the extended conformation are 
marked in red. 
Taken from Iismaa et al. (2009), modified. 
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Catalytically active TG2 is known to crosslink itself to ECM proteins like 
fibronectin, to form intramolecular cross-links stabilizing proteins and 
intermolecular isopeptide bonds, resulting in the formation of dimers and 
polymers, as shown for several ECM proteins (Belkin 2011). Thus, it was 
speculated that TG2 could also crosslink GPR56 intra- or intermolecularly, 
resulting in conformational changes or the formation of receptor dimers, 
respectively. A similar phenomenon was observed for FXIIIa, which 
crosslinks agonist-occupied AT1 receptors on the cell surface of monocytes 
from hypertensive patients. Crosslinking of AT1 resulted in enhanced 
receptor signalling promoting monocyte adhesion (Abdalla et al. 2004). 
Moreover, emerging evidence indicates that GPCRs function as oligomers in 
the cell membrane rather than as monomers (Terrillon and Bouvier 2004; 
Milligan 2004). However, results shown in figure 4.1 using catalytically 
inactive C277-S TG2, as well as western blot analysis shown in the previous 
chapter (3.2.2.1) demonstrated that the transglutaminase activity was not 
crucial for receptor activation and we were unable to detect crosslinking of 
GPR56 by TG2. Therefore, TG2 might just act as a ligand for GPR56, by 
inducing conformational changes and signalling through the receptor.  
Experiments using Open-TG2 confirmed the observations made with C277-S 
TG2, indicating the dispensability of its catalytic activity for activation of 
GPR56-dependent AP-AR shedding (Fig. 4.1). Open-TG2 remains in an 
extended conformational state, containing a covalently bound peptide 
inhibitor that occupies the catalytic site (Fig. 4.6). This prevents 
conformational changes and Open-TG2 is enzymatically inactive (Pinkas et 
al. 2007). The β-barrel domains that were proposed to be important for 
GPR56 binding (Xu et al. 2006) are accessible in Open-TG2. Moreover, there 
are additional structural motifs accessible in the core domain, as well as in 
the β-barrels. These motifs are normally buried when TG2 is in the closed 
conformation and could contribute to receptor binding (Fig. 4.6). 
Generally, it is not well understood whether the conformational state of 
inhibitor-bound Open-TG2 reflects the structure of catalytically active, Ca2+-
bound TG2, due to the lack of x-ray structural data (Pinkas et al. 2007; Király 
et al. 2011). It is still unclear how the enzymatic activity of TG2 is regulated 
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outside the cell (Pinkas et al. 2007). The extracellular milieu is high in Ca2+, 
which should activate TG2, however, TG2 is inactive under normal 
physiological conditions. It was speculated that TG2 remains in a closed, 
catalytically inactive conformation upon secretion (Pinkas et al. 2007), or 
alternatively that it is inactivated due to oxidation and disulphide formation 
(Stamnaes et al. 2010). Extracellular TG2 induces cell adhesion and 
migration independent of its enzymatic activities (Zemskov et al. 2006). Since 
GPR56 belongs to the family of adhesion GPCRs, regulating neural 
progenitor cell migration (Iguchi et al. 2008; Luo et al. 2011), these cellular 
processes might be induced through activation of GPR56 by catalytically 
inactive TG2.  
 
In order to gain additional information about conformational requirements 
regarding GPR56 activation, closed TG2 could be tested as a GPR56 ligand. 
Closed TG2 lacks transglutaminase activity, as the catalytic site is buried in 
this conformation. It is the predominant isoform of TG2 in the cytoplasm, 
where Ca2+-levels are low and GTP-levels high. TG2 adopts the closed 
conformation by binding GTP/GDP and acts as a G protein intracellularly 
(Achyuthans and Greenberg 1987; Nakaoka et al. 1994). However, in cell 
culture medium containing 1.8 mM Ca2+, the closed conformation is unstable 
and can unfold. In order to preserve a closed conformation in the assay, an 
alternative experimental approach would be employed. A stable TG2-GTPγS 
complex formed by addition of a non-hydrolysable form of GTP to TG2, 
would allow to experimentally test this scenario. 
 
Results shown in this chapter also identified two new potential ligands for 
GPR56, TG6 and TG7 (Fig. 4.2 & Fig. 4.3). Little information is available  
about TG6 and TG7, but interestingly TG6 was shown to be predominantly 
expressed in a subset of neurons (Grenard et al. 2001; Aeschlimann and 
Grenard 2006). GPR56 is involved in early brain development and mutations 
in GPR56 cause the developmental brain disease BFPP (Piao et al. 2004), 
thus TG6 might represent a physiological GPR56 ligand in the CNS. TG6 
shows close homology to TG2, and TG6 autoantibodies were associated with 
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the development of neurological disorders, such as gluten ataxia 
(Hadjivassiliou and Aeschlimann 2008). Autoantibodies interacting with TG6 
would lead to a TG6 null situation in ataxia patients. If TG6 represents a 
physiologically relevant ligand for GPR56 in the brain, then depletion of TG6 
would also affect GPR56 signalling. This, in turn could contribute to the 
development of the neurological disorders mentioned above. 
 
The function of TG7 remains elusive, but in addition to the high expression in 
testis and lung, high transcript levels were found in breast cancer cells 
(Mehta and Eckert 2005). This finding implicates an involvement in cancer 
development, which could provide the link to GPR56, which itself was 
suggested to play a potential role in diverse cancers. GPR56 functions as a 
tumour suppressor in metastatic melanoma, where its overexpression inhibits 
tumour growth and metastasis (Xu et al. 2006; Yang et al. 2011) and reduced 
GPR56 protein levels are associated with pancreatic cancer (Huang et al. 
2008). Opposing findings showed that GPR56 down-regulation is associated 
with the inhibition of melanoma progression, presenting GPR56 as a tumour 
promoter (Ke et al. 2007; Yang et al. 2014). Moreover, GPR56 mRNA was 
shown to be up-regulated in diverse cancers like pancreatic, lung, 
esophageal squamous cell carcinoma and breast cancer, where TG7 could 
be a putative ligand (Ke et al. 2007; Sud et al. 2006). GPR56 protein is also 
overexpressed in glioblastoma, where it is potentially involved in adhesion 
signalling (Shashidhar et al. 2005).  
 
Xu et al. (2006) demonstrated that the β-barrels of TG2 bind GPR56. 
However, the importance of these domains for receptor activation was 
demonstrated for the first time in my project. Experiments using truncated 
∆FXIII missing the two C-terminal β-barrels indicated that the two domains 
were indispensable for GPR56 activation (Fig. 4.4). However, it was not 
tested whether full-length FXIII activates GPR56.  
In addition, experiments using the β-barrel domains of TG2 as a ligand for 
GPR56 showed that they were sufficient to induce GPR56-dependent AP-AR 
shedding (Fig. 4.5). However, stimulation was not as pronounced as with full-
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length TG2. Thus, data presented in this project may support a model of 
GPR56 activation by TGs that requires the presence of full-length TGs. In 
this model, the C-terminal β-barrels interact with N-GPR56 and the N-
terminal domain of TG2, containing the catalytic core, potentially contributes 
by additional interactions with the 7TM-domain of C-GPR56 (Fig. 4.7). This 
hypothesis, however, requires further experimental verification. In order to 
investigate whether C-GPR56 interacts with TG2, a C-GPR56-Fc probe could 
be used to pulldown TG2. In addition, an N-terminally truncated form of 
GPR56 was tested in the AP-AR shedding assay and it was shown that this 
form, lacking the N-terminal TG2 binding domain, was not activated upon 
TG2 treatment (see Chapter 5). 
 
 
 
 
Figure 4.7 Model of potential TG2-GPR56 interactions. 
Experiments using the β-barrels of TG2 showed that GPR56 is activated only 
submaximal when compared to the induction of GPR56-dependent shedding of AP-
AR in response to treatments with full-length TG2. Therefore, it was speculated that 
interactions of the core and the β-sandwich domains of TG2 with the 7TM-domain of 
GPR56 are required in addition to the interaction between the TG2 β-barrels with N-
GPR56 in order to achieve full receptor activation.  
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In summary, results in this chapter showed that the catalytic activity of TG2 is 
not required for activation of GPR56-dependent AP-AR shedding. Two new 
potential ligands, TG6 and TG7 activated GPR56. The experiments also 
indicated that the β-barrels of TGs are essential for GPR56 interaction and 
activation. 
 
  
 
 
 
 
CHAPTER 5: 
Identifying GPR56 structural 
domains involved in downstream 
signalling
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5 Identifying GPR56 structural domains involved in 
downstream signalling 
 
5.1 Introduction 
 
Most studies looking at GPR56 functions focus on mutations causing the 
cobblestone-like brain malformation BFPP (Piao et al. 2004), which is 
associated with overmigrating neural progenitors through a defective pial BM 
in the forebrain and the rostral cerebellum. 25 BFPP-associated GPR56 
mutations, including missense, splicing and frameshift mutations were 
identified in human (Piao et al. 2004; Quattrocchi et al. 2013; Singer et al. 
2012; Fujii et al. 2013). All of the missense mutations studied in more detail 
impair receptor trafficking and cell surface expression, indicating that BFPP is 
caused by the absence of functional GPR56 at the cell surface. This is in line 
with the finding that GPR56 plays an important role in early brain 
development and reflected by analysis of Gpr56-/- mice, showing a similar 
cobblestone-like brain malformation (Piao 2004; Li 2008; Koirala 2009). 
 
Several other studies focussed on the putative role of N-GPR56 for receptor 
signalling, specifically regarding its ligand binding ability and its potential role 
as an endogenous ligand. The TG2 binding site was identified within aa108-
177 and the collagen III-interaction site within aa27-160 of N-GPR56 (Luo et 
al. 2012; Yang et al. 2011). Deletion of the TG2 binding site or removal of the 
entire N-terminal domain increased the basal activity of GPR56, indicating an 
inhibitory role of N-GPR56 in GPR56 activation (Yang et al. 2011; Paavola et 
al. 2011). In contrast, natural splice variants of GPR56 lacking huge parts of 
N-GPR56 showed reduced activities in luciferase reporter assays, indicating 
that truncation of the N-terminus does not always result in constitutive 
activation of GPR56 (Kim et al. 2010). 
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Regarding a specific role of the N-terminus, latrophilin-1, another aGPCR 
was investigated in more detail. Prömel et al. (2012) showed that the null 
allele lat-1(ok1465) of the C.elegans latrophilin homolog lat-1 results in 
development and fertility phenotypes characterised by a high lethality rate or 
infertility in surviving individuals, respectively. By expressing certain 
transgenic lat-1 proteins in lat-1(ok1465) animals both phenotypes could be 
rescued, which was highly dependent on the presence of the latrophilin-1 N-
terminus in the expressed transgene. At the same time, a construct with an 
intact GPS-site lacking the 7TM-domain (“∆TM2-7”) still rescued the fertility 
phenotype, which was independent of the presence of specific sequences in 
the remaining TM1. Therefore, the authors concluded that the receptor had 
7TM-independent functions that were not mediated by interactions of the N-
terminus and the 7TM-domain of another receptor (“split personality receptor 
model”), as observed before for the N-terminus of latrophilin-1 and C-GPR56 
(Silva et al. 2009). In contrast, Prömel et al. (2012) demonstrated that ∆TM2-
7 latrophilin-1 mutants, in addition deficient in GPS-cleavage, rescued both 
phenotypes if co-expressed with another mutant latrophilin-1 contributing a 
wild type C-terminus, although the defective C-terminus of ∆TM2-7 was 
inaccessible for replacement. The authors further showed that the presence, 
but not the cleavability of the GPS-domain was essential for latrophilin-1 
surface expression and signalling, indicating that the GPS-domain served as 
an endogenous ligand during latrophilin-1 activation that interacted with the 
homologous 7TM-domain. It was hypothesized that receptor dimerization 
occurs, in which homodimers are formed (7TM-dependent) due to the 
interaction of latrophilin-1 N-termini. Another model suggested that cis-
interactions with co-receptors like teneurin take place, which are mediated 
through the GPS-domain of latrophilin-1 and do not require activation of the 
latrophilin-1 7TM-domain.  
 
Much attention was spent on investigating the role of N-GPR56, however the 
C-terminus of GPCRs also plays a very important role, as it represents a 
docking site for intracellular proteins facilitating signalling. Expression of the 
natural splice variant ∆430-35-GPR56 was shown to result in increased 
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transcriptional activities when compared to wild type GPR56, indicating that 
the six amino acid deletion in ICL1 affects receptor signalling (Kim et al. 
2010). Since GPCRs are known to mostly signal via different types of G 
proteins (Lefkowitz 2000), it is likely that a deletion within ICL1 affects G 
protein binding or may facilitate the interaction with other signalling mediators 
like β-arrestins. For a long time, β-arrestins were only known to desensitize 
GPCRs by physically interrupting G protein-mediated signalling and 
moreover to promote internalisation via clathrin-coated pits (Shenoy and 
Lefkowitz 2003). Within seconds of GPCR activation and interaction with G 
proteins, kinases (GRKs) phosphorylate the GPCR on its cytoplasmic tail or 
ICL3, promoting the binding of β-arrestins (Lefkowitz 2007). More recently, 
however, β-arrestins were also found to represent signalling mediator 
proteins on their own (Lefkowitz and Shenoy 2005). 
 
 
5.1.1 Aims of the chapter 
 
 To investigate the role of specific domains within GPR56 such as the 
ligand-binding domain, the entire N-terminus, the C-terminus and 
potential C-terminal phosphorylation sites, for GPR56 activity and 
stimulation by TG2. 
 
 To investigate the signalling capacity of a naturally occurring splice 
variant and a BFPP-causing GPR56 mutant. 
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5.2 Results 
 
5.2.1 Cloning of the C-terminal tail phosphorylation site mutants  
∆S-A-GPR56, T688A-GPR56, ∆S/T-A GPR56 
 
The aim of the following experiments was to generate three new GPR56 
mutants with several serine and/or threonine to alanine mutations in the C-
terminal tail region between residues 684 to 691. Phosphorylation site 
prediction within ICL3 and the cytoplasmic tail of GPR56 using NetPhos 2.0 
revealed the presence of several residues likely to be phosphorylated (Fig. 
5.1). Six serines at position 684, 685, 687, 689, 690, 691 and one threonine 
at position 688, all located within the cytoplasmic tail, were selected for PCR 
mutagenesis. 
 
 
 
 
Figure 5.1 Prediction for serine, threonine and tyrosine phosphorylation sites 
and residues mutated to generate the three phosphorylation site mutants. 
Phosphorylation sites were predicted for ICL3 and the cytoplasmic tail of GPR56 
using NetPhos 2.0 (Center for Biological Sequence Analysis, CBS). 
*, mutated residue; yellow marked, residues likely to be phosphorylated (score > 0.5); green 
box, ICL3 (aa598-609); grey box, cytoplasmic tail (aa658-693). 
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The first step was to create an intermediate expression vector carrying C-
terminally truncated Gpr56 (Gpr56f), lacking the last ~400 bp (Fig. 5.2 A-B). 
Meanwhile, the three mutated C-terminal tail fragments were generated by 
PCR mutagenesis and ligated into Gpr56f in pcDNA4-GPR56f/V5-His (Fig. 
5.2 B-C). This allowed the creation of three new GPR56 mutant expression 
vectors, pcDNA4-∆S-A-GPR56/V5-His (“∆S-A-GPR56”), pcDNA4-T688A-
GPR56/V5-His (“T688A-GPR56”) and pcDNA4-∆S/T-A-GPR56/V5-His (“∆S/T-
A-GPR56”) (Fig. 5.2 C). The complete coding sequence of one bacterial 
clone for each expression construct was sent for dideoxy sequencing (MWG 
Operon). The sequencing analysis (Fig. 5.3) showed that the T688A-GPR56 
mutant carried the threonine to alanine mutation at position 688, as designed. 
DNA sequencing also revealed that the ∆S-A-GPR56 and ∆S/T-A-GPR56 
mutants had all the serine and threonine to alanine mutations except of one 
serine at position 684, which was replaced by glycine. A check-up of the 
primers used for the PCR mutagenesis reaction showed that the error was 
introduced by the primer sequence. As glycine is the smallest natural 
occurring amino acid and structurally very similar to alanine, the expression 
constructs were used to assess the contribution of the serine residues in the 
GPR56 tail towards shedding of AP-AR. 
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Figure 5.2 Cloning of three GPR56 C-terminal tail serine/threonine 
phosphorylation mutants. 
(A) The full-length coding sequence of GPR56 was cleaved with Hind III and BamH I 
to generate a truncated GPR56f fragment. GPR56f was ligated into pcDNA4/V5-His 
linearized by cleavage with the same restriction enzymes. 
(B) The obtained intermediate expression vector pcDNA4-GPR56f/V5-His was 
digested with BamH I/Xba I and the PCR products with BamH I/Xba I/Xho I. The 
400 bp long PCR fragments resulting from BamH I/Xba I cleavage were isolated and 
ligated into linearized pcDNA4-GPR56f/V5-His, respectively.   
(C) The final cloning products pcDNA4-∆S-A-GPR56/V5-His, pcDNA4-∆S/T-A-
GPR56/V5-His and pcDNA4-T688A-GPR56/V5-His were used to transform E.coli. 
Positive clones were selected by ampicillin resistance, DNA was amplified and sent 
for dideoxy sequencing. 
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Figure 5.3 Sequencing analysis of GPR56 phosphorylation site mutants. 
The results of the dideoxy sequencing (MWG operon) were used to generate 
sequence alignments of the C-terminal tail region (aa 658-693) of full-length GPR56 
and the three phosphorylation site mutants. The full amino acid sequence of wild 
type GPR56 is included in Appendix V. 
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5.2.2 Analysis of wild type and mutant GPR56 expression levels in 
transiently transfected HEK293 cells 
 
Besides the three C-terminal phosphorylation site mutants ∆S-A-GPR56, 
T688A-GPR56 and ∆S/T-A-GPR56 described above, five mutants were cloned 
by Dr. Vera Knäuper: The ligand interaction site deletion mutant ∆STP-
GPR56 lacking the TG2- and collagen III-binding sites (∆93-143), the N-
terminal domain deletion mutant ∆N-GPR56 (∆1-342), a C-terminal ∆Tail-
GPR56 mutant missing the last 23 residues (∆671-693), the natural splice 
variant ∆430-35-GPR56 carrying a six amino acid deletion in ICL1, the BFPP-
mutant R565W-GPR56 with the mutation in ECL2 and N-GPR56 consisting of 
the N-terminal domain only (∆383-693).   
Figure 5.4 illustrates all of the GPR56 constructs used in this study. 
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Figure 5.4 Schematic representation of GPR56 expression constructs. 
N-GPR56, N-terminal domain of GPR56; C-GPR56, C-terminal domain of GPR56; GPS, 
GPCR proteolytic site; V5, V5-epitope tag; Flag, Flag-epitope tag; STP, 
serine/threonine/proline-rich sequence motif within N-GPR56. 
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Firstly, immunocytochemical analysis of cell surface expression and 
localisation of the GPR56 mutants was performed in transiently transfected 
HEK293 cells using confocal microscopy. In figure 5.5 and 5.6, cells 
transiently transfected with wild type GPR56 or GPR56 mutants are shown. 
For cell surface staining, cells were fixed and stained with anti-N-GPR56 
antibody without permeabilising cells, as shown in figure 5.5. The C-terminus 
of GPR56 was stained in permeabilised cells with anti-V5 antibody, as shown 
in figure 5.6 A.  
The C-terminal phosphorylation site mutants ∆S-A-GPR56, T688A-GPR56 
and ∆S/T-A GPR56, as well as ∆Tail-GPR56, the natural splice variant 
∆430-35-GPR56 and wild type GPR56 showed high cell surface and 
cytoplasmic expression levels (Fig. 5.5 & 5.6). The ligand interaction site 
deletion mutant ∆STP-GPR56 showed very little cell surface staining and 
was mostly located in the perinuclear region, implicating folding and/or 
trafficking problems. The same was observed for the BFPP-mutant R565W-
GPR56, which is in good agreement with a previous report from the literature 
(Chiang et al. 2011). The N-terminal domain deletion mutant ∆N-GPR56 
showed normal cell surface localisation (Fig. 5.6 A). 
Cells expressing N-GPR56 were also probed with anti-N-GPR56 antibody for 
cell surface staining (Fig. 5.5), but an anti-Flag antibody was used to stain N-
GPR56 in permeabilised cells, as it contains a C-terminal Flag-epitope tag 
(Fig. 5.6 B). Although there is no membrane anchor keeping N-GPR56 at the 
cell membrane, it showed some cell surface localisation indicating binding to 
cell surface proteins, confirming previous findings by others (Paavola et al. 
2011). 
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Figure 5.5 Cell surface staining of wild type and mutant GPR56 in transiently 
transfected HEK293. 
Cells were seeded onto poly-L-lysine glass coverslips and transfected with GPR56 
or one of the mutant GPR56 expression constructs. Two days post-transfection, 
cells were fixed and stained with anti-N-GPR56 (R&D Systems) and secondary anti-
sheep Alexa549 (Jackson ImmunoResearch) antibodies (red).  
White arrow heads, GPR56 cell surface expression (red); scale bar, 10 µm. 
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Figure 5.6 Immunolocalisation of wild type and mutant GPR56 in transiently 
transfected HEK293 cells under permeabilising conditions. 
Cells were seeded onto poly-L-lysine glass coverslips and transfected with GPR56 
or one of the mutant GPR56 expression constructs. Two days post-transfection, 
cells were fixed and permeabilised.  
(A) For detection of the GPR56 C-terminal domain via the V5-epitope tag, cells were 
stained with mouse anti-V5 (Invitrogen) and anti-mouse Alexa594 (Jackson 
ImmunoResearch) antibodies (red). 
(B) To detect the C-terminal Flag-epitope tag of N-GPR56-Flag, cells were stained 
with mouse anti-Flag (Sigma-Aldrich) and secondary anti-mouse Alexa594 (Jackson 
ImmunoResearch) antibodies (red). 
White arrow heads, GPR56 cell surface expression (red); scale bar, 10 µm. 
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5.2.3 GPR56 mutants in the AP-AR shedding assay 
 
5.2.3.1 Basal- and C230-A TG2-induced AP-AR shedding is impaired in 
the BFPP-mutant R565W-GPR56 and the natural splice variant 
∆430-35-GPR56  
 
Confocal microscopy of cells stained with anti-N-GPR56 and anti-V5 
antibodies (Fig. 5.5 & 5.6) indicated reduced cell surface expression of the 
R565W-GPR56 mutant when compared to wild type GPR56. In contrast to the 
BFPP-mutant, the splice variant ∆430-35-GPR56 showed strong surface 
expression (Fig. 5.5 & 5.6).  
In order to test the activity of both GPR56 mutants, R565W-GPR56 and 
∆430-35-GPR56 were compared to wild type GPR56 in shedding assays 
(Fig. 5.7). p-NPP hydrolysis was significantly decreased in cells co-
expressing the R565W-GPR56 BFPP-mutant in non-stimulated conditions 
(Fig. 5.7 A), demonstrating some loss of constitutive activity which may be 
due to impaired cell surface expression. The mutant was not activated by 
C230-A TG2, which again can be explained by the diminished cell surface 
expression of R565W-GPR56 shown in figures 5.5 & 5.6. 
The splice variant ∆430-35-GPR56 behaved similar to R565W-GPR56 showing 
impaired p-NPP hydrolysis in non-stimulated conditions and lack of 
stimulation by C230-A TG2 (Fig. 5.7 B). The six residue deletion in ICL1 might 
influence the interaction with intracellular binding partners such as G 
proteins, altering the signalling ability of the splice variant and signalling 
pathways activated. 
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Figure 5.7 The BFPP-mutant R565W-GPR56 and the splice variant ∆430-35-GPR56 
show a significant decrease in basal- and C230-A TG2-induced AP-AR 
shedding. 
Cells were co-transfected with (A) GPR56 and AP-AR or R565W-GPR56 and AP-AR, 
or (B) ∆430-35-GPR56 and AP-AR or GPR56 and AP-AR. 48 h later, cells were serum 
starved for 1 h, followed by 1 h treatment in control buffer or 20 µg/ml C230-A TG2. 
Data presented show mean of 5 to 18 independent experiments with 4 repeats each 
+/- SEM (n=20-72). Statistical significance denoted as follows: ***, p<0.001; ns, non-
significant.   
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In order to analyse overall expression levels of the different GPR56 mutants, 
cell lysates were prepared and analysed by western blotting. Figure 5.8 
shows the analysis of total lysates from cells expressing GPR56, 
∆430-35-GPR56 and R565W-GPR56 using anti-N-GPR56 antibody (Fig. 5.8 A) 
or anti-V5 antibody (Fig. 5.8 B). Western Blot analysis revealed high 
expression levels for GPR56 and ∆430-35-GPR56 using the anti-N-GPR56 
antibody (Fig. 5.8 A), showing the typical banding pattern of four main bands 
at ~60, 65, 70 and 75 kDa.  
In contrast, the R565W-GPR56 mutant showed one prominent band at the 
lower molecular size of ~58 kDa (Fig. 5.8 A), indicating problems with N-
glycosylation, as shown by others (Jin et al. 2007; Chiang et al. 2011). A 
band running above 245 kDa was detected in lysates of R565W-GPR56 only, 
likely representing poly-ubiquitinated or multimeric protein.  
 
Staining of lysates from cells expressing GPR56 or ∆430-35-GPR56 with the 
anti-V5 antibody (Fig. 5.8 B) showed strong bands running at ~27, 50 and 
75 kDa, most likely reflecting monomeric, dimeric and full-length receptor. 
For ∆430-35-GPR56, elevated band intensities for monomeric C-GPR56 were 
detected. The signal intensity of full-length receptor running at 75 kDa was 
comparable to wild type GPR56, whereas intensities of dimeric C-GPR56 
running at 50 kDa were reduced. 
The R565W-GPR56 showed reduced expression levels for all bands 
corresponding to the C-GPR56 domain detected with the anti-V5 antibody, 
but the receptor was processed, as shown by the presence of dimeric and 
monomeric C-GPR56 (Fig. 5.8 B). Therefore, the R565W-mutation does not 
influence GPS-cleavage, as shown by others (Jin et al. 2007; Chiang et al. 
2011). As seen in figure 5.8 B, a high molecular weight band running at 
245 kDa was detected with anti-V5 antibody in lysates of R565W-GPR56 only, 
indicating protein aggregation (Chiang et al. 2011).  
Moreover, decreased expression levels of dimeric C-GPR56 in response to 
C230-A TG2 were only observed in cells expressing GPR56. The protein 
ladder between monomeric and dimeric C-GPR56 in ∆430-35-GPR56 could 
represent degraded protein. 
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Figure 5.8 Western Blot analysis of total lysates from cells expressing GPR56, 
∆430-35-GPR56 or R565W-GPR56 used in the AP-AR shedding assay. 
Total cell lysates were prepared, separated in a 10% resolving gel and blotted onto 
PVDF-membrane, which was stained with (A) anti-N-GPR56 antibody or (B) anti-V5 
antibody. Anti-GAPDH staining was used as loading control. Data are representative 
for 5 independent experiments. 
For all following western blots 10% resolving gels were used if not otherwise stated. 
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5.2.3.2 TG2-stimulated GPR56-dependent AP-AR shedding requires the 
N-terminal domain of the receptor 
 
5.2.3.2.1 The ligand interaction site deletion mutant ∆STP-GPR56 
 
Using overlap extension mutagenesis, 51 amino acids (∆93-143) of a serine, 
threonine, proline (STP)-rich region within N-GPR56 were removed (by Dr. 
Vera Knäuper). Thus, ∆STP-GPR56 lacks parts of both binding motifs for 
TG2 and collagen III, which partially overlap (Luo et al. 2012; Yang et al. 
2011; Li et al. 2008). 
Analysis by confocal microscopy revealed that ∆STP-GPR56 had a folding or 
trafficking defect, as there was only very little protein present at the cell 
surface (Fig. 5.5 & 5.6). To test the hypothesis that low surface expression 
would be reflected in loss of signalling, ∆STP-GPR56 and GPR56 were 
compared in shedding assays (Fig. 5.9 A). Co-expression of ∆STP-GPR56 
led to significantly reduced AP-activities when compared to GPR56 in non-
stimulated conditions. C230-A TG2 treatment failed to stimulate GPR56-
dependent shedding in cells co-expressing ∆STP-GPR56, indicating loss of 
receptor activation.  
 
Western Blot analysis using anti-N-GPR56 antibody (Fig. 5.9 B) showed an 
intense band at 70 kDa in cells expressing ∆STP-GPR56, likely representing 
full-length protein (FL-∆STP-GPR56). The mutant isoform was ~5 kDa 
smaller than FL-GPR56, which is in accordance to the deletion of 51 amino 
acids (Li et al. 2008). The band corresponding to FL-∆STP-GPR56 was very 
pronounced, indicating reduced processing of mutant receptor. However, a 
band of smaller molecular size was detected at ~52 kDa, likely representing 
cleaved ∆STP-N-GPR56. High molecular weight bands running around 
245 kDa were detected with anti-V5 antibody in lysates of ∆STP-GPR56, 
indicating protein aggregation.  
Staining with anti-V5 antibody (Fig. 5.9 C) showed similar band intensities for 
monomeric C-GPR56 at 27 kDa for ∆STP-GPR56, but reduced intensities for 
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the dimeric 50 kDa bands when compared to lysates of GPR56 expressing 
cells treated with control buffer. The FL-∆STP-GPR56 was also detected with 
the anti-V5 antibody and higher molecular weight bands, representing 
ubiquitinated or multimeric receptor forms, were detected in lysates of ∆STP-
GPR56 only. 
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Figure 5.9 Deletion of 51 residues within N-GPR56 results in a significant 
decrease of basal- and C230-A TG2 induced AP-AR shedding and less 
processing of the receptor. 
(A) Cells were transfected with ∆STP-GPR56 and AP-AR or GPR56 and AP-AR for 
comparison. 48 h later, cells were serum starved for 1 h, followed by treatment with 
control buffer or 20 µg/ml C230-A TG2 for 1 h. Data presented show mean of 3 
independent experiments with 4 repeats each +/- SEM (n=12). Statistical 
significance denoted as follows: ***, p<0.001, ns, non-significant.    
(B)&(C) Western Blot analysis of the cells used for the shedding assay in (A). Total 
cell lysates were prepared and analysed using (B) anti-N-GPR56 antibody and (C) 
anti-V5 antibody. Anti-GAPDH labelling was used as loading control. Data are 
representative for 3 independent experiments. 
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5.2.3.2.2 The N-terminal domain deletion mutant ∆N-GPR56 
 
In order to test the activity of ∆N-GPR56 (∆1-342) lacking the N-terminal 
domain up to the GPS domain, GPR56 and ∆N-GPR56 were tested in the 
shedding assay (Fig. 5.10 A). When compared to GPR56, p-NPP hydrolysis 
was slightly elevated in ∆N-GPR56 expressing cells in non-stimulated 
conditions, indicating enhanced constitutive activity. This is in line with 
observations made by Paavola et al. (2011), who used the same mutant.  
∆N-GPR56 did not respond to C230-A TG2 stimulation, as the ligand binding 
site was missing. Analysis by confocal microscopy using anti-V5 antibody 
showed normal cell surface localisation for ∆N-GPR56 (Fig. 5.6 A). 
 
Western Blot analysis using anti-N-GPR56 antibody confirmed the absence 
of the N-terminal domain in ∆N -GPR56 (Fig. 5.10 B).  
Staining with anti-V5 antibody (Fig. 5.10 C) showed reduced band intensities 
for ∆N-GPR56 when compared to the corresponding domain of wild type 
GPR56. The bands for monomeric and dimeric C-GPR56 ran slightly higher 
in cells expressing ∆N-GPR56 when compared to wild type GPR56. This is 
interesting, as wild type C-GPR56 and ∆N-GPR56 should have the same 
size and differences might be due to ubiquitination and require further 
analysis. 
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Figure 5.10 Deletion of the N-terminal domain enhances basal AP-AR 
shedding activity and ablates stimulation by TG2. 
(A) Cells were transfected with ∆N-GPR56 and AP-AR or GPR56 and AP-AR. 48 h 
post-transfection, cells were serum starved for 1 h and treated with control buffer or 
20 µg/ml C230-A TG2 for 1 h. Data presented show mean of 3 independent 
experiments with 4 repeats each +/- SEM (n=12). Statistical significance denoted as 
follows: ***, p<0.001; *, p<0.05; ns, non-significant. 
(B)&(C) Western Blot analysis of cells expressing GPR56 or ∆N-GPR56. Total 
lysates were separated in a 12.5% resolving gel and blotted onto a PVDF-
membrane that was stained with (B) anti-N-GPR56 antibody or (C) anti-V5 antibody. 
GAPDH loading control is shown. Data are representative for 3 independent 
experiments. 
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5.2.3.3 Multiple mutations of six serine residues alone or in conjunction 
with threonine-688 in the C-terminal tail of GPR56 do not affect 
receptor-induced signalling 
 
Several serine and threonine residues located within the C-terminal tail of 
GPR56 represent potential ligand-induced phosphorylation sites (Fig. 5.1). 
The next step was to test whether mutation of these residues would influence 
GPR56-dependent AP-AR shedding. The effect of losing six to seven 
potential phosphorylation sites in the C-terminal tail was tested by comparing 
∆S-A-GPR56 with GPR56, or ∆S/T-A-GPR56 with GPR56 in AP-AR 
shedding assays (Fig. 5.11 A&B). The mutation of six serine residues alone 
(Fig. 5.11 A) or in conjunction with threonine-688 (Fig. 5.11 B) did not 
significantly alter GPR56-dependent shedding in the absence or presence of 
C230-A TG2 when compared to GPR56. 
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Figure 5.11 Multiple serine mutations alone or in conjunction with threonine-
688 to alanine in the C-terminal tail do not impair GPR56-dependent AP-AR 
shedding. 
Cells were transfected with (A) ∆S-A-GPR56 and AP-AR or GPR56 and AP-AR or 
(B) ∆S/T-A-GPR56 and AP-AR or GPR56 and AP-AR. Two days post-transfection, 
cells were serum starved for 1 h, followed by treatment with control buffer or 
20 µg/ml C230-A TG2 for 1 h. Data presented show mean of 3 to 18 independent 
experiments with 4 repeats each +/- SEM (n=12-72). Statistical significance denoted 
as follows: ***, p<0.001. 
 164 
 
Total cell lysates were prepared and analysed by western blotting using anti-
N-GPR56 (Fig. 5.12 A&C) and anti-V5 antibodies (Fig. 5.12 B&D). Staining 
with anti-N-GPR56 antibody showed similar band intensities, as well as the 
same banding pattern for wild type GPR56, ∆S-A-GPR56 and ∆S/T-A-
GPR56, indicating normal processing of receptors (Fig. 5.12 A&C).   
Analysis using the anti-V5 antibody showed the expected bands for 
monomeric, dimeric and full-length receptor for GPR56, ∆S-A-GPR56 and 
∆S/T-A GPR56 (Fig. 5.12 B&D). However, the signal reduction of dimeric C-
GPR56 following C230-A TG2 treatment was only present in GPR56 
expressing cells, while the phosphorylation site mutants were not affected. 
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Figure 5.12 Western Blot analysis of total lysates from cells expressing 
GPR56, ∆S-A-GPR56 or ∆S/T-A-GPR56 used in the AP-AR shedding assay. 
Total cell lysates of cells used in the shedding assays were analysed by western 
blotting. Membranes were stained with (A)&(C) anti-N-GPR56 antibody or (B)&(D) 
anti-V5 antibody. GAPDH was stained for loading control. Data are representative 
for 3 independent experiments.  
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The last C-terminal phosphorylation site mutant that was compared to 
GPR56 in the shedding assays was T688-A GPR56 (Fig. 5.13 A). The 
threonine-688 to alanine mutation alone did not cause a significant change in 
GPR56-dependent basal or C230-A TG2 induced shedding of AP-AR. 
When total lysates of the same cells were analysed by western blotting and 
stained with anti-N-GPR56 antibody (Fig. 5.13 B), a banding pattern 
comparable to that of wild type GPR56 was found. Signal intensities were 
slightly elevated in lysates of cells expressing T688-A GPR56. 
Analysis using the anti-V5 antibody (Fig. 5.13 C) showed identical banding 
patterns for T688-A GPR56 and GPR56. T688-A GPR56 expression levels 
were slightly higher than GPR56. These results indicated that the threonine- 
688 to alanine mutant was normally processed. 
  
 167 
 
 
 
Figure 5.13 The mutation of threonine-688 to alanine does not alter GPR56-
dependent shedding, nor expression patterns. 
(A) Cells were transfected with T688-A-GPR56 and AP-AR or GPR56 and AP-AR. 
48 h later, cells were serum starved for 1 h and treated with control buffer or 
20 µg/ml C230-A TG2 for 1 h. Data presented show mean of 3 independent 
experiments with 4 repeats each +/- SEM (n=12). Statistical significance denoted as 
follows: ***, p<0.001. 
(B)&(C) Lysates of cells used in the shedding assay were analysed using western 
blotting. Membranes were stained with (B) anti-N-GPR56 antibody or (C) anti-V5 
antibody. GAPDH staining served as loading control. Data are representative for 3 
independent experiments.  
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5.2.3.4 The GPR56 C-terminal tail regulates basal, but not TG2-induced 
AP-AR shedding 
 
Finally, the contribution of the C-terminal tail on GPR56-dependent AP-AR 
shedding was investigated by comparing ∆Tail-GPR56 (∆671-693) to GPR56 
in shedding assays (Fig. 5.14 A). In non-stimulated conditions, AP-AR 
shedding was reduced in ∆Tail-GPR56 expressing cells when compared to 
GPR56. However, both GPR56 and ∆Tail-GPR56 responded to C230-A TG2 
treatment with an increase in p-NPP hydrolysis, indicating that the GPR56 
C-terminal tail region contributes to basal, but not TG2-inducing shedding 
activity of receptor.  
Western blot analysis of total lysates from cells co-transfected with ∆Tail-
GPR56 using anti-N-GPR56 antibody (Fig. 5.14 B) showed elevated 
expression levels for N-GPR56 and full-length ∆Tail-GPR56 compared to 
GPR56. High molecular weight bands running at ~180 to 245 kDa were 
detected for ∆Tail-GPR56 only.  
Staining of lysates with anti-V5 antibody (Fig. 5.14 C) showed monomeric 
and dimeric C-GPR56 bands in lysates of cells transfected with ∆Tail-
GPR56, running at smaller molecular sizes around ~25 and 45 kDa, as 
expected. Again, expression levels were elevated for ∆Tail-GPR56 when 
compared to GPR56 and higher molecular weight bands were detectable for 
∆Tail-GPR56 only. 
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Figure 5.14 Deletion of a 23 residues long GPR56 C-terminal tail region 
reduces basal AP-AR shedding activity and results in elevated expression 
levels of the receptor. 
(A) Cells were transfected with ∆Tail-GPR56 and AP-AR or GPR56 and AP-AR. 
Two days later, cells were serum starved for 1 h and treated with control buffer or 
20 µg/ml C230-A TG2 for 1 h. Data presented show mean of 5 independent 
experiments with 4 repeats each +/- SEM (n=20). Statistical significance denoted as 
follows: ***, p<0.001. 
(B)&(C) Western Blot analysis of cells expressing GPR56 or ∆Tail-GPR56. Total 
lysates were analysed by staining the membrane with (B) anti-N-GPR56 antibody or 
(C) anti-V5 antibody. GAPDH loading control is shown. Data are representative for 5 
independent experiments. Western blot shown was performed by Tim Wanger and 
Andreas Heil. 
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5.3 Discussion 
 
In order to gain information about the relation of structural domains and 
signalling properties of GPR56, different GPR56 mutants were analysed for 
their ability to induce AP-AR shedding in non-stimulated and C230-A TG2-
stimulated conditions. This enabled a comparison of basal and TG2-induced 
activity of mutant to wild type GPR56.  
 
The BFPP-causing GPR56 mutant R565W-GPR56 showed a very low activity 
and did not respond to C230-A TG2 stimulation (Fig. 5.7 A). This might be 
explained by the reduced cell surface expression level and its localisation in 
the perinuclear region (Fig. 5.5 & 5.6 A). These results confirm impaired 
surface expression, due to the mutant accumulating in the ER, indicating a 
trafficking defect (Chiang et al. 2011). In addition, Jin et al. (2007) failed to 
detect C-GPR56 at the cell surface of cells expressing R565W-GPR56, which 
was in contrast to wild type GPR56.  
The molecular mass of the N-terminal domain of R565W-GPR56 was reduced, 
albeit processed at the GPS site as shown by normal staining for C-GPR56 
(Fig. 5.8 B), whilst confocal microscopy showed perinuclear staining (Fig. 5.5 
& 5.6 A). Data presented in this project show incorrect trafficking as well as 
lack of N-gylcosylation as seen by others (Chiang et al. 2011; Luo, Yang, et 
al. 2011). Using Endoclycosidase H treatment, Chiang and colleagues (2011) 
demonstrated that in contrast to wild type GPR56, R565W-GPR56 carried only 
high mannose oligosaccharides added in the ER, indicating that the mutation 
would interfere with the correct trafficking of N-GPR56 into Golgi. 
Additionally, high molecular weight protein aggregates were found in lysates 
of cells expressing R565W-GPR56 potentially indicating misfolding, as shown 
in figure 5.8. Chiang et al. (2011) looked at the distribution of N- and C-
GPR56 to distinct membrane subdomains and found that wild type N-GPR56 
was localized solely in non-raft fractions, whereas C-GPR56 was evenly 
distributed to non-raft and lipid raft fractions. Lipid rafts are important for 
intracellular signalling, confirming the importance of C-GPR56 for the 
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transduction of an extracellular signal to a cellular response. However, the C-
terminal domain of R565W-GPR56 formed aggregates and was mostly located 
in non-raft fractions like N-GPR56. This indicated conformational changes in 
C-GPR56 induced by the mutation in ECL2 leading to aggregation (Chiang et 
al. 2011). 
 
The splice variant ∆430-35-GPR56 showed a reduced basal shedding activity 
and was not stimulated by C230-A TG2 (Fig. 5.7 B). This result cannot be 
explained easily, as cell surface expression levels of ∆430-35-GPR56 and wild 
type GPR56 were comparable (Fig. 5.5 & 5.6 A). However, the insertion of 
six amino acids into wild type GPR56 could potentially lead to changes in 
intracellular binding partners leading to a different signalling response upon 
ligand treatment. This is potentially supported by Kim et al.’s (2010) previous 
work demonstrating increased SRE-activation upon ∆430-35-GPR56 
overexpression when compared to wild type GPR56. The deletion of six 
residues within ICL1 could directly interfere with proteins mediating GPCR 
signalling, like G proteins or β-arrestins. Several reports demonstrated that 
activation by a ligand caused conformational changes, affecting the relative 
orientations of TM helices 3 and 6 in rhodopsin. These changes in turn 
affected the conformation of ICLs interacting with G proteins and β-arrestins 
uncovering previously buried interaction sites. However, in case of rhodopsin, 
interactions sites for Gα were identified in ICL2 and 3 and for Gβγ in α-helix 8 
(previously designated ICL4), but not in ICL1 (Farrens et al. 1996; Franke et 
al. 1990; Ernst 2000; Hamm 2001). More recently, 10 residues present in 
ICL2 that are highly conserved within the rhodopsin family GPCRs were 
shown to regulate β-arrestin binding (Marion et al. 2006), 2006), although 
these are not the sole determinants, as ICL1 and 3 were also implicated in 
arrestin-binding (Krupnick et al. 1994; Raman et al. 2003). The deletion of six 
residues within ICL1 of GPR56 could also induce conformational changes 
indirectly affecting the conformation of the entire 7TM-domain, thus 
interactions with intracellular proteins. 
Experiments using the ligand interaction site deletion mutant ∆STP-GPR56 
and the N-terminally truncated mutant ∆N-GPR56 revealed that the presence 
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of an intact N-terminal domain is required for C230-A TG2 induced GPR56-
dependent AP-AR shedding (Fig. 5.9 A and 5.10 A), which is in line with 
predictions for the location of the ligand interaction sites made by others (Li 
et al. 2008; Yang et al. 2011; Luo et al. 2012).  
∆STP-GPR56 was almost inactive in the shedding assay, likely due to 
impaired receptor processing, as indicated by a pronounced band for full-
length ∆STP-GPR56 (Fig. 5.9 B&C). GPS-cleavage was not entirely 
abolished, as ∆STP-N-GPR56, as well as monomeric and dimeric ∆STP-C-
GPR56 were detected.  
In contrast, a similar mutant lacking the TG2 interaction site (∆108-177) was 
shown to be auto-active and induced VEGF synthesis in a PKCα-dependent 
manner. Yang et al. (2011) concluded that the N-terminal domain inhibits the 
receptor, although ligand activation studies were not performed and thus their 
experiments measure ligand independent receptor activities. In contrast to 
their report (Yang et al. 2011), data presented here demonstrated impaired 
cell surface expression of ∆STP-GPR56 with most of the receptor located in 
the perinuclear region (Fig. 5.5 & 5.6 A), explaining reduced receptor 
activities. The data were corroborated by experiments performed with ∆N-
GPR56, lacking the complete ligand binding domain, which clearly 
demonstrated that the N-terminal domain is required for GPR56 activation by 
TG2 (Fig. 5.10 A). The enhanced basal activity observed with ∆N-GPR56, on 
the other hand, indicated increased constitutive activation of the receptor due 
to deletion of the N-terminal domain. This is in line with observations made 
by Yang et al. (2011) and Paavola et al. (2011). The decreased expression 
levels for ∆N-GPR56 observed with western blot analysis (Fig. 5.10 C) might 
be explained by elevated internalisation and degradation of mutant receptor, 
which was indicated by previous findings demonstrating increased co-
localisation with β-arrestin-2 and receptor poly-ubiquitination (Paavola et al. 
2011). High molecular weight bands indicating ubiquitination were also 
observed in this project, using anti-V5 antibody staining (Fig. 5.10 C). 
However, stimulation of AP-AR shedding by C230-A TG2 was abolished in 
case of ∆N-GPR56, confirming that the N-terminal domain is required for 
ligand-dependent receptor activation. 
 173 
 
It was shown for several GPCRs that β-arrestin-binding to agonist-activated 
receptors requires phosphorylation of serine and threonine residues located 
in ICL3 and the C-terminal tail (Oakley et al. 2001; Luttrell and Lefkowitz 
2002). Some GPCRs, such as the β2-adrenergic receptor (β2AR), quickly 
dissociate from β-arrestin near the cell membrane, whereas others like the 
vasopressin receptor-2 (V2R) remain tightly associated with β-arrestin and 
internalise into endocytic vesicles as a complex (Oakley et al. 1999; Oakley 
et al. 2000). Oakley et al. (2001) showed that phosphorylation of several 
residues by GRKs dramatically enhances the affinity of β-arrestins to 
GPCRs, leading to the formation of stable β-arrestin-receptor complexes. In 
case of the β2AR, GRK-phosphorylation enhanced β-arrestin binding 10-30 
fold. Therefore, it was speculated that mutation of several potential 
phosphorylation sites within the C-terminal tail of GPR56 might influence 
receptor activity or activation by C230-A TG2. However, experiments with the 
three phosphorylation site mutants ∆S-A-, ∆S/T-A- and T688-A-GPR56 did not 
result in an alteration of AP-AR shedding activity (Fig. 5.11 and 5.13 A), 
indicating that the signalling pathway is not mediated by β-arrestins. 
However, it was also speculated that the agonist-induced conformational 
change of receptors is more important for β-arrestin-binding than GRK-
phosphorylation (Marion et al. 2006), thus an involvement of β-arrestins in 
GPR56-dependent ADAM17-activation cannot be entirely excluded by 
ablating phosphorylation sites. Moreover, it remains unclear whether receptor 
internalisation that is promoted by association of β-arrestins to GPCRs is 
required for GPR56-dependent AP-AR shedding. In addition, GPR56 
internalisation may be β-arrestin-independent as shown for other GPCRs 
(Bhatnagar et al. 2001; Koppen and Jakobs 2004). 
Experiments with ∆Tail-GPR56 showed that deletion of a huge part of the 
cytoplasmic tail does not affect C230-A TG2-stimulated AP-AR shedding (Fig. 
5.14 A). This is in line with the findings made using the phosphorylation site 
mutants discussed above, indicating that GPR56-dependent ADAM17 
activation is not mediated through β-arrestins. However, western blot 
analysis showed that expression levels of ∆Tail-GPR56 were elevated when 
compared to wild type GPR56 (Fig. 5.14 B&C), which might result from 
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impaired internalisation and endocytosis mediated through β-arrestins. 
However, Cen et al. (2001) showed that C-terminal truncation of δ-opioid 
receptor (DOR) only partially impaired the interaction with β-arrestins, as this 
was compensated by the presence of ICL3, which is sufficient for β-arrestin 
binding. Moreover, it was shown that the interactions of ICL3 and the C-
terminus of DOR with the β-arrestins were additive and that both domains 
bound to different sites of β-arrestins. A similar effect might be observed with 
∆Tail-GPR56, as its overall activity was reduced when compared to wild type 
GPR56, thus the presence of ICL3 might compensate the loss of the C-
terminal tail resulting in impaired, but still detectable receptor activity and 
significant activation by its ligand TG2.  
 
Taken together, this chapter showed that mutation or deletion of several 
domains within GPR56 results in altered receptor activities. Loss of TG2-
dependent GPR56 activation was observed for R565W-GPR56 and ∆STP-
GPR56, which likely resulted from folding/trafficking defects as reflected by 
impaired cell surface expression levels. Loss of TG2-activation of ∆430-35-
GPR56 might be a result of alterations in interaction sites required for signal 
transduction, although we currently have no evidence for that. In contrast, 
ablation of potential C-terminal phosphorylation sites (∆S-A-, ∆S/T-A-, T688A-
GPR56) or deletion of the cytoplasmic tail (∆Tail-GPR56) did not influence 
C230-A TG2 induced receptor activation. This potentially indicates that 
GPR56-dependent activation of ADAM17-mediated AP-AR shedding was 
independent of β-arrestins, although experimental evidence for this 
conclusion needs to be collected. Moreover, the hypothesis of N-GPR56 
inhibiting C-GPR56 was confirmed by experiments using N-terminally 
truncated ∆N-GPR56 showing enhanced constitutive activity. The results also 
demonstrated that the N-terminal domain was required for TG2-interaction, 
as stimulation with C230- TG2 did not activate ∆N-GPR56. 
  
 
 
 
 
 
CHAPTER 6: 
Exploring the mechanism  
of GPR56-dependent 
internalisation of TG2 using  
confocal microscopy
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6 Exploring the mechanism of GPR56-dependent 
internalisation of TG2 using confocal microscopy 
 
6.1 Introduction 
 
GPCR internalisation requires either clathrin-dependent or clathrin-
independent routes. The formation of clathrin-coated vesicles is initiated by 
the invagination of membrane structures, called pits, which is promoted by 
the recruitment of adaptor proteins like AP-2 to the plasma membrane. The 
size of clathrin-coated pits depends on their cargo, e.g. a GPCR, but their 
size is limited to 200 nm (McMahon and Boucrot 2011) 
Clathrin-dependent internalisation was established by monitoring the uptake 
of transferrin (Tf) in erythropoietic cells (Harding et al. 1983). At the cell 
surface, transferrin receptors (TRs) bind Tf to import iron from the serum 
(Collawn et al. 1990). TRs are constitutively internalised via clathrin-coated 
pits and Tf-uptake was found to be temperature-dependent, i.e. TRs bind Tf 
at 4 °C and internalise at 37 °C (Harding et al. 1983). Once the internalised 
TR-Tf complex reaches the endosome, Tf does not dissociate from its 
receptor. At pH 5, the ligand-receptor pair remains associated in endosomes, 
whereas iron is removed from Tf. The iron-free TR-Tf complex recycles back 
to the cell surface, where iron-free Tf dissociates at neutral pH. New iron-
loaded Tf binds the receptor for another round of clathrin-dependent 
endocytosis (Goldstein et al. 1985). 
 
The best characterised, clathrin-independent mechanism of GPCR 
internalisation is the caveolae-dependent pathway. Lipid rafts/caveolae do 
not only play a role for vesicular transport processes 
(endocytosis/exocytosis), but are also involved in sorting of lipids, protein 
trafficking and signal transduction (Sprong et al. 2001; Johannes and 
Lamaze 2002; Chini and Parenti 2004). Besides GPCRs, receptor tyrosine 
kinases (e.g. EGFR), ion channels, transporters, Src family kinases, G 
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proteins and others are located in membrane rafts like caveolae (Patel et al. 
2008). Some GPCRs naturally assemble in these membrane structures, 
others might move their upon ligand stimulation before internalisation. Thus 
there must be targeting signals determining the localisation of the receptors 
within the cell membrane (Chini and Parenti 2004; Patel et al. 2008). It was 
speculated that cholesterol, present in caveolae, might influence the 
localisation of GPCRs in rafts by interacting with their 7TM-domain. Re-
arrangements of the 7TM-region following agonist-activation or 
oligomerisation of GPCRs could affect the affinity to cholesterol, leading to 
raft localisation. Additionally, the ECD, ICLs and the cytoplasmic tail of 
GPCRs may also be involved. The ECD could interact with proteins or lipids 
on the outer leaflet of the membrane and palmitoylation (lipid modification on 
Cys residues) or phosphorylation of the cytoplasmic tail and ICLs may act as 
a target-signal for localisation of GPCRs in rafts (Chini and Parenti 2004). 
The flask-shaped caveolae were first identified using electron microscopy 
(Palade 1953). Confocal imaging, however, represents a very useful tool to 
visualise GPCR endocytosis via caveolae by staining typical marker proteins 
such as caveolin-1 (cav-1) (Chini and Parenti 2004). Interestingly, GPR56 is 
partially located in lipid raft fractions positive for cav-1 expression (Chiang et 
al. 2011). 
 
Independent of the endocytotic machinery, the internalised vesicles fuse with 
early endosomes and the GPCR is either recycled back to the cell surface 
(resensitisation) or degraded (signal termination) (Hanyaloglu and von 
Zastrow 2008). 
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6.1.1 Aims of the chapter 
 
 To investigate whether the interaction of GPR56 and TG2 triggers 
internalisation. 
 
 To identify the mechanism of endocytosis (clathrin-dependent 
or -independent).  
 
 To shed some light on the fate of receptor and ligand (i.e. recycling or 
degradation). 
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6.2 Results 
 
6.2.1 Interaction of GPR56 and TG2 in stably transfected HEK293 cells 
 
The aim of the experiments was to confirm the specific interaction between 
GPR56 and TG2 using an additional experimental approach to the shedding 
assay. Therefore, it was investigated whether GPR56 is internalised upon 
prolonged stimulation with its ligand TG2. 
For this purpose, a stable HEK293 cell line inducibly expressing GPR56 was 
used. Firstly, conditions were established to induce GPR56 expression using 
10 µg/ml doxycycline-containing medium, which was compared to control 
medium at the 48 h time point. Total cell lysates were prepared and analysed 
for GPR56 and TG2 expression (Fig. 6.1). In order to show that the stable 
HEK293 cell line was negative for TG2 expression, stably transfected HCA2 
fibroblasts overexpressing TG2 cDNA in either sense (S) or antisense (As) 
orientation were cultured for 72 h and cell lysates were analysed next to 
those of the stable HEK293 cell line. Figure 6.1 A shows that doxycycline 
treatment for two days efficiently induced GPR56 expression in stably 
transfected HEK293 cells, whereas HCA2 fibroblasts as well as non-treated, 
stably transfected HEK293 cells were completely negative for GPR56 
expression. In contrast to HCA2 TG2 sense cells, stable HEK293 cells were 
negative for TG2 expression, independent of GPR56 expression levels (Fig. 
6.1 B).   
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Figure 6.1 GPR56 and TG2 expression in stably transfected HEK293 cells. 
Western Blot analysis of total lysates from HCA2 fibroblasts stably expressing TG2 
sense (S) or antisense (As) cDNA and the stable HEK293 cell line inducibly 
expressing GPR56. Transfected HCA2 cells were grown for 72 h before lysates 
were prepared. HEK293 cells were cultured in doxycycline-free medium (control 
cells) or 10 µg/ml doxycycline containing medium for 48 h prior to production of total 
cell lysates. Lysates were separated using a 10% resolving gel, blotted onto a 
PVDF-membrane and stained with (A) anti-N-GPR56 antibody and (B) anti-TG2 
antibody. GAPDH staining served as the loading control. 
 
 
 
To exclude an effect of TG2 on GPR56 expression levels or crosslinking of 
GPR56 by TG2, cell lysates of stable HEK293 control cells and doxycycline-
induced cells were analysed following control buffer or C230-A TG2 treatment 
for 1 h. Figure 6.2 shows the western blot analysis of total cell lysates using 
anti-N-GPR56 antibody, confirming that control cells were negative for 
GPR56 expression and that C230-A TG2 treatment did not alter the N-GPR56 
banding pattern or intensity in doxycycline-induced cells at the 1 h treatment 
point. 
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Figure 6.2 GPR56 expression in stably 
transfected HEK293 cells. 
For GPR56 expression, stably transfected 
HEK293 cells were incubated in 10 µg/ml 
doxycycline-containing medium or control 
cells in doxycycline-free medium for 48 h. 
Cells were serum starved for 1 h, followed 
by treatment with 20 µg/ml C230-A TG2 or 
control buffer for 1 h. Lysates were 
prepared, separated using a 10% resolving 
gel and blotted onto a PVDF-membrane. 
Anti-N-GPR56 and anti-GAPDH antibodies 
were used to stain the membrane. 
 
 
 
 
For confocal microscopy, stable HEK293 cells were incubated in doxycycline-
containing medium for 48 h to induce GPR56 expression and control cells in 
doxycycline-free medium. Cells were serum starved, followed by treatments 
with control buffer or 20 µg/ml C230-A TG2 for 5 sec, 15 mins or 30 mins. 
Cells were fixed and permeabilised and GPR56 and C230-A TG2 were stained 
using anti-N-GPR56 and anti-TG2 antibodies, which were detected with 
appropriate secondary antibodies leading to GPR56 staining in red and TG2 
staining in green.  
Figure 6.3 shows doxycycline pre-treated cells expressing GPR56 at the cell 
surface and in intracellular compartments. Non-induced control cells were 
GPR56 and TG2 negative and are shown in Appendix VI.  
GPR56 was present at the cell surface in doxycycline-induced cells treated 
with control buffer (Fig. 6.3 A, white arrow heads) or C230-A TG2 (Fig. 6.3 B, 
white arrow heads) after 5 sec treatment. Some GPR56 was found 
intracellularly throughout the entire experiment and slightly more after 15 or 
30 mins of incubation (Fig. 6.3 A&B, white arrow heads), which may 
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represent internalised or newly synthesised GPR56, which cannot be 
distinguished using this labelling technique. 
TG2 staining was absent in buffer control treated cells (Fig. 6.3 A), however, 
cell surface TG2 staining was detected in GPR56 positive cells within 5 sec 
of treatment and partially overlapped with GPR56 staining (Fig. 6.3 B, black 
arrow heads). This indicated a fast and specific interaction between the 
receptor and its ligand. Following C230-A TG2 treatment for 15 mins, some 
TG2 was located intracellularly (Fig. 6.3 B, white arrows) and some remained 
at the cell surface. After 30 mins treatment, even more C230-A TG2 was 
present in intracellular vesicles, demonstrating GPR56-dependent 
endocytosis of TG2 (Fig. 6.3 B, white arrows). There was very little co-
localisation between GPR56 and internalised TG2 in intracellular vesicles.  
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Figure 6.3 Internalisation of GPR56 and TG2 in stably transfected HEK293 
cells. 
The GPR56 inducible cell line was seeded onto poly-L-lysine coated glass 
coverslips and GPR56 expression was induced with 10 µg/ml doxycycline for 48 h 
prior to 1 h serum starvation. Cells were then treated for 5 sec, 15 mins or 30 mins 
with (A) control buffer or (B) 20 µg/ml C230-A TG2. Cells were fixed and 
permeabilised and GPR56 was stained with anti-N-GPR56 (red; R&D Systems) and 
anti-sheep Alexa568 antibodies (Jackson ImmunoResearch). C230-A TG2 was 
stained with monoclonal anti-TG2 (green; Thermo Scientific) and anti-mouse 
Alexa488 antibodies (Jackson ImmunoResearch). 
(A) After treatment with control buffer for 5 sec, GPR56 was present at the cell 
surface. Some GPR56 was detectable intracellularly throughout the experiment, 
which was slightly more pronounced after 15 mins and 30 mins. Cells were always 
negative for TG2 staining. 
(B) Cells treated with C230-A TG2 for 5 sec were positive for GPR56 and TG2 cell 
membrane staining, which partially overlapped. After 15 mins, GPR56 and TG2 
staining were still apparent at the cell surface and some internalisation of TG2 was 
observed. After 30 mins, more TG2 was found in intracellular vesicles of GPR56-
positive cells. Some GPR56 was found intracellularly, however, most of it was still 
apparent at the cell surface after 30 mins. The degree of co-localisation between 
internalised TG2 and intracellular GPR56 was very low. 
White arrow heads, GPR56 staining (red); white arrows, C230-A TG2 staining (green); black 
arrow heads, co-localisation of GPR56 and C230-A TG2 (yellow); scale bar, 10 µm. 
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6.2.2 Internalisation of GPR56 and TG2 in HEK293 cells transiently 
expressing SNAP-tagged GPR56 
 
In figure 6.3, binding of TG2 to GPR56 and GPR56-dependent endocytosis 
of TG2 using immunocytochemistry was demonstrated. In contrast, GPR56 
remained at the cell surface. Since immunocytochemistry is unable to 
distinguish between internalised, recycling and newly synthesised receptor, 
this methodology was not amendable to investigate endocytosis of GPR56. 
Prestaining of GPR56 with anti-N-GPR56 antibody was not an option, as 
data presented in Chapter 3 demonstrated that the antibody has agonistic 
activity. Therefore, the SNAP-tag technology (NEB) was explored.  
The SNAP-tag is a 20 kDa mutant O6-alkylguanine-DNA alkyltransferase that 
can be covalently labelled by adding specific benzylguanine substrates fused 
to fluorescent dyes. SNAP-GPR56 carrying an extracellular, N-terminal 
SNAP-tag was cloned by Dr. Vera Knäuper and cell surface GPR56 was 
fluorescently labelled prior to addition of C230-A TG2. In that way, the fate of 
the receptor-ligand pair was followed. In most experiments, SNAP-tag 
staining preceded immunocytochemical detection of TG2 and/or vesicle 
marker proteins such as LAMPs. 
 
 
6.2.2.1 Optimisation of SNAP-GPR56 staining and comparison to the 
SNAP-β2-adrenergic receptor 
 
Firstly, expression of SNAP-GPR56 was compared to GPR56 using 
transiently transfected HEK293 cells, which were treated with control buffer 
or C230-A TG2. Cell lysates were prepared and analysed by western blotting 
using anti-N-GPR56 antibody (Fig. 6.4). Two major bands running at ~80 and 
~95 kDa were detected for SNAP-GPR56, representing SNAP-tagged N-
GPR56 and full-length SNAP-GPR56. The detected bands correlate well with 
the predicted sizes for SNAP-GPR56. 
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Additionally, preliminary data revealed that SNAP-GPR56 is active in the AP-
AR shedding assay (data not shown). 
 
 
Figure 6.4 Expression of 
SNAP-GPR56 in HEK293 cells. 
Cells were transfected with 
GPR56 or SNAP-GPR56. Two 
days post-transection, cells were 
serum starved for 1 h, followed 
by treatment with 20 µg/ml 
C230-A TG2 or control buffer for 
1 h. Lysates were prepared, 
separated in a 10% resolving gel 
and blotted onto a PVDF-
membrane. Anti-N-GPR56 
antibody was used to stain the 
membrane, GAPDH served as 
loading control. 
 
 
 
In order to test SNAP-tag staining of GPR56, HEK293 cells were transiently 
transfected with SNAP-GPR56 or the control vector provided by New 
England Biolabs (NEB), encoding SNAP-β2-adrenergic receptor (SNAP-
β2AR). Staining of the two receptors was compared using confocal 
microscopy (Fig. 6.5).  
All cells shown in figure 6.5 were grown for 48 h following transfection and 
were serum starved for 1 h prior to SNAP-surface staining. In figure 6.5 A, 
cells were incubated with SNAP-surface substrate 488 or 549 for 15 mins at 
37 °C prior to fixation. Due to the incubation with the SNAP-substrates at 
37 °C for 15 mins, some receptor internalisation occurred in the absence of 
ligand addition (Fig. 6.5 A, white arrow heads indicating internalised 
receptors stained with SNAP-substrate 549 (red); white arrows indicating 
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internalised receptors stained with SNAP-substrate 488 (green)). 
Endocytosis was much more pronounced in cells expressing SNAP-GPR56 
(Fig. 6.5 A, right panels) when compared to SNAP-β2AR (Fig. 6.5 A, left 
panels), indicating different kinetics of constitutive internalisation between 
GPR56 and β2AR. 
Next, the specific interaction between GPR56 and TG2 was demonstrated 
using a combination of SNAP-tag staining and immunocytochemistry.  
Following SNAP-tag staining with SNAP-substrate 549 or 488, SNAP-GPR56 
(right panels) or SNAP-β2AR (left panels) transfected cells were treated with 
C230-A TG2 for 5 sec and fixed immediately (Fig. 6.5 B&C). TG2 was stained 
using anti-TG2 antibody and secondary Alexa488- or Alexa594-labelled 
antibodies, depending on the colour of the SNAP-surface substrate used to 
stain the receptors. Some receptor internalisation, especially in SNAP-
GPR56-expressing cells (Fig. 6.5 B&C, white arrow heads and white arrows), 
was apparent. In contrast, TG2 staining at the 5 sec time point was only 
detectable at the cell surface of SNAP-GPR56 expressing cells, with staining 
partially overlapping with GPR56 (Fig. 6.5 B&C, right panels, black arrow 
heads). This confirmed the highly specific interaction between GPR56 and 
TG2, as SNAP-β2AR positive cells did not bind C230-A TG2 (Fig. 6.5 B&C, left 
panels). Moreover, the results demonstrated that SNAP-tag staining was a 
good method to allow cell surface receptor staining, which was further 
optimised by performing the SNAP-tag labelling step at 4 °C, a temperature 
that blocked ligand independent receptor internalisation. Therefore, 
internalisation studies with this technique were combined with 
immunocytochemistry to assess receptor internalisation in response to 
ligand. 
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Figure 6.5 SNAP-tag staining of SNAP-GPR56 and SNAP-β2AR in transiently 
transfected HEK293 cells. 
Cells were seeded onto poly-L-lysine coated glass coverslips and the next day 
transfected with SNAP-GPR56 or SNAP-β2AR. 48 h post-transfection, cells were 
serum starved for 1 h. SNAP-tags were stained at 37 °C for 15 mins using SNAP-
surface substrates 488 (green receptor staining; NEB) or 549 (red receptor staining; 
NEB).  
(A) Cells were fixed immediately following SNAP-tag staining. SNAP-GPR56 (right 
panels) and SNAP-β2AR (left panels) were present at the cell surface and some 
receptor was found in intracellular vesicles, which was much more pronounced in 
case of SNAP-GPR56. 
(B) Cells were stained with SNAP-substrate 549 (red), treated with C230-A TG2 for 
5 sec, fixed and stained for TG2 (green) with anti-TG2 (Thermo Scientific) and anti-
mouse Alexa488 antibodies (Jackson ImmunoResearch). Cells showed positive 
surface staining for SNAP-GPR56 (right panels) and SNAP-β2AR (left panels) and 
there was more internalised SNAP-GPR56 than SNAP-β2AR. C230-A TG2 cell 
surface staining was only present in SNAP-GPR56-expressing cells, where it 
partially overlapped with GPR56 staining. 
(C) Same as in (B), but cells were stained with SNAP-substrate 488 (green) and 
TG2 (red) was stained using anti-TG2 antibody (Thermo Scientific) in combination 
with anti-mouse Alexa594 antibody (Jackson ImmunoResearch).  
White arrow heads, internalised receptors stained with SNAP-surface substrate 549 (red); 
white arrows, internalised receptors stained with SNAP-surface substrate 488 (green); black 
arrow heads, cell surface co-localisation of SNAP-GPR56 and C230-A TG2 (yellow); scale 
bar, 10 µm. 
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6.2.2.2 Co-internalisation of SNAP-GPR56 and TG2 
 
The results shown above introduced an alternative way to specifically stain 
cell surface GPR56 via an N-terminal SNAP-tag and demonstrated that this 
method could be used to follow receptor internalisation in living cells.  
Next, the GPR56-TG2 internalisation study presented in 6.2.1 was modified 
using a combination of SNAP-tag staining for GPR56 and immunostaining for 
TG2. Figure 6.6 shows cells that were transfected with SNAP-GPR56. 
SNAP-surface substrate 647 (shown in green) was used to stain GPR56 for 
15 mins at 4 °C, in order to prevent internalisation prior to TG2 treatment. 
Cells were pulse-treated with 20 µg/ml C230-A TG2 or control buffer for 5 sec, 
followed by direct fixation or incubation in serum-free medium for up to 
60 mins (the chase), as indicated. Pulse-chase experiments were performed 
in order to follow the fate of receptor-ligand pairs that initially formed at the 
cell surface after 5 sec of treatment with C230-A TG2. Finally, cells were fixed 
and permeabilised, followed by antibody staining of TG2 (red).  
Cells treated with control buffer (Fig. 6.6 A) showed cell surface localisation 
of SNAP-GPR56, particularly after 5 sec (upper panels, white arrows) and 
lacked TG2 staining at any time point tested. Internalisation of SNAP-GPR56 
was detectable after 15 mins and the amount of internalised receptor 
increased over time, with little SNAP-GPR56 left at the cell surface after 
60 mins (white arrows indicating internalised receptor).  
SNAP-GPR56 cells treated for 5 sec with TG2 (Fig. 6.6 B) showed surface 
staining for GPR56 (upper panels, white arrows) and partial co-localisation of 
receptor and ligand (upper panels, black arrow heads), indicating specific 
binding of C230-A TG2 to the receptor. After 15 mins of incubation, 
intracellular vesicles stained positive for SNAP-GPR56 (white arrows 
indicating internalised receptor) and TG2 positive vesicles were also positive 
for SNAP-GPR56 (yellow; black arrow heads), indicating that internalisation 
of C230-A TG2 was highly GPR56-dependent. At the 30 mins and 60 mins 
time points, increasing numbers of vesicles were positive for SNAP-GPR56 
alone (white arrows), although some vesicles remained positive for both 
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receptor and ligand (yellow; black arrow heads). Little SNAP-GPR56 and 
even less C230-A TG2 was left at the cell surface after 60 mins incubation. 
Over the 60 mins time period receptor or ligand recycling to the cell 
membrane was not evident. 
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Figure 6.6 SNAP-GPR56 and C230-A TG2 internalise simultaneously in 
transiently transfected HEK293 cells. 
Cells were seeded onto poly-L-lysine coated glass coverslips, transfected with 
SNAP-GPR56 and two days later serum starved for 1 h. SNAP-GPR56 was stained 
at 4 °C for 15 mins using SNAP-surface substrate 647 (shown in green; NEB). Cells 
were treated with (A) control buffer or (B) 20 µg/ml C230-A TG2 for 5 sec, followed by 
immediate fixation or incubation in serum-free medium for 15, 30 or 60 mins prior to 
fixation. Cells were permeabilised and TG2 (red) was stained using anti-TG2 
(Thermo Scientific) and secondary anti-mouse Alexa594 antibodies (Jackson 
ImmunoResearch).   
(A) Control buffer treated cells showed cell surface staining for SNAP-GPR56, with 
increasing amounts of internalised SNAP-GPR56 over time, beginning after 
15 mins. Little SNAP-GPR56 was left at the cell surface after 60 mins. Cells were 
negative for TG2 staining. 
(B) In cells treated with C230-A TG2 for 5 sec, SNAP-GPR56 surface and intracellular 
staining looked similar to staining in cells treated with control buffer over the entire 
time. Cells were positive for C230-A TG2 surface staining and internalised TG2 was 
detectable after 15 mins in a highly GPR56-dependent manner. SNAP-GPR56 
positive, as well as SNAP-GPR56 and C230-A TG2-positive vesicles were found, with 
very little C230-A TG2 and little SNAP-GPR56 left at the cell surface after 60 mins. 
White arrows, SNAP-GPR56 staining (green); black arrow heads, co-localisation of SNAP-
GPR56 and C230-A TG2 (yellow); scale bar, 10 µm. 
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6.2.2.3 Internalisation of GPR56 and TG2 is clathrin-dependent 
 
Following the interaction of GPR56 and TG2 over time in SNAP-GPR56 
transfected cells showed that both the receptor and its ligand ended up 
intracellularly, where they partially co-localised in the same intracellular 
vesicles. A well described mechanism of GPCR internalisation is clathrin-
dependent endocytosis and experiments presented in this chapter set out to 
investigate whether GPR56-internalisation was mediated by clathrin-coated 
pit formation. 
 
6.2.2.3.1 The clathrin-inhibitor sucrose prevents internalisation 
 
Treatment of cells with hypertonic medium (0.45 M sucrose) is known to 
prevent the interaction of clathrin and the AP-2 adaptor protein, inhibiting 
clathrin-dependent receptor internalisation (Hansen et al. 1993).  
In the following experiments, cells were transfected with SNAP-GPR56. 48 h 
later, cells were serum starved for 30 mins in serum-free medium containing 
0.45 M sucrose. SNAP-GPR56 (shown in green) was stained with SNAP-
surface substrate 647 at 4 °C for 15 mins, followed by pulse-treatment with 
control buffer or C230-A TG2 for 5 sec. Cells were either fixed directly or 
incubated for 30 mins in serum-free medium in the presence or absence of 
0.45 M sucrose prior to fixation. TG2 (red) was immunocytochemically 
stained as outlined before. 
In figure 6.7 A, cells were fixed immediately after the 5 sec pulse treatment 
with control buffer (left panels) or C230-A TG2 (right panels). As observed 
before (Fig. 6.6), cell surfaces stained positive for SNAP-GPR56 (white 
arrows), partially overlapping with TG2 staining in those cells treated with 
C230-A TG2 (yellow; black arrow heads).  
Following incubation in the absence of sucrose for 30 mins (Fig. 6.7 B), 
SNAP-GPR56 was found in intracellular vesicles (white arrows) and only little 
receptor was left at the cell surface in either control or TG2 treated cells. In 
cells treated with C230-A TG2, some intracellular vesicles were positive for 
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both SNAP-GPR56 and TG2 (yellow; black arrow heads) after 30 mins, as 
described before. This indicated that 30 mins pre-incubation in 0.45 M 
sucrose medium was insufficient to prevent receptor internalisation.  
In contrast, incubation in hyperosmotic sucrose medium for 30 mins following 
pulse treatment with buffer control or C230-A TG2 completely abolished 
receptor and ligand internalisation in all cells (Fig. 6.7 C). Staining was 
similar to what was observed in cells fixed immediately (Fig. 6.7 A). Both 
SNAP-GPR56 (white arrows) and TG2 were present at the cell surface, 
where they partially co-localised (yellow; black arrow heads). All cells lacked 
intracellular vesicles after 30 mins incubation in 0.45M sucrose, indicating 
that both internalisation of GPR56 and GPR56-mediated endocytosis of TG2 
were clathrin-dependent.  
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Figure 6.7 Sucrose treatment abolishes internalisation of GPR56 and TG2 in 
SNAP-GPR56 transfected HEK293 cells. 
Cells were seeded onto poly-L-lysine coated glass coverslips and transfected 
with SNAP-GPR56. Two days post-transfection, cells were serum starved for 
30 mins in 0.45 M sucrose-containing medium, followed by staining of SNAP-
GPR56 with SNAP-surface substrate 647 (shown in green; NEB) for 15 mins at 
4 °C. Cells were treated with buffer control or 20 µg/ml C230-A TG2 for 5 sec and 
(A) fixed immediately, (B) incubated in serum free medium for 30 mins or (C) 
incubated in hyperosmotic medium (0.45 M sucrose) for 30 mins pior to fixation. 
Following permeabilisation, TG2 (red) was stained using monoclonal anti-TG2 
(Thermo Scientific) and anti-mouse Alexa594 antibodies (Jackson 
ImmunoResearch). 
(A) Control buffer treated cells that were fixed directly, showed cell surface 
staining for SNAP-GPR56 (left panels). C230-A TG2 treated cells (right panels) 
showed SNAP-GPR56 and TG2 surface staining, partially overlapping (yellow). 
(B) Following incubation in serum-free medium for 30 mins, SNAP-GPR56 was 
found in intracellular vesicles, with little receptor left at the cell surface. In cells 
treated with C230-A TG2 (right panels), intracellular vesicles were partially positive 
for both SNAP-GPR56 and TG2 staining. Little C230-A TG2 was left at the cell 
surface. 
(C) SNAP-GPR56 and C230-A TG2 internalisation was prevented by incubation in 
0.45 M sucrose for 30 mins following treatment with buffer control (left panels) or 
C230-A TG2 (right panels) for 5 sec. 
White arrows, SNAP-GPR56 staining (green); black arrow heads, co-localisation of 
SNAP-GPR56 and C230-A TG2 (yellow); scale bar, 10 µm. 
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In addition to analysing the effect of sucrose treatment on GPR56 
internalisation by confocal microscopy, GPR56-dependent shedding of AP-
AR in the presence of sucrose was investigated using the shedding assay. 
GPR56 and AP-AR co-transfected cells were treated with  20 µg/ml C230-A 
TG2 in the absence or presence of 0.45 M sucrose for 1 h. As shown in 
figure 6.8, the presence of sucrose during the treatment led to a massive 
increase in p-NPP hydrolysis that was ~12-13 fold higher compared to 
medium without sucrose. Thus, AP-activity probably reached a maximum, as 
there was no further increase in p-NPP hydrolysis due to the addition of 
C230-A TG2. The increase in AP-AR shedding could be explained by the 
inhibition of GPR56 internalisation. Due to the accumulation of receptor at the 
cell surface, more AP-AR was shed by ADAM17, leading to a higher AP-
activity in the medium. The result also demonstrated that GPR56 endocytosis 
attenuates receptor signalling normally inducing ADAM activation. 
 
 
 
 
Figure 6.8 Shedding of AP-AR is potentiated in the presence of sucrose. 
Cells were transfected with GPR56 and AP-AR. Two days later, cells were serum 
starved for 1 h and treated with control buffer or 20 µg/ml C230-A TG2 for 1 h in the 
presence or absence of 0.45 M sucrose. 
Data presented show mean of 3 independent experiments with 4 repeats each 
+/- SEM (n=12). Statistical significance denoted as follows: ***, p<0.001. 
 198 
 
6.2.2.3.2 SNAP-GPR56 internalises with transferrin receptors 
 
Treatment with sucrose inhibited GPR56 internalisation, as well as GPR56-
dependent endocytosis of TG2, indicating clathrin-dependency of these 
events. The next step was to confirm that endocytosis of GPR56 is clathrin-
dependent by co-staining for transferrin receptors (TR) using fluorescent-
labelled transferrin (Tf).  
In the following experiments, TR and GPR56 endocytosis were observed 
over time in order to investigate whether both receptors would internalise in 
the same way. In figure 6.9, SNAP-GPR56 transfected cells were incubated 
with Alexa488-labelled Tf (green, Tf-488) at 4 °C for 30 mins to prevent 
preliminary Tf-uptake (Harding et al. 1983). SNAP-GPR56 (shown in red) 
was then stained with SNAP-surface substrate 647 at 4 °C for 15 mins. Cells 
were pulse-treated with 20 µg/ml C230-A TG2 or control buffer for 5 sec and 
fixed immediately or incubated in serum-free medium for 15 min prior to 
fixation.  
 
Cells that were fixed directly after treatment showed cell surface staining for 
SNAP-GPR56 (white arrow heads) and staining for Tf-488 (white arrows), 
which appeared slightly below the cell surface (Fig. 6.9 A). It was first tried to 
co-label the TR and SNAP-GPR56 simultaneously at 4 °C. This approach, 
however, was not amendable due to lack of TR staining (data not shown).  
Therefore, TR-Tf complexes were established first, prior to SNAP-GPR56 
labelling. Remarkably, the degree of co-localisation (yellow; black arrow 
heads) between the two proteins was low at 5 sec, as TR-Tf complexes had 
already started to internalise (Fig. 6.9 A). This probably occurred because of 
the timely separated staining for SNAP-GPR56 and TR. Labelling in the 
presence of sucrose was also evaluated, which should prevent receptor 
internalisation and increase the amount of TR at the cell surface, but was not 
successful (data not shown). It is likely that a component present in the 
SNAP-substrate prevents Tf-488 to bind to TR, however, the exact 
composition of the solution is unknown (NEB). Since the SNAP-substrate is 
dissolved in DMSO, I also tested labelling of TR with Tf-488 in the presence 
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of DMSO, which did not interfere with TR-Tf complex formation (data not 
shown). 
Following incubation in serum-free medium for 15 mins (Fig. 6.9 B), SNAP-
GPR56 and TR-Tf complexes appeared in the same intracellular vesicles 
(yellow; black arrow heads). Only a few intracellular vesicles were positive 
solely for SNAP-GPR56 (white arrow heads) or Tf-488 (white arrows). Some 
SNAP-GPR56, but very little Tf-488 was left at the cell surface after 15 mins. 
The staining pattern of SNAP-GPR56 and TR-Tf complexes looked similar in 
cells treated with control buffer (left panels) and C230-A TG2 (right panels). 
Incubation for 30 mins and longer resulted in a complete loss of TR-Tf 
complexes in the cells (data not shown). It is likely that Tf-488 was already 
recycled back to the cell surface and dissociated, since this process takes 
~20-30 mins (Harding et al. 1983; Goldstein et al. 1985). This might explain 
why TR-Tf complexes were not detectable in cells at later time points. 
 
Although it was difficult to demonstrate cell surface co-localisation of GPR56 
and TR initially, the high amount of co-staining in intracellular vesicles after 
15 mins (black arrow heads) indicated co-internalisation. Therefore, the 
experiments confirmed the clathrin-dependent endocytosis of GPR56.     
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Figure 6.9 Transferrin-receptors co-localise with SNAP-GPR56 following 
endocytosis. 
Cells were seeded onto poly-L-lysine coated glass coverslips and transfected with 
SNAP-GPR56. Two days later, cells were serum starved for 1 h, followed by 
incubation with 10 µg/ml transferrin-488 solution (green, Tf-488; Molecular Probes) 
for 30 mins at 4 °C. SNAP-GPR56 (shown in red) was stained with SNAP-surface 
substrate 647 (NEB) for 15 mins at 4°C. Cells were treated with control buffer (left 
panels) or 20 µg/ml C230-A TG2 (right panels) for 5 sec, followed by (A) direct 
fixation or (B) incubation in serum-free medium for 15 mins prior to fixation. 
(A) Initially, cells were positive for SNAP-GPR56 surface staining. Tf-488 appeared 
slightly below the cell surface, indicating beginning of TR internalisation. 
(B) After 15 mins incubation, little SNAP-GPR56 and even less Tf-488 was left at the 
cell surface. Intracellular vesicles, mostly positive for both SNAP-GPR56 and Tf-TR 
complexes (yellow), were detectable. 
White arrow heads, SNAP-GPR56 staining (red); white arrows, Tf-488 staining (green); black 
arrow heads, co-localisation of SNAP-GPR56 and Tf-488 (yellow); scale bar, 10 µm. 
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6.2.2.3.3 Endocytosis of SNAP-GPR56 is caveolae-independent 
 
The results presented above indicated that GPR56 endocytosis was 
dependent on the formation of clathrin-coated pits. Internalisation by 
caveolae (“little caves”), a clathrin-independent pathway, is also known for 
GPCRs (Chini and Parenti 2004). In order to investigate non-clathrin-
internalisation, one of the main structural proteins of caveolae, caveolin-1 
(cav-1), was co-stained in cells expressing SNAP-GPR56. The expression of 
the ~20 kDa protein cav-1 is necessary and sufficient for the formation of 
caveolae, thus cav-1 represents a good marker for caveolae-staining (Fra et 
al. 1995). 
SNAP-GPR56 transfected cells (shown in red) were stained with SNAP-
surface substrate 647 for 15 mins at 4 °C and treated with buffer control or 
20 µg/ml C230-A TG2 for 5 sec. Cells were either fixed immediately or 
incubated in serum-free medium for up to 60 mins prior to fixation and 
permeabilisation. A polyclonal anti-cav-1 antibody was used to stain caveolae 
(green).  
At 5 sec (Fig. 6.10 A), cells treated with control buffer (left panels) or C230-A 
TG2 (right panels) showed cell surface staining for SNAP-GPR56 (white 
arrow heads), which partially overlapped with cav-1 (yellow; black arrow 
heads). Additionally, cav-1 was also located intracellularly at this stage (white 
arrows), since caveolae endocytose several proteins.  
After 15 mins of incubation in serum-free medium (Fig. 6.10 B), intracellular 
vesicles positively staining for SNAP-GPR56 (white arrow heads) were found 
in all cells. After 60 mins (Fig. 6.10 C), the amount of internalised SNAP-
GPR56 increased, with little left at the cell surface. 
The overall pattern of cav-1 staining remained similar for all time points and 
conditions investigated, showing some surface staining and some staining of 
vesicles (white arrows). There was very little co-localisation of cav-1 and 
SNAP-GPR56 in the intracellular vesicles (yellow; black arrow heads). 
These results indicated that GPR56 internalisation was independent of 
caveolae, confirming the idea of clathrin-mediated endocytosis.  
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Figure 6.10 Internalisation of SNAP-GPR56 is not mediated by caveolae. 
Cells were seeded onto poly-L-lysine glass coverslips and transfected with 
SNAP-GPR56. 48 h post-transfection, cells were serum starved for 1 h, followed 
by SNAP-GPR56 staining (shown in red) with SNAP-surface substrate 647 (NEB) 
for 15 mins at 4 °C. Cells were treated with control buffer (left panels) or 20 µg/ml 
C230-A TG2 (right panels), followed by (A) direct fixation or incubation in serum-
free medium for (B) 15 mins or (C) 60 mins prior to fixation and permeabilisation. 
Caveolae (green) were stained using anti-cav-1 (Abcam) and anti-rabbit 
Alexa488 antibodies (Jackson ImmunoResearch). 
(A) After 5 sec, the cell surface was positive for SNAP-GPR56 staining, partially 
overlapping with cav-1 (yellow). Cav-1 staining was also present intracellularly.  
(B) After 15 mins, some internalisation of SNAP-GPR56 occurred, but there was 
little intracellular co-localisation with cav-1 positive vesicles (yellow). 
(C) Following 60 mins of incubation in serum-free medium, the amount of SNAP-
GPR56-positive vesicles increased, still there was little co-localisation with cav-1 
intracellularly, indicating caveolae-independent internalisation of GPR56. 
White arrow heads, SNAP-GPR56 staining (red); white arrows, cav-1 staining (green); 
black arrow heads, co-localisation of SNAP-GPR56 and cav-1 (yellow); scale bar, 10 µm. 
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6.2.2.4 Internalised GPR56 and TG2 do not co-localise in lysosomes 
 
So far, the interaction between GPR56 and TG2 resulted in simultaneous 
internalisation of both proteins, which was most likely mediated by clathrin. 
The results indicated that recycling of GPR56 within the 1 h time window 
investigated was slow and that TG2 did not traffic back to the cell surface. 
Thus, the fate of receptor and ligand following endocytosis was still unclear 
and was investigated further.  
In addition to recycling via early endosomes, a likely event following 
internalisation of transmembrane proteins and their ligands is degradation, 
which usually occurs in lysosomes carrying proteolytic enzymes (Sorkin and 
von Zastrow 2009). In order to investigate whether GPR56 and TG2 were 
sorted into lysosomes, co-staining for lysosome-associated membrane 
proteins LAMP1 and LAMP2 was performed. 
Cells were transfected with SNAP-GPR56 (shown in red) stained with SNAP-
surface substrate 647 at 4 °C for 15 mins. Cells were pulse-treated with 
control buffer or 20 µg/ml C230-A TG2, followed by incubation in serum-free 
medium for up to 6 h prior to fixation and permeabilisation. Cells were then 
co-stained for TG2 (shown in cyan) and the lysosomal marker LAMP1 
(green). 
Cytoplasmic staining for lysosomes was present over the entire incubation 
time in both buffer treated (A) and C230-A TG2 treated (B) cells (Fig. 6.11, 
white arrows).  
In control buffer treated cells (Fig. 6.11 A), SNAP-GPR56 was present at the 
cell surface after 5 sec and in endocytic vesicles (white arrow heads), which 
were apparent after 30 mins and increased over 60 mins with very little 
SNAP-GPR56 left at the cell surface. There was very little co-localisation 
between internalised SNAP-GPR56 and LAMP1-positive lysosomes (black 
arrow heads) after 30 mins or 60 mins in control buffer treated cells.  
Fig. 6.11 B shows that SNAP-GPR56 and TG2 partially co-localised at the 
cell surface of C230-A TG2 treated cells after 5 sec and in endocytic vesicles 
(white; black arrows) that were detectable after 30 mins and increased over 
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60 mins, with little SNAP-GPR56 and TG2 left in the plasma membrane. 
There was little to no colocalisation between LAMP1-positive lysosomes and 
the endocytosed receptor-ligand pair. Strikingly, the amount of intracellular 
TG2 dramatically decreased after the 60 mins time point, with almost nothing 
left after 6 h (Fig. 6.11 B). However, even at the 3 h time point, the remaining 
TG2 did not co-localise with LAMP1. This finding and the fact that TG2 is not 
recycled back to the cell surface could indicate degradation via a different 
pathway, e.g. proteasomal degradation.     
  
 206 
 
 
 207 
 
Figure 6.11 Internalised SNAP-GPR56 and C230-A TG2 are not targeted to 
LAMP1-positive lysosomes. 
Cells growing on poly-L-lysine coated glass coverslips were transfected with SNAP-
GPR56 and 48 h serum starved for 1 h. SNAP-surface substrate 647 (NEB) was 
used to stain SNAP-GPR56 (shown in red) for 15 mins at 4 °C. Cells were treated 
with (A) control buffer or (B) 20 µg/ml C230-A TG2, followed by immediate fixation or 
incubation in serum-free medium for 30 mins, 60 mins, 3 h or 6 h prior to fixation 
and permeabilisation. C230-A TG2 (shown in cyan) was stained with mouse anti-TG2 
(Thermo Scientific) and anti-mouse Alexa594 antibodies (Jackson 
ImmunoResearch). Late endosomes/early lysosomes (green) were stained using 
anti-LAMP1 (Sigma-Aldrich) and anti-rabbit Alexa488 antibodies (Jackson 
ImmunoResearch). 
(A) Control buffer treated cells were negative for TG2 staining at any time. SNAP-
GPR56 (red) was internalised as observed before, with little receptor left at the cell 
surface after 1 h incubation in serum free medium. There was very little co-
localisation of GPR56 and LAMP1-positive lysosomes intracellularly (yellow). 
(B) After 5 sec incubation, SNAP-GPR56 and TG2 showed overlapping cell surface 
staining (white). Over time, the ligand-receptor pair internalised simultaneously 
(15 mins to 3 h time points). After 6 h, GPR56 was only found intracellularly with 
very little left at the cell surface and no TG2 present in the cells, indicating 
degradation that was not LAMP1-dependent. 
White arrow heads, SNAP-GPR56 staining (red); white arrows, LAMP1 staining (green); 
black arrow heads, co-localisation of LAMP1 and SNAP-GPR56 (yellow); Black arrows, co-
localisation of SNAP-GPR56 and TG2 staining (white); scale bar, 10 µm.   
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Next, LAMP2 was tested as a second lysosomal marker in experiments using 
immunocytochemistry. Figure 6.12 shows SNAP-GPR56 (shown in red) 
expressing cells that were treated with control buffer (A) or C230-A TG2 (B), 
followed by fixation, permeabilisation and co-staining with mouse anti-LAMP2 
antibody (green). In comparison to LAMP1, LAMP2 staining seemed more 
prominent (white arrows). Regarding co-localisation with SNAP-GPR56, 
there was no difference between LAMP1 and LAMP2 staining. SNAP-GPR56 
was apparent at the cell surface after 5 sec and was partially internalised 
after 30 mins, with little left at the cell surface after 60 mins (Fig. 6.12 A & B, 
white arrow heads). The majority of intracellular vesicles containing SNAP-
GPR56 were negative for LAMP2 staining, indicating that GPR56 was not 
targeted to lysosomes once it entered the cell. Again there was no evidence 
for degradation of GPR56 in lysosomes.   
 
 
Taken together, experiments using SNAP-tagged GPR56 presented in this 
chapter demonstrated that SNAP-tag staining is a good method to follow N-
terminal domain receptor internalisation that can be combined with 
immunocytochemistry to stain other proteins, or ligand. In contrast to pure 
antibody staining of GPR56 and TG2 (6.2.1), SNAP-tag staining enabled the 
analysis of GPR56-dependent TG2-internalisation, as well as it revealed the 
clathrin-dependency of this event. The question of the receptor-ligand fate 
inside the cell could not entirely be answered, but experiments performed 
excluded lysosome-dependent degradation. 
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Figure 6.12 Internalised SNAP-GPR56 and C230-A TG2 do not co-localise with 
LAMP2-positive lysosomes. 
Cells growing on poly-L-lysine coated glass coverslips were transfected with SNAP-
GPR56 and 48 h later serum starved for 1 h. SNAP-surface substrate 647 (NEB) 
was used to stain SNAP-GPR56 (shown in red) for 15 mins at 4 °C. Cells were 
treated with (A) control buffer or (B) 20 µg/ml C230-A TG2, followed by immediate 
fixation or incubation in serum-free medium for 30 mins or 60 mins prior to fixation 
and permeabilisation. Late endosomes/early lysosomes (green) were stained using 
mouse anti-LAMP2 (DHSB) and anti-mouse Alexa488 antibodies (Jackson 
ImmunoResearch).  
White arrow heads, SNAP-GPR56 staining (red); white arrows, LAMP2 staining (green); 
black arrow heads, co-localisation of LAMP2 and SNAP-GPR56 (yellow); Scale bar, 10 µm. 
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6.3 Discussion 
 
In this chapter, confocal microscopy was used to investigate whether GPR56 
is internalised constitutively and/or upon TG2-stimulation. Confocal 
microscopy cannot be used to identify membrane invaginations or lipid rafts, 
as they are too small and dynamic, but it is very useful to study intracellular 
trafficking of GPCRs in combination with markers for clathrin-dependent and 
-independent endocytosis or intracellular compartments like endosomes 
(Chini and Parenti 2004). 
The first attempt to follow the fate of the receptor-ligand pair, antibody 
staining against GPR56 and TG2 was used on fixed and permeabilised 
HEK293 cells inducibly expressing GPR56 (Fig. 6.3). Using this approach, it 
was shown that C230-A TG2 exclusively bound to cells expressing GPR56. 
Moreover, as a result of the receptor-ligand interaction, TG2 was internalised 
in a GPR56-dependent manner. These findings confirm the conclusion drawn 
from the previous chapters, illustrating TG2 as a bona fide ligand for GPR56.  
Zemskov et al. (2007) showed that TG2 binds to the lipoprotein-receptor 
related protein-1 (LRP1) at the cell surface and undergoes endocytosis and 
lysosomal degradation upon prolonged incubation (> 90 mins). LRP1-
dependent constitutive internalisation of TG2 was shown to occur via both 
clathrin- and caveolae-dependent pathways. HEK293 cells are negative in 
LRP-1 expression (Montel et al. 2007) and thus represent a very good cell 
model to investigate GPR56-dependent and LRP1-independent TG2 
internalisation. 
Immunostaining of GPR56 was not feasible to follow endocytosis of GPR56, 
since the antibody stains all N-GPR56 present in the cell, so that it is 
impossible to distinguish between maturing and endocytosed GPR56. 
Additionally, the degree of co-localisation between GRP56 and internalised 
TG2 was very low. This might be explained by sterical hindrance between the 
GPR56 and TG2 antibodies, preventing the GPR56 antibody or the 
secondary antibody to bind. However, this did not account for the initial time 
point, showing co-localisation between GPR56 and TG2 at the cell surface 
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prior to internalisation. Therefore, epitopes of N-GPR56 that are accessible at 
the cell surface may be non-accessible upon endocytosis due to 
conformational changes. Moreover, prolonged agonist stimulation, as 
performed here with TG2 treatments for up to 60 mins, can influence the fate 
of the endocytosed receptor, leading to down-regulation of the GPCRs by 
degradation, a phenomenon that is implicated in the development of drug 
resistance (von Zastrow 2001).  
 
Therefore, another biochemical approach was used for further experiments. 
Using HEK293 cells transiently transfected with SNAP-tagged GPR56, it was 
possible to follow receptor internalisation, as this method only stains receptor 
initially present at the cell surface. Western blot and confocal analyses of 
cells expressing SNAP-GPR56 showed that the receptor was normally 
processed (Fig. 6.4) and that receptor trafficking to the cell surface was not 
influenced by the presence of the SNAP-tag (Fig. 6.5 & 6.6). A comparison of 
SNAP-GPR56 and SNAP-β2AR, the control receptor, showed that the SNAP-
tag did not influence C230-A TG2 binding to GPR56. In addition, the results 
confirmed the specific interaction of the ligand-receptor pair, as SNAP-β2AR 
did not bind TG2 (Fig. 6.5 B&C).  
A comparison of ligand-independent internalisation of GPR56 and β2AR 
showed that there was a lot of GPR56 endocytosed after 15 mins at 37 °C, 
whereas there was little β2AR present in intracellular vesicles (Fig. 6.5 A). 
This may indicate a faster recycling of β2AR. The β2AR belongs to class A 
GPCRs that only weakly interact with β-arrestin and recycle rapidly (Oakley 
et al. 2001). GPR56 associates with β-arrestin2 (Paavola et al. 2011) and 
might belong to the family of class B receptors that associate tightly with β-
arrestin and recycle slowly back to the cell surface. However, in order to 
confirm this speculation, β-arrestin and SNAP-GPR56 stainings should be 
combined.  
On the other hand, the β2AR was described to be relatively stable at the cell 
surface for up to 1 h in HEK293 cells under ligand-free conditions (von 
Zastrow and Kobilka 1994). This explains the low amount of internalised 
β2AR observed in our experiment and indicates a higher degree of 
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constitutive internalisation of GPR56 as a result of a high basal activity, as 
observed for the melanocortin MC4 receptor (Mohammad et al. 2007).  
 
In order to investigate whether TG2 and GPR56 internalise together, SNAP-
GPR56 expressing cells were treated with C230-A TG2 for 5 sec (the pulse), 
followed by incubation in TG2-free medium for up to 1 h (the chase) (Fig. 
6.6). GPR56 and TG2 co-localised at the cell surface, and simultaneous 
endocytosis was detected after 15 mins. GPR56-TG2 complexes 
accumulated in intracellular vesicles, with little GPR56 and even less TG2 left 
at the cell surface at 60 mins, indicating degradation and slow recycling. 
GPR56 also rapidly internalised constitutively in the absence of TG2. The 
results potentially show a higher degree of internalisation in the presence of 
TG2, however, the experiments were not analysed quantitatively and 
conclusions in this direction cannot be drawn. 
 
The next step was to shed some light on the mechanism of GPR56 
internalisation. GPCRs can switch the mode of endocytosis upon agonist-
activation. In HeLa cells, the β2AR and the M3 acetylcholine muscarinic 
receptors switch from a clathrin-independent mechanism of constitutive 
internalisation to clathrin-dependent endocytosis upon agonist stimulation 
(Scarselli and Donaldson 2009). Sucrose is a non-toxic clathrin inhibitor 
(McMahon and Boucrot 2011) that is cheap and easy to handle, thus SNAP-
GPR56 expressing cells were pulse-treated with C230-A TG2, followed by 
incubation in 0.45 M sucrose-containing medium for 30 mins (Fig. 6.7 C). The 
treatment with sucrose completely prevented constitutive as well as TG2-
induced endocytosis of GPR56, therefore constitutive internalisation of 
GPR56 and GPR56-dependent internalisation of TG2 are both dependent on 
clathrin. 
In order to confirm that endocytosed GPR56 was present in clathrin-coated 
vesicles, the transferrin-receptor (TR) was co-localised (Fig. 6.9). In the 
beginning of the experiment, Tf-488 and GPR56 were present at the cell 
surface. However, the degree of co-localisation between the two proteins 
was low, as Tf-uptake had already started. This was probably due to the 
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experimental procedure, as the cells were first incubated with Tf-488 prior to 
SNAP-tag staining. However, simultaneous incubation with Tf-488 and 
SNAP-substrate abolished staining of TR, which might be due to the 
presence of a component in the SNAP-substrate solution that interferes with 
TR-Tf complex formation. The SNAP-substrates themselves, benzylguanine 
derivatives, are probably too small to sterically interfere with Tf-488 or TR. 
Nonetheless, Tf-488 and GPR56 co-localised in the same endocytic vesicles 
after 15 mins of incubation in serum-free medium at 37 °C (Fig. 6.9), again 
indicating that GPR56 internalisation was mediated by clathrin-coated pits. 
 
In order to exclude a contribution of caveolae in GPR56 endocytosis, a cav-1 
antibody was used to co-stain SNAP-GPR56 expressing cells pulse-treated 
with C230-A TG2 (Fig. 6.10). Cav-1 staining was pronounced at the cell 
surface, but also present intracellularly, since caveolae are formed in the ER 
and cav-1 also plays a role as a molecular chaperone (Cohen et al. 2003). 
Following incubation for up to 1 h, GPR56 internalised, as observed in 
previous experiments. The distribution of cav-1, however, did not change 
significantly over time and the degree of co-localisation between cav-1 and 
the GPR56 was very low. These results indicate that internalisation of 
GPR56 is not mediated by caveolae. In addition, the pattern of GPR56 
endocytosis was the same in the absence or presence of TG2, as also 
observed with labelled Tf-488 (Fig. 6.9), again indicating that constitutive and 
ligand-induced internalisation of GPR56 are mediated by clathrin.  
Zhang et al. 1996 showed that some receptors switch to clathrin-independent 
endocytosis when a mediator for clathrin-dependent endocytosis like β-
arrestin is inhibited. In order to exclude the possibility that GPR56 could 
internalise via clathrin-independent mechanisms, the same experiment could 
be repeated in Cos-7 cells, which show low endogenous β-arrestin levels 
(Zhang et al. 1996). Moreover, depending on the cell type, some GPCRs use 
different mechanisms of endocytosis. The β2AR for example internalises via 
clathrin-dependent endocytosis in HEK293 cells, whereas it uses caveolae 
for internalisation in A431 epithelial carcinoma cells (von Zastrow 2001).  
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Thus, the mechanism of endocytosis seems to be dependent on the GPCR, 
the presence of agonist and the cell type. 
 
Finally, experiments using lysosomal markers were performed in order to 
investigate the fate of endocytosed GPR56 and TG2. At 60 mins, plasma 
membrane levels for GPR56 and TG2 were low, with most of the receptor-
ligand pair present in endocytic vesicles. After 3 h and 6 h, GPR56 was still 
present in endocytic vesicles, whereas most of intracellular TG2 staining was 
lost, indicating degradation. Lysosomal degradation is an important function 
of endocytosis and many cells use it to regulate the composition of their 
plasma membrane and to attenuate signal transduction (von Zastrow 2001). 
Co-staining of the lysosomal integral membrane proteins LAMP1 and LAMP2 
did not indicate co-localisation with GPR56 or TG2. Results recently 
presented by Yang et al. (2014) indicated GPR56-dependent internalisation 
of TG2, followed by lysosomal degradation of TG2 after 60 mins. Treatment 
of GPR56-expressing MC-1 melanoma cells with the lysosomal inhibitors 
chloroquine and NH4Cl increased the amount of TG2 present in the ECM. 
Additionally, the results showed accumulation of N-GPR56 in the ECM, 
raising questions about potential exocytosis of the N-terminus. However, 
these experiments were performed in a completely different cell system and 
the endocytic machinery as well as the receptor/ligand fate upon 
internalisation can vary between different cell types for the same receptor 
(von Zastrow 2001). In contrast to the TG2 pulse treatments (5 sec) 
performed in my experiments, Yang et al. (2014) treated their cells for 
prolonged times (up to 60 mins) with TG2, an important difference that 
potentially influences the outcome for the internalised receptor-ligand pair.   
In order to further investigate whether TG2 is degraded in GPR56-expressing 
HEK293 cells upon endocytosis, cells could be pulse treated with C230-A TG2 
for 5 sec, then incubated in serum-free medium for 60 mins and longer, 
followed by analysis of cell lysates for TG2 degradation products using 
western blot analysis. This experiment could clarify whether TG2 is 
degraded, but not how this might happen. 
 216 
 
Experiments presented in this chapter may indicate that GPR56 and TG2 are 
degraded by another, non-lysosomal mechanism in HEK293 cells, such as 
the 26S proteasome, the megaprotease complex degrading most cellular 
proteins. However, endocytosis via clathrin-coated pits is generally believed 
to be associated with receptor ubiquitination and lysosomal degradation, as 
shown for the β2AR and δ-opioid receptors in HEK293 cells  (Shenoy et al. 
2008; Tsao and von Zastrow 2000; Keith et al. 1996). The β2AR is mainly 
recycled, but can be detected in lysosomes after >6 h of prolonged agonist 
stimulation. The δ-opioid receptors are mainly degraded and detected in 
lysosomes ~60 mins after endocytosis (Moore et al. 1999; Tsao and von 
Zastrow 2000). In addition, the δ-opioid receptor was shown to undergo 
substantial proteloytic degradation even after the removal of agonist (pulse 
treatment) (Tsao and von Zastrow 2000). However, another report 
demonstrated basal and agonist-induced proteasomal degradation of δ-
opioid receptors in HEK293 cells following polyubiquitination of the receptors 
(Chaturvedi et al. 2001). Proteolysis of the receptors was apparent 2-4 h after 
agonist stimulation and it was suggested that the ubiquitin/proteasome-
pathway operates upstream of lysosomes. A similar observation was made 
with the platelet-derived growth factor that is degraded by the proteasome, 
but remaining peptide fragments are further degraded in lysosomes (Mori et 
al. 1995). Thus, GPR56 might behave similar to the δ-opioid receptors, i.e. it 
is internalised via clathrin-coated pits, followed by polyubiquitination and 
degradation in the proteasome. This hypothesis would support my finding 
that GPR56 and TG2 are not detected in lysosomes within the timeframe of 
the performed experiments. 
In order to further investigate how GPR56 and TG2 are degraded, their fate 
could be chased in the presence of lysosomal protease inhibitors or 
proteasomal inhibitors (Chaturvedi et al. 2001). If intracellular TG2 or GPR56 
levels remained constantly high over time in the presence of one of the 
inhibitors, this would point towards degradation in the respective 
compartment. 
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Additionally, it must be noted that co-localisation of C-GPR56 with LAMP-
positive lysosomes cannot be excluded, as SNAP-surface staining does only 
follow the fate of N-GPR56. N-GPR56 mainly localises in non-raft fractions, 
whereas C-GPR56 is partially found in lipid rafts (Chiang et al. 2011). 
Therefore, it is possible that their endocytic routes differ and it cannot be 
excluded that C-GPR56 is internalised via a clathrin-independent 
mechanism. Experiments setting out to follow the fate of the C-GPR56 
domain were performed, in which HEK293 cells were transfected with a 
SNAP-GPR56-mCherry expression construct. The N-terminal SNAP-tag was 
stained with SNAP-surface substrate 488 in order to monitor potential co-
localisation of SNAP-N-GPR56 and C-GPR56-mCherry at the cell surface or 
in endocytic vesicles upon internalisation (data not shown). However, 
analysis using confocal microscopy and western blotting revealed that 
mCherry is cleaved from the C-terminal tail and localised in huge intracellular 
vesicles independently of the localisation of N-GPR56, thus this methodology 
was not useful to follow the fate of C-GPR56.  
 
 
Taken together, data presented in this chapter indicate that GPR56 is 
internalised via clathrin-coated pits in HEK293 cells under ligand-free and 
TG2-stimulated conditions. GPR56 internalises rapidly (detected after 
15 mins), but seems to recycle slowly. Moreover, neither receptor nor ligand 
seem to be degraded by lysosomes. 
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7 Generation and preliminary characterisation of 
stable GPR56 knockdown glioblastoma cells  
 
7.1 Introduction 
 
Glioblastoma multiforme (GBM) is a grade IV astrocytoma and the most 
aggressive type of brain cancer in humans. One of the hallmarks of GBM is 
its invasive behaviour due to cell subpopulations within the tumours that 
migrate into the normal brain tissue, but rarely metastasise outside the brain. 
The highly invasive potential of these glioblastoma cells often leads to tumour 
recurrences, despite surgery and chemo- or radiation therapies. In most 
cases, the cells have already invaded the surrounding healthy areas of the 
brain at the time of surgery (Angers-Loustau et al. 2004; Demuth and Berens 
2004). The process of motility is out of control in cancer cells, enabling them 
to migrate and invade healthy tissue (Demuth and Berens 2004). Invasion is 
a complex process including cell shape modifications, cell polarisation, 
interactions with adjacent cells and the ECM, as well as degradation of the 
ECM (Belkin et al. 2001). Cell invasion is a balance between cell adhesion 
and detachment, in which cell adhesion receptors and their ligands play 
important roles (Shashidhar et al. 2005).  
GPR56, an adhesion GPCR, is involved in cell adhesion and migration since 
members of the adhesion GPCR family mainly facilitate cell-cell and cell-
ECM contacts (Araç, Aust, et al. 2012). GPR56 was identified as a neural 
stem cell marker (Terskikh et al. 2001; Bai et al. 2009) and as a regulator of 
neural progenitor cell migration (Iguchi et al. 2008; Luo et al. 2011). Gliomas 
arise from astrocytes and their precursors, as well as from transformation of 
normal stem cells (Berger et al. 2004; Shashidhar et al. 2005). GPR56 
mRNA and protein levels in normal adult brain are very low (Shashidhar et al. 
2005). However, GPR56 protein expression is significantly up-regulated in 
the tested glioblastoma cell lines U87, G122 and D566, as well as in 
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glioblastoma tumour tissue. Moreover, immunohistochemical analysis of 
GPR56 expression revealed that GPR56 was specifically up-regulated in 
astrocytic tumours, whereas other brain tumours showed low expression 
levels. Thus, GPR56 seems to play a role for the development of 
astrocytomas (Shashidhar et al. 2005). GPR56 co-localised with α-actinin in 
extended membrane structures and focal adhesion complexes in U87 cells, 
indicating a role of the receptor in cell adhesion and migration. Luciferase 
reporter assays performed in HEK293 cells transiently transfected with 
GPR56 revealed that GPR56 activated PAI-1, TCF and NF-κB responsive 
elements. PAI-1 and TCF are implicated in processes such as cell invasion, 
metastasis, adhesion and progression, thus involved in tumourigenesis 
(Shashidhar et al. 2005). 
A good way to investigate the role of GPR56 in cancer is its down-regulation 
in specific cell types. So far, shRNA approaches were used to knockdown 
GPR56 in neural progenitor cells (NPCs) (Iguchi et al. 2008), NIH/3T3 cells 
(Luo et al. 2011), rostral granule cells (Koirala et al. 2009), acute myeloid 
leukemia (AML) cells (Saito et al. 2013) and melanoma cell lines (Yang et al. 
2014; Ke et al. 2007), but not in glioblastoma cells. NPCs and AML cells 
failed to activate RhoA upon GPR56 knockdown, resulting in decreased 
cellular adhesion (Luo et al. 2011; Saito et al. 2013). A similar result was 
observed in the GPR56-knockdown granule cells that showed decreased 
adherence to fibronectin or laminin-1 (Koirala et al. 2009), confirming a role 
of GPR56 in cell adhesion. In addition, loss of GPR56 expression or 
mutations affecting GPR56 cell surface expression are associated with 
overmigration of neurons through a defective pial basement membrane, 
leading to the brain malformation observed in BFPP patients (Li et al. 2008; 
Luo et al. 2012; Piao et al. 2004). 
 
7.1.1 Aims of the chapter 
 
 To generate GPR56-silenced glioblastoma cell lines by using shRNA. 
 
 To characterise the GPR56 knockdown cells. 
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7.2 Results 
 
7.2.1 Hygromycin dose-response  
 
The first step in order to generate GPR56-silenced U373 cells using stable 
transfection with shRNA targeting plasmids was to determine the effective 
hygromycin B concentration to kill all non-transfected cells. Parental U373 
cells were seeded in hygromycin-free or in hygromycin-supplemented growth 
medium containing concentrations ranging from 100 to 800 µg/ml. Figure 7.1 
shows that 200 µg/ml hygromycin was sufficient to kill most cells. Further 
improvement in the killing effectiveness at higher hygromycin doses could not 
be achieved, thus 200 µg/ml hygromycin was used to establish the stable 
shGPR56 cell lines.  
Three different shRNAs, two targeting Gpr56 at two different sites of the gene 
(shGPR56.2 and shGPR56.4) and a non-coding control shRNA (shRNA.NC) 
were used to transfect U373 cells. Following transfection, cells were cultured 
in the selection medium containing 200 µg/ml hygromycin and single cell 
clones were isolated. In case of shGPR56.2 transfected cells, eight single 
cells clones and one pooled population were isolated. For shGPR56.4, only 
one pooled population could be isolated, as well as one single clone for the 
non-coding shRNA.  
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Figure 7.1 Hygromycin kill curve of U373 cells. 
Non-transfected U373 cells were seeded at 10% confluence in a 6-well plate 
containing growth medium that was hygromycin B free or supplemented with 100-
800 µg/ml hygromycin B. Medium was changed every other day and cells were 
cultured until cells in the hygromycin-free medium reached confluence. The effective 
hygromycin concentration killing all non-transfected cells was determined at 
200 µg/ml hygromycin. 
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7.2.1.1 GPR56 expression levels and pattern 
 
In order to characterise the GPR56 knockdown cells, total cell lysates were 
analysed for GPR56 expression using western blotting. Figure 7.2 shows that 
the overall degree of GPR56 down-regulation was not very high among the 
isolated cell clones transfected with shGPR56.2, as this depends on the site 
of integration in the cellular genome. Only one pooled population consisting 
of several small single colonies could be rescued for shGPR56.4 transfected 
cells. Although single clones were tentatively isolated, they did not survive 
the expansion step.  
Of the nine polyclonal or clonal cell populations expressing shGPR56.2, only 
the single clones #3 and #4 showed a significant decrease in GPR56 
expression (Fig. 7.2 A). However, the pattern of GPR56 expression in the two 
cell clones looked different, since clone #3 showed a prominent reduction in 
expression for the band likely representing full-length GPR56, whereas clone 
#4 mainly showed a reduction for the bands likely representing N-GPR56. 
Preliminary data of a cell growth curve experiment indicated that there are no 
differences in cell proliferation between the parental U373 cells and several 
shRNA-transfected cell populations under serum-containing conditions (data 
not shown). However, these experiments would need to be expanded and 
performed in serum-free medium. 
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Figure 7.2 GPR56 expression in GPR56-silenced U373 cell clones. 
Two shRNAs targeting Gpr56 (shGPR56.2 and shGPR56.4) and one non-coding 
control shRNA (shRNA.NC) were used for stable transfection of U373 cells. 
Following selection of stably transfected cells in 200 µg/ml hygromycin-containing 
selection medium, single cell clones were isolated and grown until confluent. Total 
cell lysates of non-transfected U373 cells and U373 cells stably transfected with 
shRNA were prepared and analysed using western blotting. Cell lysates were 
separated in a 10% resolving gel, followed by blotting onto a PVDF-membrane and 
immunostaining using anti-N-GPR56 antibody (R&D Systems). GAPDH was stained 
as a loading control.  
(A) Clone #3 and clone #4 of cells transfected with shGPR56.2 showed the best 
down-regulation of GPR56 expression. 
(B) Non-transfected U373 cells and cell clone #1 of U373 cells transfected with 
shRNA.2 show high GPR56 expression levels. 
(C) Non-transfected U373 cells and cell clones #5, #6 and #7 derived from U373 
cells transfected with shGPR56.2, which show a low degree of GPR56 down-
regulation. 
 
 
In order to further evaluate cellular localisation of remaining GPR56 in the 
two shGPR56 clones with the highest degree of knockdown, confocal 
microscopy was performed using anti-N-GPR56 staining, which was 
compared to staining of the parental U373 cell line. Parental U373 cells were 
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polarised, with N-GPR56 staining at the leading edge (Fig. 7.3 A). In contrast, 
upon GPR56 knockdown both shGPR56.2 clones investigated adopted a 
more round morphology and showed loss of GPR56 staining at the cell 
surface (Fig. 7.3 B & C). Due to a lack of a C-terminal GPR56 antibody, the 
localisation of this domain could not be investigated. 
 
 
 
Figure 7.3 GPR56 expression in U373 non-transfected and GPR56 knockdown 
cells. 
(A) Parental U373 cells, (B) cells of clone #3 stably transfected with shGPR56.2 and 
(C) cells of clone #4 stably transfected with shGPR56.2 were seeded onto poly-L-
lysine coated glass coverslips and grown for 72 h. Cells were fixed and GPR56 
expression detected using anti-N-GPR56 (red; R&D Systems) and secondary anti-
sheep Alexa568 antibodies (Jackson ImmunoResearch).  
White arrow heads, GPR56 staining. 
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7.3 Discussion 
 
This is the first report demonstrating GPR56 knockdown in a glioblastoma 
cell line by stable transfection with shRNA. Two shRNAs targeting Gpr56 
were used to transfect U373 glioblastoma cells, followed by isolation of 
several stably transfected cell clones. Western Blot analysis using anti-N-
GPR56 antibody showed high expression levels of GPR56 in non-transfected 
U373 cells (Fig. 7.2), confirming GPR56 as a biomarker for GBM (Shashidhar 
et al. 2005). GPR56 knockdown in the isolated cell clones was incomplete, 
which may indicate the importance of GPR56 expression for the survival of 
the glioblastoma cells. It was shown that re-expression of GPR56 in highly 
metastatic melanoma cells, in which GPR56 is down-regulated, leads to 
inhibition of tumour growth and metastasis (Xu et al. 2006). Thus, it could be 
the other way around in glioblastoma cells, in which GPR56 is normally 
highly expressed and GPR56 down-regulation may be lethal. As shown with 
the contradictory reports about GPR56 as a tumour suppressor or promoter, 
GPR56 seems to play varying roles in tumour development and progression, 
depending on the cancer type and stage (Xu et al. 2006; Shashidhar et al. 
2005; Ke et al. 2007; Xu et al. 2010; Yang et al. 2011; Yang et al. 2014). 
ShRNAs are inserted randomly into the genome and there are regions within 
the genomic DNA that are transcribed more efficiently than others, which 
may explain the differences in the degree of GPR56 down-regulation among 
the isolated U373 cell clones. Nonetheless, two clones of cells transfected 
with shGPR56.2, clone #3 and #4, showed significant down-regulation of 
GPR56 protein and were chosen for further analysis using confocal 
microscopy (Fig. 7.3). A comparison of the two clones with the parental cell 
line indicated that GPR56 was located at the cell front in non-transfected 
cells, which is in good agreement with the report from Shashidhar et al. 
(2005). In their study, the authors demonstrated that GPR56 was located at 
the leading edge of extending cell membrane structures of migrating cells, 
co-localising with α-actinin. I showed that GPR56 expression was missing in 
shGPR56.2 transfected cells, reflecting shRNA-mediated down-regulation. In 
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addition, the cell shape of the transfected cells looked different to the shape 
of the parental cells, indicating loss of cell polarisation.  
Cell polarisation is a very important, initial step in the process of cell 
migration, which can be induced by extracellular factors like chemokines, 
hormones, growth factors or ECM molecules (Ridley et al. 2003). GPCRs are 
associated with cell polarisation, since they sense these extracellular stimuli 
and are activated. This leads to the activation of different signalling cascades 
resulting in the remodelling of the actin cytoskeleton via small GTPases of 
the Rho family, including Cdc42, Rac and Rho (Cotton and Claing 2009). 
Membrane protrusions at the leading front, such as lamellipodia or filopodia, 
are formed by actin polymerisation, mediated by Cdc42 and Rac. Rho activity 
on the other hand is inhibited at the front, but present at the rear of the cell 
inducing the formation of contractile actin:myosin filaments. These 
actin:myosin bundles are crosslinked by α-actinin and anchored to focal 
adhesions that connect the actin cytoskeleton to the ECM (Ridley et al. 
2003). The small GTPases involved in cell polarisation can be activated by 
several GPCRs, usually signalling via G12/13 or Gq, but it was also shown for 
Gi-coupled GPCRs in some cell types (Cotton and Claing 2009). 
Overexpression of GPR56 in HEK293 cells, neural progenitors and NIH/3T3 
fibroblasts or treatment of NIH/3T3 cells with collagen III results in activation 
of RhoA via Gα12/13 (Iguchi et al. 2008; Luo, Jeong, et al. 2011). RhoA 
activation led to actin reorganisation and inhibition of migration. RhoA was 
reported to suppresses the activity of Rac1, thus limiting the number of 
membrane protrusions and inhibiting cancer cell invasion (Legg 2011; Vega 
et al. 2011; Simpson et al. 2004). It is possible that in glioblastoma cells the 
down-regulation of GPR56 affects the activities of small GTPases like RhoA, 
resulting in the observed changes of cell morphology. However, it is unclear 
as to which role GPR56 potentially plays in glioblastoma cells, in which it is 
overexpressed. Taking into account that GPR56 was demonstrated to 
activate signalling pathways involved in the regulation of cell adhesion and 
oncogenesis, it likely plays a role as an oncogene in these cells (Shashidhar 
et al. 2005). Additionally, GPR56 seems to have some tumour-promoting 
functions in melanoma, since only a complete knockdown of TG2 and 
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GPR56 ablates tumour growth, whereas GPR56-positive melanomas still 
grow in a TG2-depleted environment (Yang et al. 2014). However, further 
investigations will be necessary to confirm my preliminary data and to 
elucidate the functions of GPR56 in the development and progression of 
glioblastoma.
  
 
 
 
 
 
CHAPTER 8: 
General discussion and 
future experiments
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8 General discussion and future experiments 
 
8.1 Summary of the results  
 
The results presented in this thesis demonstrate for the first time that TG2 
activates GPR56, which requires the presence of the N-terminal domain of 
GPR56. Activation of GPR56 by TG2 results in activation of ADAM17-
dependent shedding of the membrane-tethered EGFR-ligand amphiregulin 
and involves RhoA/ROCK signalling in HEK293 cells. This signalling 
mechanism might be involved in glioblastoma development and progression, 
since GPR56 is overexpressed in glioma cells and down-regulation of 
GPR56 induces changes in cell morphology that might be caused by 
impaired Rho signalling. Moreover, GPR56-dependent internalisation of TG2 
is mediated by clathrin in HEK293 cells. The fate of the receptor-ligand pair 
largely remains elusive, since results indicated that they are not recycled 
back to the cell surface within the investigated time frame and are not 
degraded in lysosomes.  
Figure 8.1 schematically summarises the findings of this thesis. 
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Figure 8.1 Summary of the main findings of this thesis. 
GPR56 is activated by TG2, the β-barrels of TG2, TG6 and TG7. Activation of 
GPR56 induces signalling via RhoA and ROCK, which is potentially mediated by 
Gα12/13 and leads to shedding of amphiregulin by ADAM17.  
Activation of GPR56 by TG2 furthermore induces clathrin-dependent internalisation 
of the GPR56-TG2 pair. 
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8.2 Conclusions 
 
8.2.1 TG2 stimulates GPR56-dependent activation of ADAM17 
 
Previous work by Edwards (2010) in the Aeschlimann laboratory had shown 
that keratinocytes placed on TG2-containing ECM were able to activate 
ADAM17, leading to EGFR ligand release into the medium. It was shown that 
the keratinocytes expressed GPR56 and at the same time a paper by Xu et 
al. (2006) described a direct interaction between TG2 and GPR56. Thus, the 
hypothesis was developed that TG2-dependent GPR56 signalling may 
represent the missing link leading to ADAM17 activation and subsequent 
EGFR ligand release in keratinocytes. 
Thus, a sensitive, cell-based shedding assay was established in order to 
investigate GPR56-induced, ADAM-dependent cleavage of the membrane-
tethered proform of the alkaline phosphatase-tagged EGFR ligand 
amphiregulin (AP-AR) in response to TG2 treatment. Inoue et al. (2012) 
recently showed that a similar assay, measuring GPCR activity as 
ectodomain shedding of AP-TGF-α, is a very useful tool to investigate 
signalling through Gα12/13- and Gαq-coupled receptors. 
 
Data presented in this project demonstrate that overexpression of GPR56 in 
HEK293 cells activates ADAM17, leading to cleavage of AP-AR (Chapter 3). 
Activation of ADAMs by GPCRs leading to transactivation of the EGFR was 
demonstrated for Gq-, Gi- and G13-coupled GPCRs (Faure et al. 1994; 
Gschwind et al. 2001; Gohla et al. 1998). The role of the G protein that is 
likely involved in GPR56-dependent ADAM17 activation will be discussed in 
more detail in section 8.2.3.  
Activation of ADAM17 by GPR56 overexpression in the absence of ligand 
indicates that the receptor is auto-active. This was shown by others for 
GPR56, using Rho pulldown and luciferase reporter assays (Iguchi et al. 
2008; Kim et al. 2010; Shashidhar et al. 2005). Inoue et al. (2012) 
demonstrated ADAM17 activation by several constitutively active GPCRs, 
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inducing shedding of TGF-α. Many GPCRs exhibit some basal (constitutive) 
activity, which is defined by the equilibrium of inactive and active GPCR 
conformations in the absence of a ligand (Kobilka 2007).  
 
The nature of the GPR56-TG2 interaction has been discussed 
controversially, since no GPR56-dependent cellular signalling response to 
TG2 treatment was demonstrated before. It remains elusive whether TG2 
acts as a GPR56 ligand inducing downstream signalling. Adhesion GPCRs 
are supposed to play dual roles in signalling and adhesion (Yona et al. 2008; 
Araç, Aust, et al. 2012), therefore TG2 might form a complex with GPR56 in 
the ECM, mediating cell-ECM contacts.  
Using the shedding assay, data presented in this thesis demonstrated for the 
first time GPR56-dependent signalling in response to TG2. Treatment with 
exogenous TG2 activates GPR56-dependent AP-AR shedding, 
demonstrating TG2 as a bona fide ligand for GPR56 (Chapter 3).  
 
8.2.2 TG2-dependent GPR56 signalling is independent of TG2 
crosslinking activity 
 
Extracellular TG2 is localised on the cell surface and in the ECM and some of 
its functions require its catalytic activity. Crosslinking of ECM-components 
such as fibrin(ogen), collagen or fibronectin (FN) stabilises the ECM and 
promotes cell-ECM adhesion (Akimov et al. 2000; Belkin et al. 2005). 
However, extracellular TG2 is mostly inactive, but can be activated by high 
Ca2+-levels and may be stabilised by cell surface/ECM proteins in an activate 
conformation. However, the exact mechanism of activation is still under 
investigation  (Nurminskaya and Belkin 2012; Király et al. 2011; Pinkas et al. 
2007). Independent of its catalytic activity, cell surface TG2 interacts with 
fibronectin (FN) and β1/β3/β5-integrins. Cell surface TG2 mediates the 
association of FN with integrins, acting as a co-receptor for FN (Akimov et al. 
2000). The integrin co-receptor function of extracellular TG2 was 
demonstrated in normal and transformed cells and potentiates integrin-
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signalling, which is important for cell adhesion, migration, spreading, survival 
and differentiation (Belkin 2011; Zemskov et al. 2006). Since these and other 
functions of extracellular TG2 are independent of its enzymatic activity, it was 
investigated whether transglutaminase activity was required for activation of 
GPR56 signalling. The enzymatically inactive, inhibitor-bound Open-TG2 and 
the C277-S TG2 mutant lacking transglutaminase activity activated GPR56 
signalling to comparable levels as wild type or the oxidation-resistant C230-A 
TG2 mutant (Chapter 4). Additionally, western blot analysis did not detect 
crosslinked GPR56 products when incubated with catalytically active TG2. 
Finally, the two β-barrel domains of TG2 also activated GPR56. The data 
presented in this project show activation of signalling by the β-barrels, while 
Xu et al. (2006) had shown that these domains were sufficient for the 
interaction with N-GPR56. However, activation was less pronounced, which 
indicates that the other domains of TG2 such as the core and the N-terminal 
β-sandwich domains might also be involved in GPR56 activation. This could 
be further investigated by testing a C-terminally truncated TG2 mutant 
lacking the β-barrels or by using an N-terminally truncated C-GPR56-Fc 
probe for pulldown experiments with TG2. 
In summary, the results obtained with the shedding assay indicated that TG2 
acts as an agonist for GPR56, independently of its crosslinking activity, 
leading to downstream signalling. This is in contrast to the tumour promoting 
functions of TG2 demonstrated in melanoma, which requires its crosslinking 
function. Experiments using a xenograft tumour model showed that only the 
injection of GPR56-depleted MC-1 melanoma cells overexpressing 
enzymatically active, wild-type TG2 into mice reduced tumour growth (Yang 
et al. 2014). Expression of the enzymatically inactive TG2 mutants C277-S 
and W241-A TG2 in the MC-1 cells did not affect melanoma growth. However, 
these experiments were performed using GPR56-independent conditions and 
thus cannot reflect GPR56 activation by extracellular TG2.  
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8.2.3 GPR56 downstream signalling 
 
8.2.3.1 GPR56 activates RhoA signalling 
 
The signal transduction pathways downstream of GPR56 where investigated 
in this project and it was shown that RhoA is involved in ADAM17-dependent 
shedding of AP-AR. Experiments using an inhibitor of Rho-associated protein 
kinase (ROCK) demonstrated for the first time that RhoA, which functions 
upstream of ROCK, is activated by GPR56 in response to TG2 stimulation 
(Chapter 3).  
Interestingly, the natural splice variant ∆430-35-GPR56 was not activated by 
TG2 (Chapter 5), although this mutant was demonstrated to be more active 
than GPR56 and induced Rho-dependent, SRE-mediated transcription (Kim 
et al. 2010). However, the authors compared the activities of wild type and 
∆430-35-GPR56 using ligand-free conditions. TG2 binding likely induces a 
conformational change of GPR56, similar to other GPCR ligands (Deupi and 
Kobilka 2007), which affects the affinity for a particular G protein, in this case 
likely Gα12/13. Since the splice variant lacks six amino acids within ICL1, it 
might not be able to adjust an active confirmation upon TG2 binding like wild 
type receptor, thus it is not stimulated by TG2. 
On the one hand, ROCK activity is associated with increased cell migration 
and tumour cell invasion (Bourguignon et al. 1999; Riento and Ridley 2003). 
GPCR-dependent signalling through Gα12/13 and RhoA is associated with 
migratory and invasive phenotypes (Ridley 2004). RhoA activates endothelial 
cell invasion through regulation of MMP-9 expression and also regulates the 
expression of MT1-MMP in glioma cells (Meriane et al. 2006; Annabi et al. 
2005). Shedding of EGF-like ligands by ADAM17 leads to activation of the 
EGFR, which activates downstream signalling pathways such as Ras-Raf-
MAPK or PI3K signalling that induce cell proliferation, growth, survival and 
migration (Fischer et al. 2003). Therefore, GPR56-dependent activation of 
ROCK and ADAM17 could induce pro-survival and pro-migratory signalling 
responses, which may also be involved in tumour development and 
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progression, since TG2 likely represents the ligand for GPR56 in the tumour 
microenvironment (Xu et al. 2006; Yang et al. 2011; Yang et al. 2014). These 
data would agree with previous findings observed by Edwards (2010), where 
TG2-containing ECM supported increased migration of keratinocytes due to 
ADAM17-dependent shedding of EGFR ligands.  
On the other hand, excessive Rho activation is associated with the inhibition 
of cell migration (Riento and Ridley 2003). GPR56 constitutively activates 
RhoA in a Gα12/13-dependent way (Iguchi et al. 2008; Luo et al. 2011; 
Shashidhar et al. 2005), which is further elevated by treatment with collagen 
III, the GPR56 ligand in the developing brain, leading to inhibition of neural 
progenitor migration (Luo et al. 2011; Iguchi et al. 2008). This signalling 
mechanism is likely involved in early brain development, since GPR56 
mutations that affect cell surface expression such as R565W-GPR56 (Chapter 
3), or loss of GPR56 expression, cause the developmental brain disease 
bilateral frontoparietal polymicrogyria (BFPP). Gpr56-/- mice and BFPP 
patients develop a cobblestone-like cortex that is characterised by a 
defective pial basement membrane (BM), through which neurons and radial 
glial cells migrate, leading to the formation of neural ectopias at the cortex 
surface (Piao et al. 2004; Li et al. 2008; Koirala et al. 2009). Histological 
analysis of mouse brain slices revealed that the pial BM of Gpr56-/- mice 
appears normal during early embryonic development, suggesting that GPR56 
is dispensable for the initial BM assembly. Around embryonic day 12.8, 
however, breaches in the pial BM are detected. It was suggested that the 
ECM polymer assembly is instable in the absence of GPR56, thus cannot 
sustain the tension generated by the expanding cortex. Additionally, loss of 
GPR56 expression might cause up-regulation of enzymes that degrade the 
pial BM, resulting in BM breaches through which the neural progenitors 
migrate, leading to the brain malformation (Li et al. 2008). 
In conclusion, neurons and their precursors express GPR56 that binds 
collagen III in the pial BM, activating RhoA. This interaction is required to 
arrest neural migration, a process implicated in early brain development and 
cortical patterning (Fig. 8.2).  
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Figure 8.2 Collagen III-induced signalling through GPR56 and its role in early 
brain development. 
A) Collagen III activates GPR56 that couples to Gα12/13, inducing RhoA signalling, 
whcih contributes to inhibition of neural progenitor cell migration. 
B) Top: in normal brain, the preplate neurons (PP, green) and the end feet of the 
radial glial cells (black), which extend from the ventricular zone (VZ), are in direct 
contact with an intact pial BM (red). Postmitotic neurons (blue) migrate along radial 
glial processes to their respective layer, eventually forming the six-layered cortex 
found in adult brain; Bottom: Gpr56-/- or Col3a1-/- brains show a cobblestone-like 
cortex that is characterised by a defective pial BM in combination with overmigrating 
neurons and radial glial cells that place their end feet beyond the breaches in the 
pial BM.  
Taken from Singer et al. (2012) and Strokes & Piao (2010), modified. 
 
 
The Rho-family GTPases Cdc42, Rac and Rho regulate the assembly and 
re-organisation of the actin cytoskeleton, which is involved in the regulation of 
cell migration (Riento and Ridley 2003). Rho is especially active at the rear of 
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the cell body and activates its downstream effector ROCK, enhancing actin-
myosin contractility and tail retraction, which promotes cell movement. Actin-
myosin contractility also leads to the assembly of focal adhesions and 
dysregulation or excessive activity of Rho can inhibit migration due to the 
formation of strong focal adhesion complexes (Riento and Ridley 2003). This 
is likely the case in the neural progenitor cells with high GPR56 expression. 
Interestingly, genetic deletion of the Gα12/13 genes in the CNS also result in a 
cobblestone-like malformation, similar to BFPP, indicating a link between 
GPR56 and Gα12/13 in brain development (Moers et al. 2008). 
 
8.2.3.2 GPR56-mediated ADAM17-activation is independent of 
Gq-signalling 
 
In order to exclude an involvement of Gq in GPR56-dependent ADAM17-
activation, experiments using inhibitors of PLC/PKC-signalling were 
performed (Chapter 3). GPR56 was shown to exist in a complex with the 
tetraspanins CD81/9 and Gq (Little et al. 2004). The activation of Gq-coupled 
AT1R induces ADAM17-dependent HB-EGF shedding via PLC-signalling and 
mobilisation of Ca2+ (Mifune et al. 2005). Therefore, this signalling 
mechanism could also be involved in GPR56-dependent ADAM17 activation. 
The results obtained using different inhibitors targeting PLC, PKC and IP3-
receptors (Ca2+-flux) require cautious evaluation. The shedding assay used 
to investigate GPR56 downstream signalling does not always allow a 
distinction between inhibition of GPR56-dependent signalling leading to 
ADAM17 activation, or direct inhibition of ADAM17 activity, independent of 
GPR56. ADAM17 has some constitutive shedding activity that is independent 
of GPR56, as seen with co-expression of N-GPR56. PKC phosphorylates 
and activates ADAM17 (Dang et al. 2011; Kveiborg et al. 2011), thus the data 
could measure ADAM17-activity independent of GPR56. Inhibition of PKC 
ablated the TG2-induced shedding response, indicating that PKC may be 
activated downstream of GPR56. In contrast, inhibition of PLC, which is 
active upstream of PKC, did not affect TG2-induced shedding. However, 
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PLC-inhibition increased basal AP-AR shedding dramatically, an effect that 
was also observed to a lesser extent with the PKC-inhibitor. It was 
speculated that this could be explained by elevated cell surface expression 
levels of GPR56, but this was not confirmed by confocal analysis. However, 
the PLC-inhibitor has non-specific side effects leading to an increase of 
intracellular Ca2+-levels, which might activate ADAM17 (Mifune et al. 2005). 
This hypothesis, however, is not supported by experiments blocking the 
release of intracellular Ca2+, which did not affect ADAM17 activation. 
Additionally, luciferase reporter assays indicated that GPR56 does not couple 
Gq (Dr. Vera Knäuper) and Iguchi et al. (2008) demonstrated that Ca2+-
signalling was not activated upon treatment of GPR56-expressing cells with 
an agonistic anti-N-GPR56 antibody. 
Together with the results presented by Shashidhar et al. (2005) and Iguchi et 
al. (2008), showing GPR56-dependent activation of Gα12/13 and RhoA, results 
presented in this project point towards an involvement of Gα12/13- and not Gq-
signalling in GPR56-dependent activation of ADAM17. Future experiments 
should further address which G protein is involved, by co-expressing 
dominant-negative Gq and G12/13 proteins together with GPR56 and AP-AR or 
specific inhibitors for G proteins could be applied. In order to identify the G 
proteins involved in GPCR-dependent TGF-α shedding, Inoue et al. (2012) 
used siRNAs targeting Gα12/13, as well as chimeric G proteins. In these 
chimeric Gα proteins, six amino acids within the C-terminus, critical for 
GPCR binding, are replaced by residues from another Gα protein. For 
example, chimeric Gαq/s consists of a Gq backbone with a Gs C-terminus, 
thus binds to Gαs-coupled GPCRs and activates Gαq-downstream signalling. 
A similar approach could be used to further investigate whether Gα12/13 or 
Gαq is required for GPR56-dependent shedding of AP-AR by ADAM17. 
 
8.2.3.3 A role for β-arrestins in GPR56-dependent signalling? 
  
An involvement of β-arrestin in GPR56-dependent activation of ADAM17, 
similar to a report showing that β1AR activates an unidentified MMP (Noma 
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and Lemaire 2007), cannot entirely be excluded. Interactions with β-arrestins 
were not investigated in this thesis. In future experiments, fluorescently 
labelled β-arrestins could be co-expressed with GPR56 and their potential 
interaction upon TG2 treatment analysed by confocal microscopy. 
Additionally, truncated β-arrestins lacking GPCR interaction sites might be 
co-expressed in cells and analysed using the shedding assay. Interestingly, 
investigations of GPR56 and TG2 internalisation showed that this mechanism 
was clathrin-dependent (Chapter 6). Clathrin-dependent internalisation of 
GPCRs is usually mediated by β-arrestins that desensitise G protein-
dependent signalling and recruit components of the clathrin-endocytosis  
machinery (Zhang et al. 1996). Therefore, β-arrestin could well play a role in 
GPR56-dependent activation of ADAM17. On the other hand, GPR56 
mutants lacking potential serine and threonine phosphorylation sites in the 
tail region that could contribute to GRK phosphorylation and subsequent β-
arrestin binding, as well a C-terminal tail truncation mutant, showed TG2-
dependent GPR56 activation. These results point towards G protein-
dependent signalling, although it is not clear whether the particular residues 
or the entire C-terminal tail of GPR56 are required for β-arrestin interactions, 
which could be investigated using immunoprecipitation approaches. 
 
8.2.4 Novel GPR56 ligands 
 
In order to investigate the hypothesis that other TGs expressed in brain are 
able to activate GPR56, TG6 and TG7 were tested using the shedding assay 
for a signalling response (Chapter 4). The functions of TG6 and TG7 remain 
elusive, however, they are close TG2 homologues and the residues of the 
catalytic triad are conserved among these members of the TG family 
(Grenard et al. 2001) and both TG6 (Thomas et al. 2013) and TG7 (Zedira 
GmbH, Darmstadt) are catalytically active. TG7 is expressed ubiquitously in 
human and TG7 mRNA was detected in breast cancer cells (Mehta and 
Eckert 2005). GPR56 mRNA is also up-regulated in breast cancer (Ke et al. 
2007), therefore TG7 could represent a ligand for GPR56 in these cells. 
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However, to date studies evaluating GPR56 and TG7 in breast cancer have 
not been presented. 
TG6 is expressed abundantly in the CNS, where it could act as a ligand for 
GPR56 in neurons (Aeschlimann and Grenard 2006; Thomas et al. 2013). 
Although there is no proof for any physiological role of TG6, TG6 gene 
mutations were recently associated with autosomal dominant ataxia (Wang et 
al. 2010) and TG6 autoantibodies were associated with the development of 
gluten ataxia (GA) (Hadjivassiliou et al. 2008). GA is a neurological disorder 
that involves the cerebellum. GA is a manifestation of gluten sensitivity, an 
autoimmune disorder that was originally described in patients with coeliac 
disease (CD). CD is caused by the development of antibodies against TG2-
deamidated peptides present in gliadin, a major component of wheat gluten 
protein, in combination with TG2-autoantibodies. This causes an autoimmune 
reaction involving specific human leucocyte antigen (HLA) alleles, resulting in 
damage to the small intestine. Patients with GA are usually free of the 
gastrointestinal symptoms observed in CD patients, including diarrhea, 
bloating or abdominal pain. However, GA can be treated with a gluten-free 
diet, similar to CD. In addition, GA patients also develop autoantibodies 
against TG6, which is primarily expressed in neural tissue and represents the 
targeted auto-antigen in the CNS. The immune-mediated damage and 
shrinkage of the cerebellum cause ataxia in GA patients, which is manifested 
by impaired muscle coordination, resulting in problems with balance, gait or 
vision (Hadjivassiliou et al. 2008). These results indicate an important role for 
TG6 in motor neurons.  
GA patients are usually diagnosed at the age of 40-50. GA does not develop 
during embryogenesis and is caused by gluten consumption. GPR56 
expression levels are known to be very low in the adult brain, thus it is 
unlikely that the interaction of GPR56 with TG6 is involved in the 
pathogenesis of GA. Nonetheless, GPR56 is expressed in neurons and their 
progenitors in the developing cortex and TG6 could represent a physiological 
ligand for GPR56 in the developing brain, as TG6 expression was recently 
associated with neurogenesis in mice (Thomas et al. 2013). Analysis of the 
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phenotype of TG6-/- mice, which may show similarities to Gpr56-/- mice, could 
help to address this issue in the future. 
 
8.2.5 Internalisation of GPR56 
 
In this project, internalisation of TG2 in a GPR56-dependent way was 
demonstrated (Chapter 6) and information about the mechanism of 
endocytosis was provided. GPR56-dependent internalisation of extracellular 
TG2 was apparent after 15 mins and TG2 was not internalised in control cells 
lacking GPR56 expression. Internalisation of GPCRs is a common 
mechanism used by cells to dampen receptor signalling and can result in 
receptor recycling or degradation, but can also be the cause of biased 
intracellular signalling (Ferguson 2001; Lefkowitz and Shenoy 2005). GPCR 
endocytosis was originally observed for agonist-bound receptors, however, 
constitutively active receptors also internalise, as seen for GPR56 in the 
absence of TG2, as well as β2AR. Constitutive internalisation rates for β2AR 
were slower than for GPR56, as the number of GPR56-positive vesicles 
under ligand-free conditions was higher. 
Co-staining of the lysosomal-associated markers LAMP1 and LAMP2 did not 
indicate that GPR56 or TG2 co-localise in lysosomes upon internalisation in 
HEK293 cells. A time frame of up to 6 h was investigated and recycling of 
TG2 and GPR56 was not detectable. However, the signal intensity of 
intracellular TG2 staining decreased over time. There are additional 
pathways leading to receptor/ligand degradation and it is possible that 
GPR56 and its ligand TG2 are targeted to the proteasome, where they are 
degraded as observed for δ-opoid receptors (Chaturvedi et al. 2001). It is 
also possible that TG2 dissociates from N-GPR56 and that only TG2 is then 
degraded in the proteasome. Western blot analysis of GPR56 indicated that 
the expression of the GPR56 dimer is reduced following stimulation with TG2 
for 1 h, which potentially indicates that this is the receptor form interacting 
with TG2 at the cell surface, leading to its degradation. Yang et al. (2014) 
demonstrated GPR56-dependent internalisation of Alexa488-labelled TG2 in 
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MC-1 melanoma cells. Confocal and western blot analysis showed a 
decrease of TG2 after treating GPR56-expressing cells with TG2 for 1 h, 
indicating its degradation. The use of lysosomal inhibitors over a time frame 
of 1h blocked degradation of TG2 in GPR56-expressing cells and resulted in 
ECM-deposition of TG2 and N-GPR56 (Yang et al. 2014). 
To further address the question of the GPR56 fate, markers of recycling 
endosomes, such as members of the Rab family could be stained using 
confocal analysis (Griffiths and Gruenberg 1991). Moreover, lysosomal and 
proteasomal inhibitors could be used during the experiments, in order to 
distinguish between the two mechanisms (Chaturvedi et al. 2001).  
 
Internalisation of GPR56 and GPR56-dependent TG2 internalisation is 
mediated by clathrin-coated pits, as shown by sucrose treatments and 
staining for transferrin receptors and caveolae (Chapter 6). Endocytosis via 
clathrin is the prototypical mechanism of GPCR endocytosis (McMahon and 
Boucrot 2011; Doherty and McMahon 2009). Sucrose, which inhibits the 
association of clathrin and AP-2 adaptor protein (Hansen et al. 1993), ablates 
GPR56 internalisation, as shown by confocal analysis. In addition, sucrose 
treatments dramatically increase ADAM17-dependent shedding of AP-AR, as 
observed in the shedding assay. This result may indicate that GPR56-
dependent activation of ADAM17 is not a result of signalling by internalised 
GPR56 from endocytic vesicles. 
 
8.2.6 Controversial roles of GPR56 in cancer 
 
GPR56 is up- or down-regulated in several human cancers and its role in 
tumour development and progression is controversial. Studies focussing on 
the role of GPR56 in melanoma progression provided information about 
potential interactions between GPR56 and TG2 in vitro and in vivo. GPR56 
mRNA and protein are down-regulated in highly metastatic melanoma cells 
(Zendman et al. 1999; Xu et al. 2006). In a xenograft cancer model, 
overexpression of GPR56 in highly metastatic MC-1 melanoma cells inhibits 
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tumour growth and metastasis, when cells are injected into immunodeficient 
mice (Xu et al. 2006). However, GPR56 expression does not alter melanoma 
cell progression in vitro. It was speculated that TG2, present in the tumour 
microenvironment, modulates the inhibitory function of GPR56 (Xu et al. 
2006).  
Tumours derived from melanoma cells transfected with GPR56 show 
significantly fewer blood vessels than control cells (Yang et al. 2011). 
However, N-terminally truncated C-GPR56 or a TG2-interaction site deletion 
mutant of GPR56 fail to inhibit melanoma tumour growth and angiogenesis in 
vivo and induce vascular epidermal growth factor (VEGF) production, which 
requires PKCα activity (Yang et al. 2011). Addition of N-GPR56-Fc to C-
GPR56 expressing cells results in a significant reduction of VEGF production, 
thus recovering the tumour inhibiting functions of GPR56 (Fig. 8.3).  
 
 
 
 
Figure 8.3 C-GPR56-dependent induction of VEGF production requires PKCα 
activity and is inhibited by N-GPR56. After Yang et al. (2011). 
 
 
These results indicated that N-GPR56 inhibits C-GPR56 and that removal of 
N-GPR56 constitutively activates the receptor, inducing VEGF production. It 
was proposed that TG2 might mediate the inhibiting effect of N-GPR56, since 
deletion of the TG2-binding domain inactivates N-GPR56. This is in line with 
results presented in this thesis, demonstrating that the entire N-terminus of 
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GPR56 is required for receptor activation by TG2, since N-terminal deletion 
mutants are not activated by TG2 (Chapter 5). 
Further investigations using a xenograft tumour model revealed that TG2 
promotes melanoma growth and metastasis. A complete ablation of TG2 in 
the recipient mice and the injected melanoma cells reduces tumour weight 
and the number of lung metastasis. The data demonstrate that extracellular 
TG2, present in tumour stroma, promotes melanoma metastasis (Yang et al. 
2014). Overexpression of GPR56 in the injected melanoma cells inhibits 
tumour growth. GPR56 antagonises the tumour promoting effects of TG2 by 
internalisation, likely leading to its degradation. However, GPR56 itself has 
some tumour promoting functions independent of TG2 and a combined 
knockdown of GPR56 and TG2 entirely ablates tumour growth (Fig. 8.4) 
(Yang et al. 2014). 
 
 
 
Figure 8.4 Summary of mouse experiments performed by Yang et al. (2014), 
investigating the role of GPR56 and TG2 in melanoma tumour growth.  
A) Melanoma cells, ablated in GPR56 expression and endogenously expressing 
TG2, grow large melanoma tumours in TG2-positive, immunodeficient mice;  
B) Melanoma cells, overexpressing GPR56 and endogenous levels of TG2, grow 
only small tumours in TG2-positive mice. The results indicate that GPR56 
antagonises the tumour promoting effects of TG2. 
C) Melanoma cells, overexpressing GPR56 and ablated in TG2 expression, grow 
small melanoma tumours in TG2-knockout, immunodeficient mice;  
D) Melanoma cells, ablated in both GPR56 and TG2 expression, do not grow 
tumours in TG2-knockout mice, indicating that GPR56 itself has some tumour 
promoting functions. 
Mouse illustrations taken from Kühn & Wurst (2009), modified. 
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It must be noted that MC-1 cells were transfected with empty vector as a 
control for GPR56 overexpression in the study by Yang et al. (2014). 
Overexpression of GPR56 results in reduced tumour growth, which might 
also be induced by cellular stress, independently of GPR56 function. 
Therefore, expression of an inactive GPR56 mutant, for example a BFPP-
mutant with impaired membrane trafficking ability, would represent a better 
control than empty vector transfections in order to show that the reduction in 
tumour growth is induced by cell-surface GPR56 and not caused by a cellular 
stress reaction such as apoptosis. 
Moreover, a critical control experiment, in which TG2-depleted MC-1 cells 
overexpressing GPR56 are injected into TG2-expressing mice, was not 
performed in their study (Yang et al. 2014). This experiment would yield 
results for many cancer cells, where GPR56 is overexpressed and might 
interact with extracellular TG2 in the microenvironment. This experiment 
would also reproduce the in vitro experiments described in this thesis.  
 
Analysis of endogenous cancer progression in Gpr56-/- mice using a 
transgenic cancer model indicated that GPR56 has no effect on endogenous 
melanoma progression (Xu et al. 2010). Thus, GPR56 might have different 
effects on tumour progression in xenograft models compared to endogenous 
tumour progression or the results might be explained by different genetic 
backgrounds of the mice used. 
 
Data presented in this project rather point to a tumour promoting function of 
GPR56, since the activation of ADAMs and the shedding of EGF-like ligands 
is connected to the activation of EGFR signalling, promoting cell survival and 
tumour progression. However, it is not clear whether GPR56 signals via this 
mechanism in tumour cells, as this was only investigated in HEK293 cells 
and downstream signalling caused by GPR56 activation could potentially 
vary between different cell populations. 
GPR56 mRNA levels are up-regulated in esophageal squamous cell 
carcinoma and many other cancers, such as breast, ovarian, colon, lung and 
brain, suggesting a general role in cell transformation and tumorigenesis 
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(Sud et al. 2006; Ke et al. 2007). In addition, GPR56 protein is highly 
expressed in glioblastoma (Shashidhar et al. 2005), which was confirmed by 
analysis of U373 glioblastoma cells (Chapter 7). This is the first report 
demonstrating knockdown of GPR56 in glioblastoma cells using stable 
shRNA transfection. GPR56 knockdown was incomplete in U373 cells, which 
may be explained by a lethal effect of GPR56 depletion in these cells. 
Nonetheless, confocal analysis of GPR56 expression in parental U373 cells 
and two cell clones that showed the highest GPR56 knockdown, indicate 
changes in the cell morphology upon GPR56 down-regulation. GPR56 was 
expressed at the migrating front of normal U373 cells, confirming results of 
U87 glioblastoma cells, in which GPR56 is localised at the leading edge of 
membrane protrusions, where it co-localises with α-actinin (Shashidhar et al. 
2005). In GPR56-silenced U373 cells, however, GPR56 is absent at the cell 
surface and in addition, the cells acquire a different shape, indicating loss of 
cell polarity. Induction of cell polarity is important for cell motility and involves 
the activities of the small GTPases Cdc42, Rac and Rho (Cotton and Claing 
2009). The effect of Rho and ROCK activation in glioblastoma is 
controversial. Several studies have shown that activation of this pathway 
inhibits glioblastoma migration and that inhibition of Rho and ROCK 
increases cell motility (Tabu et al. 2007; Salhia et al. 2005). Another study, 
however, showed that inhibition of ROCK suppresses glioblatoma cell 
migration. ROCK inhibition also affected glioblastoma proliferation and a link 
to ERK signalling was established (Zohrabian et al. 2009). The different 
results may be explained by different inhibitors or varying inhibitor 
concentrations applied, as well as genetic alterations between the 
glioblastoma cell lines used. GPR56 is up-regulated in glioblastoma cells, 
therefore it is possible that GPR56-dependent activation of RhoA contributes 
to the invasive behaviour of glioblastoma cells, as observed for other cell 
systems (Iguchi et al. 2008; Luo et al. 2011). Further experiments are 
required to address these questions. Firstly, experiments such as detailed 
analysis of cytoskeletal rearrangements in GPR56-silenced U373 cells 
compared to parental cells using cytoskeletal markers and confocal 
microscopy might be considered. Cell growth curves and Rho pulldown 
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assays should be performed. In addition, the effect of extracellular TG2 on 
glioblastoma proliferation and migration should be addressed, since TG2 
might represent the ligand for GPR56 in the glioma microenvironment. TG2 
activity is increased in glioblastomas compared to normal brain tissue and 
increased amounts of fibronectin co-localise with TG2 in the ECM. 
Glioblastoma cells secrete high levels of TG2 and application of a TG2 
inhibitor blocks the remodelling of fibronectin in the ECM of glioblastomas, 
increasing apoptosis and sensitising the tumours to chemotherapy (Yuan et 
al. 2007; Alderton 2006). In order to investigate a link between GPR56-TG2 
interaction and cell migration, scratch wound assays could be performed, in 
which a scratch within a monolayer of glioblastoma cells is performed and the 
ability of the cells to close the wound is monitored using time lapse 
microscopy. These experiments can include the addition of TG2 to the 
medium. Migration experiments according to the protocol by Edwards (2010), 
in which glioblastoma spheroids are placed on a TG2-containing or TG2-
depleted matrix and migration of cells from the spheroids observed over time, 
also represent an interesting approach to investigate a link between the TG2-
GPR56 interaction and cell migration. 
 
 
8.3 Future outlook 
 
In order to further advance the understanding of signalling mechanisms 
mediated by GPR56, future experiments should focus on the mediator 
proteins involved in GPR56-depenent downstream signalling, such as G 
proteins or β-arrestins. Moreover, the potential link between the GPR56 
signalling response to TG2, as observed in HEK293 cells, and glioblastoma 
cell migration and proliferation should be investigated in detail in order to gain 
additional information about the role of GPR56 in glioblastoma. 
To achieve this, the GPR56-depleted glioblastoma cells generated in this 
project should be further characterised regarding potential changes in their 
morphology and in respect of their ability to proliferate and migrate in 
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comparison to control glioblastoma cells expressing high levels of GPR56. If 
knockdown of GPR56 had a tumour suppressing function in the glioblastoma 
cells, such as reduced tumour cell growth and migration, GPR56 could 
represent an attractive drug target. Generally, targeting GPR56 in adult 
patients should be feasible, as there are no known post-developmental 
defects resulting from the GPR56 loss-of-function mutations in humans (Ke 
et al. 2007). This is in contrast to the developmental brain malformation 
BFPP, which is caused by GPR56 loss-of-function mutations during 
embryonic development (Piao et al. 2004). In adult human brain, however, 
GPR56 might not play a crucial role, since GPR56 expression levels are low, 
which is in contrast to the high expression levels in glioblastoma (Shashidhar 
et al. 2005). Therefore, GPR56 might represent an interesting candidate for 
therapeutic intervention in the context of GBM. Nonetheless, further intensive 
investigations would be necessary to exclude potential risks caused by 
silencing GPR56 and interfering with its downstream signalling pathways. 
One important point is the ability of aGPCRs to form heterodimers, as shown 
for latrophilin-1 and GPR56 (Silva et al. 2009). The ability to form such 
heterodimers is based on the GPS cleavage of aGPCRs that produces two 
fragments, the N- and the C-terminus, which are able to act independently in 
the cell membrane (Volynski et al. 2004). The hybrid receptors described by 
Silva et al. (2009) consist of a C-terminus from one aGPCR and an N-
terminus of another aGPCR. This was shown for N-EMR4 with C-EMR2 
(Huang et al. 2012), as well as N-EMR2 with C-latrophilin-1 (Silva et al. 
2009). In the same study, N-latrophilin-1 was shown to co-immunoprecipitate 
with C-GPR56 (Silva et al. 2009). The “split personality receptor model” 
implicates that ligand binding to one aGPCR N-terminus could induce 
signalling via the C-terminus of another aGPCR, generating a very 
complicated signalling network (Silva et al. 2009). Thus, it is possible that 
signals sensed by latrophilin-1 may induce GPR56-mediated signalling.  
Latrophilin-1 was associated with a function in the CNS in the light of 
neurotransmitter release (Davletov et al. 1998).  Therefore, the hybrid 
receptor consisting of N-latrophilin-1 and C-GPR56 might play an important 
role in the adult human body, which could cause problems when silencing 
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GPR56 in the context of an anti-glioblastoma therapy. In order to further 
investigate potential heterodimer formation between GPR56 and other 
aGPCRs such as latrophilin-1, the bioluminescence resonance energy 
transfer (BRET) technology could be used, which allows a direct examination 
of GPCR dimerisation. The BRET technology is based on biosensors 
including the bioluminescent donor Renilla luciferase (luc) and a variant of 
green fluorescent protein (GFP) as the fluorescent acceptor (Angers et al. 
2000). In order to detect receptor heterodimerisation, it would be feasible to 
generate GPR56-luc and latrohilin-1-GFP constructs (or any other aGPCR) 
and investigate their association at the cell surface by measuring BRET 
signals. These experiments would indicate whether there are any relevant, 
complex interactions between GPR56 and other aGPCRs that need to be 
considered when thinking about targeting and silencing GPR56 in regards of 
anti-cancer therapies. 
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Appendix I: Solutions and buffer 
 
Buffer Recipe 
1% agarose gel 
1g agarose 
99ml TEA buffer 
10µl ethidium bromide  
4% stacking gel 
 
3.2 ml ddH20 
0.5 ml 40% acrylamide/bis-acrylamide solution, 29:1 
(Geneflow) 
1.25 ml 0.5M Tris-HCl, pH 6.8 
100 μl 10% SDS 
100 μl 10% ammonium persulfate  
10 μl TEMED  
10% resolving gel 
 
4.9 ml ddH20 
2.5 ml 40% acrylamide/bis-acrylamide solution, 29:1  
2.5 ml 1.5M Tris-HCl, pH 8.8 
100 μl 10% SDS 
100 μl 10% ammonium persulfate 
10 μl TEMED 
Luria-Bertani broth (LB) 
medium (1L) 
10g tryptone 
5g yeast extract 
10g NaCl 
Phosphate buffered saline 10 PBS tablets (OXOID)/1L H2O 
Reducing sample buffer (2x) 
 
3.5 ml dH2O 
1.25 ml 0.5M Tris-HCl, pH 6.8 
2.5 ml glycerol 
2 ml 10% SDS 
0.2 ml 0.5% bromophenol blue  
0.5 ml β-mercaptoethanol  
SDS-PAGE running buffer 
 
25 mM Tris-HCl 
190 mM glycine 
0.1% SDS 
TEA buffer 40 mM Tris acetate 1 mM EDTA 
Tris buffered saline (TBS) 50 mM Tris-HCl, pH 8.0 150 mM NaCl 
Western blot transfer buffer 
 
25 mM Tris 
190mM glycine 
20% methanol 
Western blot stripping buffer 
62.5 mM Tris-HCl pH 6.8  
2% SDS 
100 mM β-mercaptoethanol 
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Appendix II: Chemicals 
 
Chemical Manufacturer 
Acrylamid / Bisacrylamid-Lösung, 
40%, 29:1 
National Diagnostics, Hessle, UK 
Agar-agar Fisher Scientific, Loughborough, UK 
Agarose Invitrogen Ltd., Paisley, UK 
Ammonium persulfate Sigma-Aldrich Company Ltd., Gillingham, UK 
Benzamidine Sigma-Aldrich Company Ltd., Gillingham, UK 
Bromophenol blue Sigma-Aldrich Company Ltd., Gillingham, UK 
BSA Promega, Southhampton, UK 
β-mercaptoethanol Sigma-Aldrich Company Ltd., Gillingham, UK 
Dimethylsulfoxide (DMSO) Sigma-Aldrich Company Ltd., Gillingham, UK 
dNTPs Agilent Technologies, Inc., Edingburgh, UK 
EDTA Melford, Chelsworth, UK 
Ethanol Fisher Scientific, Loughborough, UK 
Glycerol Fisher Scientific, Loughborough, UK 
Glycine Fisher Scientific, Loughborough, UK 
HCl Fisher Scientific, Loughborough, UK 
HEPES Fisher Scientific, Loughborough, UK 
Isopropanol Fisher Scientific, Loughborough, UK 
Magnesium chloride Sigma-Aldrich Company Ltd., Gillingham, UK 
Methanol Fisher Scientific, Loughborough, UK 
Nonident P-40 Sigma-Aldrich Company Ltd., Gillingham, UK 
Paraformaldehyde Fisher Scientific, Loughborough, UK 
Saponin from quillaja bark Sigma-Aldrich Company Ltd., Gillingham, UK 
Skimmed milk powder Milbona, Lidl, UK 
Sodium acetate Sigma-Aldrich Company Ltd., Gillingham, UK 
Sodium chloride Fisher Scientific, Loughborough, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich Company Ltd., Gillingham, UK 
Sodium fluoride Sigma-Aldrich Company Ltd., Gillingham, UK 
Sucrose Sigma-Aldrich Company Ltd., Gillingham, UK 
Tetramethylethylendiamine 
(TEMED) 
Sigma-Aldrich Company Ltd., Gillingham, UK 
Tris Base Fisher Scientific, Loughborough, UK 
Trypan blue Sigma-Aldrich Company Ltd., Gillingham, UK 
Tryptone Fisher Scientific, Loughborough, UK 
Tween-20 Sigma-Aldrich Company Ltd., Gillingham, UK 
Yeast extract Fisher Scientific, Loughborough, UK 
Vectashield mounting medium Vector Laboratories, Burlingame, USA 
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Appendix III: Consumables and laboratory equipment 
 
Consumable Manufacturer 
Developer G153  Agfa, Mortsel, Belgium  
Fixer G354  Agfa, Mortsel, Belgium 
Cryo vials Greiner Bio-One Ltd., Stonehouse, UK 
Pipette tips (10, 100, 200, 1000 μl) Elkay Laboratory Products (UK) Limited, Hampshire, UK 
Foams Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Filter paper Fisher Scientific, Loughborough, UK 
 
Equipment Manufacturer 
Balance MXX-212 Denver Instrument GmbH, Göttingen, Germany 
Combs (0.75 or 1 mm) Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Glass coverslips VWR International Inc., Chicago, USA 
Glass plates (0.75 or 1 mm) Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Freezing container  Nalgene Labware, Thermo Fisher Scientific, Basingstoke, UK 
Gel electrophoresis tank, Mini-proteanII Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Incubator Binder GmbH, Tuttlingen, Germany 
Labofuge H00 R Heraeus Thermo Fisher Scientific, Basingstoke, UK 
Magnetic stirrer Falc instruments, Tremglio, Italy 
Microcentrifuge (Centrifuge 5415 R) Eppendorf UK Limited, Cambridge, UK 
Microscopy slides Carl Zeiss AG, Oberkochen, Germany 
Mini Trans-Blot cell Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Neubauer counting chamber VWR International Inc., Chicago, USA 
OMEGA plate reader BMG Labtech, Offenburg, Germany 
pH meter (pH209) Hanna instruments 
Pipettes Starlab, Milton Keynes, UK and Gilson Scientific Ltd., Bedfordshire, UK 
Pipette boy Integra Biosciences Ag, Zizers, Switzerland 
Power supply (Power Pac HC) Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Rotator plate (Luckham 802 
suspension mixer) Luckham Ltd., Sussex, UK 
Shaker plate (IKA-VIBRAX-VXR, Type 
VX7) 
IKA-Werke GmbH & CO. KG, Staufen, 
Germany 
Tweezers VWR International Inc., Chicago, USA 
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UVP UV gel doc (Gel doc – It TS 
Imaging System) 
Ultra-Violet Products Ltd, Cambridge, UK 
UVP UV gel doc (Gel doc – It TS 
Imaging System) 
Ultra-Violet Products Ltd, Cambridge, UK 
X-ray hypercassettes Amersham Bioscience, GE Healthcare Ltd., Buckinghamshire, UK 
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Appendix IV: DNA sequences endcoding shRNAs 
used to stably transfect U373 glioblastoma cells 
 
 
• shGPR56.2 (21 bp):  GAACCGACATGCTGGGAGATT 
 
• shGPR56.4 (21 bp):  ACTGACCTCTGTGAGATTCAT 
 
• shNON-CODING(21 bp): GGAATCTCATTCGATGCATAC 
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Appendix V: Sequence of wild type GPR56, 693 aa 
 
 
MTPQSLLQTTLFLLSLLFLVQGAHGRGHREDFRFCSQRNQTHRSSLHYKPT
PDLRISIENSEEALTVHAPFPAAHPASRSFPDPRGLYHFCLYWNRHAGRLH
LLYGKRDFLLSDKASSLLCFQHQEESLAQGPPLLATSVTSWWSPQNISLPS
AASFTFSFHSPPHTAAHNASVDMCELKRDLQLLSQFLKHPQKASRRPSAAP
ASQQLQSLESKLTSVRFMGDMVSFEEDRINATVWKLQPTAGLQDLHIHSRE
EEQSEIMEYSVLLPRTLFQRTKGRSGEAEKRLLLVDFSSQALFQDKNSSQV
LGEKVLGIVVQNTKVANLTEPVVLTFQHQLQPKNVTLQCVFWVEDPTLSSP
GHWSSAGCETVRRETQTSCFCNHLTYFAVLMVSSVEVDAVHKHYLSLLSY
VGCVVSALACLVTIAAYLCSRVPLPCRRKPRDYTIKVHMNLLLAVFLLDTSFL
LSEPVALTGSEAGCRASAIFLHFSLLTCLSWMGLEGYNLYRLVVEVFGTYV
PGYLLKLSAMGWGFPIFLVTLVALVDVDNYGPIILAVHRTPEGVIYPSMCWIR
DSLVSYITNLGLFSLVFLFNMAMLATMVVQILRLRPHTQKWSHVLTLLGLSLL
GLPWALIFFSFASGTFQLVVLYLFSIITSFQGFLIFIWYWSMRLQARGGPSPL
KSNSDSARLPISSGSTSSSRI 
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Appendix VI: Stably transfected HEK293 control cells 
stained for GPR56 and TG2. 
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Figure Appendix VI: Stable HEK293 control cells stained for GPR56 and TG2. 
The GPR56 inducible cell line was seeded onto poly-L-lysine coated glass 
coverslips and cultured for 48 h without antibiotics prior to 1 h serum starvation. 
Cells were then treated for 5 sec, 15 mins or 30 mins with (A) control buffer or (B) 
20 µg/ml C230-A TG2. Cells were fixed and permeabilised and GPR56 was stained 
with anti-N-GPR56 (red; R&D Systems) and anti-sheep Alexa568 antibody (Jackson 
ImmunoResearch). C230-A TG2 was stained with monoclonal anti-TG2 (green; 
Thermo Scientific) and anti-mouse Alexa488 antibodies (Jackson 
ImmunoResearch). 
(A)&(B) Cells are negative for GPR56 expression and TG2 staining at any time. 
 
